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Background: Since its discovery about three decades ago, the Human Immunodeficiency Virus 
(HIV) has claimed over millions of lives globally. Although our understanding of the mode of 
transmission and action of this causative agent for the Acquired Immune Deficiency Syndrome 
(AIDS) has increased through research, and treatment regimens developed and improved, in 
certain parts of the world the pandemic continues to expand. Sub-Saharan Africa, which is the 
epicentre of this global health concern, accounts for approximately 66% of the total number of 
individuals affected, with South Africa enduring the heaviest burden.  
 
South Africa has the world’s largest antiretroviral therapy (ART) programme and as such, HIV 
infected people are living longer, and consequently the incidence of HIV co-morbidities has 
increased dramatically. HIV/AIDS defining cancers are such co-morbidities with Non-
Hodgkin’s lymphomas (NHL) being the second most common HIV-associated cancer. Diffuse 
Large B-cell lymphoma (DLBCL) and Burkitt’s lymphoma (BL) are the main subtypes and 
both present aggressively in HIV positive patients with rapid progression. The use of highly 
active antiretroviral therapy (HAART) has decreased the incidence of DLBCL in HIV positive 
patients, however the prevalence of these cancers still remain high in some settings.  
 
It has been suggested that the pathogenesis of these cancers in HIV infected individuals is 
complex and different to that in HIV uninfected individuals, with the possibility that the virus 
may have an oncogenic role. This has already been demonstrated in the case of the HIV/AIDS-
defining cancer Kaposi Sarcoma. However, the same has not been unequivocally demonstrated 
in HIV-associated NHL. In light of this, the mechanisms through which viruses and viral 
components promote cellular transformation is an area of active research.  
 
One of these mechanisms manipulated by viruses is through the dysregulation of cellular 
microRNAs (miRNAs) which are small non-coding RNA molecules that are key regulators of 
gene expression. While they are essential for normal cellular functioning, their expression has 
been found to be deregulated in diseases including cancer. Several studies have described 
specific miRNA signatures for NHLs including for DLBCL and BL but none have been 
described for the HIV-association of these cancers.  
 
Aim: The aim of this project was to identify and characterise miRNAs involved in the 
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pathogenesis of HIV-associated NHLs. This thesis reports on the changes in expression of 
miRNAs in B-cells exposed to an attenuated form (structurally intact but non-infectious) of 
HIV. 
 
Methods: We designed a custom miRNA microarray to identify deregulated miRNAs in the 
BL cell line Ramos that were exposed to HIV compared to microvesicle treated cells. It was 
initially planned to use both normal B-cells (L1439A) and BL cells for analysis but Ramos was 
selected due to technical reasons for this step. Thereafter we validated selected miRNAs by 
quantitative real-time PCR (qPCR) using single-tube TaqMan® Assays which was 
predominantly performed in the lymphoblastoid cell line L1439A, which is derived from a 
healthy donor. We then focused on further characterising the role of one miRNA in the 
development of HIV-associated NHL by using prediction programmes to predict its putative 
gene targets and then confirmed its target by using qPCR and western blot analyses.  
 
Results: Extensive and comprehensive analysis of the array data led to the identification of a 
large number of miRNAs which were differentially expressed, with 32 being selected for 
further studies. These 32 miRNAs include 16 upregulated and 16 downregulated miRNAs, and 
were selected because they displayed changes in expression by two or more folds. Thereafter, 
four miRNAs, namely miR-363-3p, miR-222-3p, miR-200c-3p and miR-575, were chosen for 
validation based on their reported involvement in cancer for validation. The results of two 
miRNAs (miR-575 (upregulated) (p<0.05) and miR-200c-3p (downregulated) (p<0.05)) were 
found to be consistent with the results obtained from the miRNA microarray whilst the other 
two were opposite to that result (both downregulated) (p<0.05).  
 
Using online tools as well as the published literature, several potential target genes of miR-575 
were identified, namely DENND5A, CDK1, CSTA and ATAD5. One particular target, the BH3-
like motif containing inducer of cell death (BLID), which is involved in apoptosis, has 
previously been confirmed as a gene target in non small cell lung cancer. Using qPCR, we 
found that BLID messenger RNA (mRNA) was downregulated in normal B-cells when exposed 
to HIV-1 AT-2. Unfortunately, the BLID protein could not be detected using western blot 
analysis despite several attempts at detecting varying concentrations of the protein and using 




Conclusion: The reverse correlation, between miR-575 and BLID mRNA expression in the 
same cell line and under the same treatment conditions, supports the notion that the 
downregulation of miR-575 may be physiologically relevant.  However, this could not be 
further verified as the BLID protein could not be detected in the L1439A cells, even in the 
microvesicle treated control cells. Future studies should look at further characterisation of miR-
575 in the pathogenesis of HIV-associated NHLs by investigating other predicted gene targets 
of the miRNA. This will then be followed by loss and gain of function assays to confirm the 
miRNA:mRNA relationship. Furthermore, functional analyses, such as measure of apoptosis, 
expression of key regulators of the cell cycle, and other cellular events characteristic of cancer 
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CHAPTER 1: INTRODUCTION 
___________________________________________________________________________ 
 
1.1  MICRORNAS 
 
MicroRNAs (miRNAs) are a group of small (17-25 nucleotides) of non-coding RNA molecules 
that bind to the 3’ untranslated region (UTR) of protein coding transcripts. These highly 
conserved molecules first discovered in 1993 (Lee et al., 1993), are thought to regulate up to 
30% of human protein coding genes (Sassen et al., 2008). Research in the last decade has 
shown that miRNAs regulate gene expression post-transcriptionally, either by complete 
degradation of messenger RNA (mRNA) through the RNA interference (RNAi) pathway or by 
inhibiting protein translation (Sassen et al., 2008; Lee et al., 1993). The latter mode of 
regulation is however, dependent on the degree of miRNA-mRNA target sequence 
complementarity. 
 
1.1.1 Biogenesis of miRNAs 
Functional miRNAs are formed from longer precursor molecules (designated as mir) encoded 
by miRNA genes (Figure 1.1) that undergo two ribonuclease reactions. This process firstly 
begins in the nucleus whereby the primary transcripts (pri-mir) are several kilobases long 
which is polyadenylated at the 3’ end and contains a 7-methylguanosine cap at the 5’ end (Lee 
et al., 2002). Initiated via transcription by RNA polymerase (RNAP) II, a stem loop structure 
is created which is then cleaved into several precursor miRNAs (pre-mir). As shown in Figure 
1.1, cleavage of miRNAs are performed by a 500-650 kDa microprocessor complex that 
consists of the RNAP III enzyme, Drosha and its co-factor, the double stranded RNA binding 
domain (dsRBD) protein DiGeorge Syndrome critical region 8 (DGCR8) molecule (Gregory 
et al., 2004). At this stage pre-miRNAs (60-100 nucleotides) contain a two nucleotide overhang 
that is bound to exportin-5 and Ran-guanosine triphosphate (GTP). These molecules not only 
protect the pre-miRNA from cellular digestion but also mediates its translocation from the 
nucleus into the cytoplasm (Guttler & Gorlich, 2011). 
 
The second ribonuclease reaction takes place in the cytoplasm by the RNAP II enzyme, Dicer 
along with dsRBD protein Tar RNA binding protein (TRBP) and protein activator of PKR 
(PACT) (Figure 1.1). A mature miRNA (designated as miR) approximately 22-25 nucleotides 
in length is produced with a two nucleotide overhang on each 3’ end by removal of the stem 
 2 
loop structure. Two strands are therefore produced in which the mature guide miRNA forms 
part of the functional centre of the RNA-inducing silencing complex (RISC) and the other 
passenger miRNA becomes degraded (Sand et al., 2011).  
 
The nomenclature of miRNAs are distinct in that they are assigned sequential numerical 
identifiers with abbreviated three or four letter prefixes to designate the species (e.g. hsa-miR 
for Homo sapiens and mmu-miR for the mouse species) whilst paralogous sequences whose 
mature miRNAs differ at only one or two positions are given lettered suffixes (e.g. hsa-miR-
200c) and finally distinct hairpin loci that give rise to identical mature miRNAs have numbered 
suffixes (e.g. hsa-miR-10-1). The two mature strands produced can also either be excised from 
opposite arms of the same hairpin precursor and are designated by the suffixes, 5p or 3p, 
indicating which arm the mature miRNA arises from (Griffith-Jones et al., 2006). 
 
Mature miRNAs recognise their target messenger RNAs (mRNAs) by sequence 
complementarity between nucleotides 2-8 of the miRNA at the 5’ end (known as the seed 
region) and complementary nucleotides in the 3’ untranslated region (3’ UTR) of mRNAs 
which determine their function (Kuhn et al., 2008). RISC along with Argonaute 2 (AGO2) 
associated with cellular miRNA fragments bind to the 3’ UTR of their target mRNA (Wang et 
al., 2009). Thereafter, the miRNA/RISC complex anneals to this region and mRNA 
degradation is performed should complete complementarity be found. Alternatively, 
translational repression can occur when there is limited complementarity with this complex 





Figure 1.1: Biogenesis of miRNAs. Two maturation processes are involved by RNase enzyme action by Dicer and 
Drosha. The first reaction takes place in the nucleus whilst the second takes place in the cytoplasm to produce 
two miRNAs strands. The mature guide strand performs either translational repression or degradation of mRNA 
(Reproduced from Sand, 2014). 
 
 
1.1.2 Biological Function of miRNAs 
The first miRNA, lin-4 was discovered in the nematode, Caenorhabditis elegans. The role of 
lin-4 was reported to be involved in developmental timing (Lee et al., 1993). Thereafter, 
Reinhart et al., (2000) discovered let-7 in the same organism, which led to the subsequent 
identification of homologs in humans and other animals (Pasquinelli et al., 2000). Since the 
discovery by Lee and colleagues, miRNAs have been found in other species and the 
conservation across species suggests a fundamental biological role. To date, 2588 mature 
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miRNAs have been identified in the human genome and the number is ever increasing 
(http://www.mirbase.org).  
 
The biological function of many miRNAs to date are not known or are poorly understood. 
Studies among invertebrates have however, shown that miRNAs regulate a range of cellular 
processes including developmental timing (Lee et al., 1993) and neuronal differentiation in C. 
elegans (Johnston & Hobert, 2003), whilst cell proliferation has been shown in the bantam 
gene of Drosophila (Brennecke et al., 2003). In mammals, roles for miRNAs in embryogenesis 
and stem cell maintenance have been identified in mouse models (Bernstein et al., 2003), but 
computational biology has been largely relied upon to infer miRNA targets and functions, 
especially in humans (Liu et al., 2012). In addition, several studies have demonstrated 
deregulated expression of miRNAs in a wide range of diseases, including cancer. It remains 
unknown however, if this deregulated expression is a cause or consequence of pathogenesis.  
 
1.2  ROLE OF MIRNAS IN CARCINOGENESIS 
 
Cancer is a complex disease that involves an ongoing battle between oncogenes and tumour 
suppressor genes which is ultimately won by oncogenes. It is caused by the alteration of gene 
expression and structural abnormalities of both coding and non-coding genes (Calin & Croce, 
2006; Fabbri, 2013).  This altered gene expression is known to lead to uncontrolled cell 
proliferation, and it is becoming increasingly evident that miRNAs play a role in the 
development and pathogenesis of cancer. This statement can be supported by three 
observations. 
 
Firstly, the earliest miRNAs discovered in C. elegans and Drosophila were shown to control 
cell proliferation and apoptosis (Lee et al., 1993; Brennecke et al., 2003). Deregulation of these 
fundamental biological miRNAs have suggested that these regulatory molecules may 
contribute to proliferative diseases such as cancer.  
 
Secondly, the discovery of human miRNAs have been located at fragile sites in the genome or 
regions that were commonly amplified or deleted in human cancers. This is supported by the 
first genome wide location analysis of 186 miRNAs (Calin et al., 2004). It was reported that 
98 out of 186 (52.5%) miRNAs were located in cancer associated genomic regions or fragile 
sites, in minimal regions of loss of heterozygosity, regions of amplification and common 
 5 
breakpoint regions. Deregulated expression levels were further shown in conjunction with their 
location. These fragile sites were found to contain oncogenes and tumour-associated viruses 
that in turn would influence the development of cancer (Calin et al., 2004).   
 
Lastly, widespread deregulated expression of miRNAs was found in malignant tumour cell 
lines compared to normal tissue. The first comprehensive profile of cancers with miRNA 
expression analysis was conducted in 2006. A total of 540 samples were analysed which 
included 363 solid tumours from six malignancies compared to 177 normal tissue samples. It 
was found that 36 miRNAs were upregulated and 21 were downregulated, with several of these 
being well characterised miRNAs such as, miR-17-5p, miR-20a, miR-21, miR-92, miR-106a 
and miR-155 (Volinia et al., 2006). These observations together suggest a direct link between 
miRNAs and cancer of which evidence supporting their further roles are provided in the next 
section. 
 
1.2.1 OncomiR & tumour suppressor miRNAs 
The potential role of miRNAs in the development of cancer was found in early observations, 
however the first suggested direct link was only reported in 2002 by Calin et al., (2004) in B-
cell chronic lymphocytic leukeamia (B-CLL). Two miRNAs, miR15 and miR16 were found to 
be downregulated in the majority (68%) of cases when compared to normal tissue. Though the 
first profile of cancers with miRNA expression analysis was performed in 2006, significant 
deregulated miRNA expression was first shown in a variety of human cancers (breast, 
pancreatic and liver cancers and B-cell lymphoma), by Lu et al., (2005) in the previous year. 
Significant global reduction of miRNAs was observed when compared to normal tissues in this 
study. A total of 334 samples were analysed with particular interest in 217 mammalian 
miRNAs (Lu et al., 2005). Despite the significant finding, the question remained whether 
miRNAs were a cause or consequence of cancer. Evidence was later provided by Kumar et al., 
(2007) that miRNAs promoted tumourigenesis in lung cancer. Using knock out mice that 
contained the missing allele of the microprocessing enzymes, Drosha and Dicer, they were able 
to show that the mice had developed an increased tumour burden (Kumar et al., 2007). This 
supported earlier discoveries, that reduced let-7 expression was associated with lung cancer 
(Takamizawa et al., 2004) and that it was a negative regulator of the oncogene, RAS which is 
involved in cell growth, differentiation and survival (Johnson et al., 2005).  
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Subsequent studies thereafter began to identify miRNAs as having either an oncogenic 
(oncomiR) or tumour suppressor miR role (Volinia et al., 2006; Gaur et al., 2007). Gaur et al., 
(2007) revealed that miRNA expression correlates to cell proliferation indices, and therefore 
indicate that those miRNAs are important in regulating proliferation. They were able to identify 
a total of 145 miRNAs as either candidate oncomiRs or tumour suppressor miRs in four 
different cell lines. Although many studies have found miRNAs to be downregulated in cancer, 
miRNAs which are upregulated have also been found in many types of cancers. A key issue 
though, is the level of expression that can be considered biologically significant (Calin et al., 
2006). In addition, it has also been found that miRNAs can also regulate gene expression 
through other mechanisms such as through epigenetic factors, other non-coding RNAs, or by 
directly binding to proteins (transcription factors or receptors), and the triggering of cell signal 
transduction (Fabbri, 2013). Over the years it has also become apparent that miRNAs are tissue 
specific and may have more than one mRNA target (Zhou et al., 2013a). This suggests that a 
single miRNA may have multiple roles supporting further exploration into their biological 
function as an oncomiR or tumour suppressor miR depending on their gene target and tissue 
of origin (Esquela-Kerscher & Slack, 2006; Sand, 2014).  
 
1.2.2 Deregulation of miRNAs in lymphomas 
The deregulation of several miRNAs, and their target genes, has been associated with the 
development of lymphomas (Lawrie, 2012; Thapa et al., 2011; Farazi et al., 2013; Lim & 
Marra, 2013). Expression profiling studies of miRNAs have identified miRNAs that are 
associated with different types of B-cell lymphomas including Burkitt’s lymphoma (BL), 
Diffuse Large B-cell lymphoma (DLBCL) and Follicular lymphoma (FL) (Onnis et al., 2010; 
Bueno et al., 2011; Lenze et al., 2011; Robertus et al., 2010). Additionally, animal models 
further provides evidence for miRNA involvement in lymphomagenesis (Lawrie, 2012; 
Sandhu et al., 2013).  This has led to the recent identification of specific miRNA signatures for 
different types of B-cell lymphomas (Di Lisio et al., 2012; Lim & Marra, 2013).  
 
The dysregulation of miRNAs in the above cancers can be caused by several mechanisms, 
which range from copy number alterations to chromatin modifications (Lim & Marra, 2013). 
Translocations are a frequent cause which can result in the gain or loss of miRNA function 
(Calin et al., 2004). The disruption of miRNA expression patterns can also be caused by 
deregulation of transcription factor activity, such as MYC, seen in BL (Spender & Iman, 2014). 
Furthermore, disruption of Drosha and Dicer expression at the post-transcriptional level can 
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occur resulting in alterations at the miRNA biogenesis level (Lim & Marra, 2013). Lastly, viral 
infections can be associated with lymphomagenesis, such as the Epstein-Barr virus (EBV) and 
human immunodeficiency virus (HIV), which may lead to alteration in miRNA expression 
(Lim & Marra, 2013).    
 
1.3  HIV-ASSOCIATED LYMPHOMAS 
 
1.3.1 HIV and non-Hodgkin lymphoma 
An estimated 36.7 million people globally were living with HIV in 2016 with 1.1 million deaths 
attributed to AIDS-related illnesses (UNAIDS, 2016). Sub-Saharan Africa accounts for the 
bulk of this burden with 24.2 million (66%) infected people with South Africa bearing the brunt 
of the burden hosting an alarming 6.8 million people of the global total (UNAIDS, 2016). South 
Africa has the largest antiretroviral therapy (ART) programme for the treatment of HIV 
(Abayomi et al., 2011). The standard treatment is the combination of three or more 
antiretroviral drugs known as highly active antiretroviral therapy (HAART) (also known as 
combination ART) (Egger et al., 2002). Whilst HIV infects and destroys the host’s CD4+ T–
cells causing a loss of immune regulation leading to Acquired Immune Deficiency Syndrome 
(AIDS), a clear link between HIV and certain types of cancers has been identified which are 
described as HIV/AIDS-defining cancers.  
 
Non-Hodgkin lymphoma (NHL) in particular is a well defined HIV/AIDS associated disease 
and the risk of developing NHL increases by 60-165 folds (based on different reports, wehre 
the variation is dependent on the setting and the level of health care available) in HIV positive 
patients when compared with HIV negative patients (reviewed by Vishnu & Aboulafia, 2012; 
Bohlius et al., 2009; Cote et al., 1997). In addition, the types of NHL that affect HIV positive 
individuals are distinct from the types that affect the HIV negative population (Abayomi et al., 
2011) (Figure 1.2). Several factors have been implicated in the development of these particular 
cancers which not only include the dysregulated immune system but also the involvement of 
the tumour environment (Fowler & Saksena, 2013; reviewed by Grewal et al., 2015; Dolcetti 
et al., 2016), the late introduction of ART in developing countries, and the contribution of 
different strains of HIV to the type of lymphoma (Grewal et al., 2015). South Africa has the 
predominant strain subtype C which has the most immunosuppression associated lymphoma 
subgroups (Dietrich et al., 1993). 
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B-cells are a critical component of the adaptive immune system protecting the host from 
pathogens. Whilst HIV does not infect B-cells, studies have shown that HIV and/or its encoded 
proteins may induce polyclonal B-cell activation by indirect mechanisms (Schnittman et al., 
1986; Moir & Fauci, 2009; Perise-Barrios et al., 2012). B-cells can firstly be influenced by 
HIV-1 infected macrophages, dendritic cells and T-cells in the extranodal sites where NHL 
usually occurs (Schnittman, 1986; Sparano, 2001). They can also be prompted to overproduce 
stimulatory cytokines (reviewed by Epeldegui et al., 2010; Haij et al., 2015) that may result in 
B-cell activation via activation induced-cytidine deaminase (AID) associated DNA 
modification errors and oncogenic translocations (Huysentruyt & McGrath, 2010; Perise-
Barrios et al., 2012). Whilst the above evidence has been shown in vitro, they have also been 
observed in patients infected with HIV (Lane et al., 1983; Titanji et al., 2006; Moir & Fauci, 














Figure 1.2: The distribution of lymphoma in HIV negative and HIV positive populations.  
Certain lymphomas such as Burkitt’s lymphoma have an increased incidence in the HIV positive population 
(Reproduced from Abayomi f 2011). 
 
Patients living with AIDS have been shown to exhibit hyperimmunoglobulineamia, depletion 
of memory B-cells, and altered differentiation of naïve B-cells that could result in class switch 
recombination (CSR) of non specific immunoglobulins, supporting the indirect mechanisms 
promoted by the virus (Lane et al., 1983; Titanji et al., 2006; Moir & Fauci, 2009; Perise-
Barrios et al., 2012). Interestingly however, the immune systems of patients on HAART are 
not restored suggesting additional dysregulatory pathways of B-cells (Jacobson et al., 2002; 
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Abudulai et al., 2016). This evidence collectively has lead to the description and identification 
of several changes in B-cell subsets in association with HIV-1 plasmavireamia (Figure 1.3) 
(Moir & Fauci, 2009). These alterations include differences in cell surface markers during 
stages of B-cell differentiation in both the periphery and bone marrow but the mechanism 














Figure 1.3: Alterations in human B-cells induced by HIV-1.  
Cell surface markers differ during the stages of B-cell differentiation induced by HIV infection (Reproduced from 
Moir & Fauci, 2009). 
 
Consistent with the notion that an additional factor may be implicated in B-cell dysregulation, 
HIV-encoded viral proteins have provided some evidence for direct interference. For instance, 
HIV-1 Nef has been shown to be delivered into B-cells through interactions between the 
receptor CD21 and HIV-infected macrophages (Moir et al., 2000) and through the gp120 
proteins and dendritic cells (Swinger et al., 1999). This has been shown both in vivo and in 
vitro but the mechanism here once again is not clear. Later on, Perise-Barrios et al., (2012) 
confirmed the phenotypical dysregulation and activation of peripheral primary B-cells after 
direct HIV-1 contact. Further evidence was shown by Viau et al., (2007) using XenoMouse® 
mice models. In our lab this emerging idea is further supported whereby ectopic expression of 
Nef showed an increase in both oncogene, c-MYC and AID in lymphoma cultured cells 




As mentioned earlier, certain types of cancers are more prevalent in the HIV positive 
population (Figure 1.2). The two most prevalent HIV-associated NHLs, which differ in 
histology, molecular alterations, prognosis and treatment, are Diffuse Large B-cell lymphoma 
(DLBCL) and Burkitt’s lymphoma (BL). Both these lymphomas will be discussed further in 
the sections below.  
 
1.3.1.1 HIV-associated Diffuse Large B-Cell Lymphoma 
Accounting for more than 80% of lymphoma cases in the world, DLBCL is the most common 
form of NHL in the adult population (representing 30-40% of all NHLs) (Campo et al., 2011). 
Whilst it has a high incidence rate in the general population (40%) (Müller et al., 2005), 
amongst HIV positive patients it has an even higher prevalence rate of 50% with 80% of cases 
associated with the Epstein-Barr virus (EBV) (reviewed by Gloghini et al., 2013).  Affecting 
the B-cells, DLBCL represents a heterogeneous group of diseases comprising of different 
genetic abnormalities, molecular subgroups, clinical characteristics, therapy responses and 
prognoses. Histological studies have revealed DLBCL to present with large cells having 
vesicular nuclei, prominent nucleoli, basophilic cytoplasm and a high B-cell proliferation rate 
(Mazan-Mamczarz & Gartenhaus, 2013). The standard treatment for DLBCL consists of 
immunochemotherapeutic agents rituximab, cyclophosphomide, doxorubicin, vincristine and 
oral prednisone (R-CHOP) (Wang & Castillo, 2011). Based on molecular and genetic 
characteristics, three subtypes of DLBCL have been defined, namely germinal centre B-cell 
like (GCB), activated B-cell like (ABC) and primary mediastinal large B-cell lymphoma 
(PML-BCL) (Puvvada et al., 2013). These three subtypes differ significantly in their clinical 
outcome after treatment. A five-year survival rate of 59%, 30% and 64% has been reported in 
patients with GCB, ABC, and PML-BCL DLBCL, respectively (Lenz et al., 2008). 
 
Deregulated miRNAs have been shown to be associated with the pathogenesis, diagnosis, 
prognosis and potential treatment of DLBCL (Troppan et al., 2014). In addition, miRNAs have 
been described for the three subtypes mentioned above and reviewed extensively by Lim & 
Marra (2013), Zheng et al., (2016) and Ni et al., (2016) to name but a few. Examples of these 
deregulated miRNAs include miR-331-3p, miR-3934-3p, miR-589-5p, miR-210, miR-138-1-
3p for the GCB type and miR-221-3p, miR-92a-1-5p, miR-21-3p, miR155-5p for the non-GCB 
types (Lim et al., 2015). 
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1.3.1.2 HIV-associated Burkitt’s Lymphoma 
BL is an aggressive cancer that occurs relatively rarely in the general population, but has an 
increased frequency (200-1000 fold) (due to geographical location and age groups) (Muller et 
al., 2005) and an estimated 40% prevalence rate amongst HIV positive patients (Corti et al., 
2013; Gloghini et al., 2013). First described in African children by Dr. Dennis Burkitt, BL 
affects B-cells that express a germinal centre phenotype (Burkitt, 1958). Clinical 
representations include a high B-cell proliferative rate and extra-nodal tumours affecting the 
bones of the jaws and the abdominal area (Ziegler, 1982; Corti et al., 2013; Mangani et al., 
2013).  
 
As mentioned earlier, a compromised immune system (CD4 count < 200 cell/µL) and advanced 
stages of HIV have been associated with the development of NHL. However, the risk of 
developing BL in HIV infected patients has been found to be linked to a less immunodeficient 
status (CD4 counts of >200 cell/µL) (Corti et al., 2013; Gloghini et al., 2013). A competent 
immune system therefore seems to play a role in the development of this lymphoma (Donadoni 
et al., 2013). Also mentioned earlier, the introduction of HAART has reduced the incidence of 
NHL subtypes such as DLBCL amongst HIV positive individuals (Aboulafia et al., 2004). 
However, this has not been demonstrated for HIV-associated BL, especially in poorly 
resourced settings, where the cancer continues to progress unabated (Carbone & Gloghini, 
2005; Lim et al., 2005; Gloghini et al., 2013). The mechanisms for this is currently unknown 
and suggests that the pathogenesis of BL in HIV positive patients is unique and needs 
elucidation. 
 
Three variants of BL have been described namely, sporadic, endemic and HIV-associated. The 
sporadic variant affects any age group and is most often found in the western world. Endemic 
BL affects mostly children and is most commonly found in equatorial Africa, and is associated 
with malaria and EBV infection. The last type is associated with immunodeficiency, such as 
infection with HIV. Co-infection with EBV is found in more than 40% of cases but the hallmark 
of the disease for all variants is the translocation of the transcription factor, c-MYC to the 
highly active immunoglobulin heavy chain (IGH) locus, resulting in overexpression of this 
known oncoprotein (Figure 1.4) (Dang, 2012; Ott et al., 2013; Spender & Inman, 2014). 
 
As found in DLBCL, several miRNAs have also been shown to be deregulated in BL (Onnis 
et al., 2010; reviewed by Di Lisio et al., 2012). In a study that compared BL tissue with normal 
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lymph nodes, 43 miRNAs were found to be deregulated with 26 upregulated (miR-17-92 
cluster; miR-210; miR-575; miR-202) and 17 downregulated (miR-29b, let-7d, miR-155, miR-















Figure 1.4: Translocation of the c-MYC transcription factor (8;14) (q24;q25) as the most common translocation in 
Burkitt’s lymphoma.  
The translocation results in the overexpression of c-MYC that is involved in cell proliferation resulting in 
lymphoma development (Reproduced from Nossal, 2003).  
 
 
1.4  VIRUSES AND MIRNAS 
 
miRNA mediated gene silencing has been shown to play important roles in viral pathogenesis 
(Nathans et al., 2009; reviewed by Flor & Blom, 2016). This can be done by cellular miRNAs 
targeting viral RNAs or cellular RNAs that encode proteins necessary for promoting viral 
replication (Sun et al., 2011). In this way, the replication of viruses can be inhibited and latency 
ensues. This has been demonstrated for several viruses including the primate foamy virus type-
1, (Lecellier et al., 2005), the H1N1 Influenza A virus (Song et al., 2010) as well as the 
Hepatitis C virus (Jopling et al., 2005).  
 
Additionally, several viruses have been found to encode their own miRNAs, known as 
vmiRNAs, to regulate the host’s system (Bennasser et al., 2004; Harwig et al., 2014). For 
instance, herpes viruses have been shown to encode up to 35 distinct miRNAs which have roles 
in regulating cellular genes involved in cell cycle regulation, apoptosis and immunity 
(Grundoff & Sullivan, 2011). Among retroviruses only the bovine leukeamia virus has been 
shown to express miRNAs (Kincaid et al., 2012). This retrovirus was shown to encode a RNA 
polymerase III-transcribed miRNA cluster that is functionally similar to the human miR-29 
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which contributes to the development of B-cell tumours. It has been suggested that miRNAs 
expressed by RNA viruses have not been detected due to the fact that cleavage by Drosha leads 
to degradation of the pri-miRNA precursor, which in the case of most RNA viruses would 
likely be genomic RNA or viral mRNA (Skalsky & Cullen, 2010). Whilst recent deep 
sequencing technology has led to the discovery and identification of vmiRNAs and miRNA-
like sequences in HIV-1 infected T-cells (Yeung et al., 2009; Schopman et al., 2012; Holland 
et al., 2013), the miRNA coding potential of HIV remains controversial. 
 
Viruses have been shown to exploit host miRNAs by manipulating their expression to their 
own advantage to transform cells. For instance, the herpes virus saimiri (HVS) has been shown 
to express a non-coding RNA (ncRNA) which degrades cellular miR-27, and this is linked to 
the transformation of T-cells (Guo & Steitz, 2014). Cellular miR-197 was found to be 
downregulated in EBV-positive BL tumours compared to EBV-negative BL tumours, 
predicted to regulate BCL6 which is implicated as a key regulator of B-cell differentiation 
(Ambrosio et al., 2014). In this study, miR-127 was overexpressed by the EBV encoded nuclear 
antigen 1 (EBNA1) leading to impaired B-cell differentiation and possibly responsible for 
lymphoma development. EBV also upregulates miR-155, an oncogenic miRNA (Yin et al., 
2008).  
 
1.4.1 HIV and miRNAs 
The first report of a potentially HIV encoded miRNA was in 2004 using computer algorithms 
(Bennasser et al., 2004), and was later confirmed by other groups (Omoto & Fujii., 2005; 
Pfeffer et al., 2005; Whisnant et al., 2013; Klase et al., 2013). The miRNA, MiR-TAR 
promotes HIV-1 persistence (Klase et al., 2013), whilst Kaul et al., (2009) identified hiv1-mir-
H1 that was found to suppress c-MYC and downregulate cellular miR-149 that targets the HIV 
viral protein, Vpr. Another HIV encoded miRNA was identified namely miR-H3 (Zhang et al., 
2014) whilst vmiR88 and vmiR99 where found in the sera and exosomes of HIV-1 positive 
individuals (Bernard et al., 2014). Along with Vpr mentioned above, HIV-1 seems to regulate 
its own replication by using nef miRNA, Nef-U3-miR-N367 (Omoto et al., 2004). Other 
potential vmiRNAs have been found to be similar in sequence to cellular miR-195, miR-30d, 
miR-30e, miR-374a and miR-424 (Holland et al., 2013). These vmiRNAs together may 
represent therapeutic strategies to limit progression to AIDS but warrants further investigation.  
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1.4.2 Modulation of cellular miRNAs by HIV 
It has been proposed that HIV can modulate the expression of cellular miRNAs to promote its 
replication (Yeung et al., 2005; Triboulet et al., 2007) and contributes to HIV-1 latency in 
primary CD4+ T-cells. Some of these cellular miRNAs include miR-28, miR-125b, miR-150, 
miR-223 and miR-382 (Huang et al., 2007) that target the 3’UTR of HIV-1 transcripts 
promoting productive infection towards latency. Furthermore, the knockdown of several 
miRNA processing pathway proteins including Dicer, Drosha and DGCR8 were shown to 
increase viral replication (Benasser & Jeung, 2006). There is also evidence to suggest that the 
HIV-1 encoded protein Tat can act to suppress the miRNA processing system (Benasser & 
Jeung, 2006). In addition, HIV-transcripts were shown to be co-localised with the RNA 
interference pathway effector proteins in P-bodies (Nathans et al., 2009).  
 
Work by Munshi et al., (2014) further suggests that miRNA expression can be predicted for 
HIV disease progression and therapy. They compared miRNA expression in peripheral blood 
mononuclear cells (PBMC) between healthy and HIV-1 infected individuals and found high 
levels of cellular miR-150 and miR-146b-5p to be a predictor of increased disease progression. 
Further studies have also identified an association between HIV-1 vireamia and cellular 
miRNAs (Ma et al 2014; Farberov et al., 2015; Monteleone et al., 2015).  Specific miRNA 
signatures for four classes of HIV-1 based on their CD4+ T-cell counts and viral loads were 
found in early 2008 by Houzet et al. They reported an overall general downregulation of most 
of the miRNAs in vivo (Houzet et al., 2008). Recently, the miR-29 family was found to 
influence the clinical progression of the infection. When the miRNAs levels in HIV positive 
patients were compared with HIV negative patients, a significant upregulation was found 
(p<0.001) (Monteleone et al., 2015). 
  
What has been a contested topic is understanding why some patients infected with HIV-1 are 
able to maintain a viral load below the limit of detection, known as elite controllers (EC) 
(Witmer et al., 2012; Seddiki et al., 2013; Reynoso et al., 2014; Egana-Gorrono et al., 2014). 
Understanding the mechanisms behind this may be able to provide diagnostic and prognostic 
value. Reynoso et al., (2014) showed that 16 miRNAs were differentially expressed in vitro 
between the plasma of chronically HIV infected patients compared to healthy donors. 
However, specifically miR-29b-3p and miR-33a-5p were found to be overexpressed in EC in 
MT2 and primary CD4+ T-cells and was associated with reduced viral production. In addition, 
Zhu et al., (2012) showed that six out of a set of 18 miRNAs were significantly related to CD4 
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T-cell count decline as an indicator for identifying the outcome of HIV disease at the chronic 
stage. 
 
In contrast, increased virion release was observed upon upregulated miRNA levels of let-7c, 
miR-34a and miR-124a that was associated with a downregulation of p21 in HeLa-CCR5 cells. 
This downregulation of p21 was also found to be associated in a recent study with the 
overexpression of miR-106b and miR-20 (Guha et al., 2016) whilst miR-9 induced B-
lymphocyte induced maturation protein 1 (BLIMP-1) repression indicative of progressive 
HIV-1 infection (Seddiki et al., 2013).  
 
To date Sun et al., (2011) has reported the first comprehensive miRNA microarray analysis of 
in vitro HIV-1 infected CD4+ cells with several cellular miRNAs found to be downregulated 
(miR-29a/b; miR-155, miR-21) and miR-223 being upregulated. However, though it is widely 
accepted that HIV does not play a direct oncogenic role in HIV-associated cancers, emerging 
evidence in HIV-associated Karposi Sarcoma (KS) has contested this supporting role of HIV 
in promoting the progression and initiation of KS through several mechanisms. Of these, HIV-
1 Nef and the oncogene Karposi Sarcoma Herpes Virus (KSHV) K1 was demonstrated to 
synergistically promote angiogenesis by inducing miR-718 to regulate the PTEN/AKT/mTOR 
signalling pathway (Xue et al., 2014). Furthermore, Yan et al., (2014) recently showed that 
HIV-1 Vpr upregulated miR-942-5p that directly targets IκBα whilst HIV-1 Tat was shown to 
promote KSHV vIL-6-induced angiogenesis and tumourigenesis by regulating the 
PI3K/PTEN/AKT/GSK- 3β signalling pathway (Zhou et al., 2013b). 
 
The findings discussed above provide the first insights into an emerging potential role for HIV 
in modulating cellular miRNAs in the context of cancer, more specifically, NHLs. Research is 
limited in this area with a few recent reviews discussing the possibility of the role of miRNAs 
in the pathogenesis of HIV associated NHLs (Klase et al., 2012; Swaminathan et al., 2013; 
Grewel et al., 2015) but further validation is required in larger cohort sizes with detailed in 
vitro analyses at the molecular level.  
 
1.5  RATIONALE 
 
Currently, miRNAs have been suggested as serum biomarkers (Di Leva et al., 2014; Manterola 
et al., 2015) for prognosis and diagnosis of cancers as well as predictors of treatment outcomes 
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(Shepshelovich et al., 2015; Ni et al., 2016). The development of novel and more targeted 
anti-cancer therapies by exploiting the involvement of miRNAs in cancer is promising 
(Vasilatou et al., 2009). Two possible scenarios can be forecasted in the near future where 
miRNAs can be used as treatment to target oncogenes or drugs can be developed to target 
those miRNAs which affect tumour suppressor genes. Already, pharmaceutical companies are 
exploring miRNA based therapy and a few miRNAs have entered preclinical and clinical stage 
of testing (Christopher et al., 2016). 
 
As mentioned earlier, recent evidence suggests that HIV proteins and miRNAs may have a 
direct role for the development of HIV-associated malignancies such as DLBCL and BL. In 
light of the findings linking HIV-1 and cellular miRNA modulation, it is predicted that one of 
the mechanisms for the development and/or progression of lymphoma in HIV positive 
individuals is via the modulation of miRNAs in B-cells (Curreli et al., 2013). Based on 
literature, we have constructed a venn diagram in Figure 1.5 to align those miRNAs that are 
differentially expressed in DLBCL and BL. We have then overlapped these miRNAs within 
each disease and then with HIV. Collectively we hope to identify a miRNA signature for HIV-
associated DLBCL and BL which can contribute towards identifying dysregulated cellular 
pathways. This will aid in our understanding of the HIV and miRNAs link to potentially 




















Figure 1.5: Venn diagram representing the overlap of differentially expressed miRNAs identified in DLBCL and BL 
with the possible association in HIV-associated NHLs.  
Several miRNAs have been implicated in the pathogenesis of BL and DLBCL as well as associated with HIV 
infection. The smaller circles represent the overlap between DLBCL, BL and HIV respectively whilst the diamond 
shape represent the overlap of all three diseases. These miRNAs could be predicted in the pathogenesis of HIV-
associated B-cell NHL, BL and DLBCL.  
BL – Burkitt’s lymphoma; DLBCL – Diffuse large B-cell lymphoma; HIV – Human Immunodeficiency Virus; 
miRNA – microRNA; NHL – non-Hodgkin’s lymphoma.  
 
References: Sampson et al., (2007); Chang et al., (2008); Leucci et al., (2008); Malumbres et al., (2009); Imig et 
al., (2010); Jima et al., (2010); Robertus et al., (2010); Bueno et al., (2011); Sun et al., (2011); Di Lisio et al., 
(2012); Forte et al., (2012); Witmer et al., (2012); Chiang et al., (2013); Seddiki et al., (2013); Egana-Gorrono et 
al., (2014); Reynoso et al., (2014); Zhu et al., (2014); Guha et al., (2016) 
 
 
1.6  AIMS & OBJECTIVES 
 
The aim of this project was to identify and characterise miRNAs involved in the pathogenesis 
of HIV-associated non-Hodgkin’s lymphoma. Previous research in our laboratory had found 
that B-cells derived from healthy individuals respond differently to cancerous cells when 
exposed to components of HIV, such as Tat and Nef. Therefore, in this project, the response 
of both types of cells was investigated. Following identification of differentially expressed 
miRNAs, selected miRNAs and their predicted or confirmed targets were further 
characterised. This project ultimately aimed to identify cellular miRNAs whose expressions 
are altered by HIV and which could potentially contribute to the development or progression 
of HIV-associated lymphomas. The objectives of the project were as follows: 
 
• To identify miRNAs that are differentially expressed in human B-cells exposed to HIV, 
compared to microvesicle treated control cells by utilising a miRNA microarray  
• To validate selected miRNAs by performing qPCR using single-tube TaqMan® 
miRNA assays 
• To identify putative mRNA gene targets of a selected miRNA identified in Aim (i) by 
using prediction programmes, confirm its potential target by qPCR and western blotting 






CHAPTER 2: MATERIALS & METHODS 
___________________________________________________________________________ 
 
2.1  TISSUE CULTURE 
 
2.1.1 Cell lines and storage 
Two suspension cell lines were used, namely a human B–cell line L1439A, immortalised using 
EBV which has been derived from a healthy individual (produced at the University of Cape 
Town by Ms Ingrid Baumgarten, Division of Chemical Pathology, using an adapted protocol 
by Freshney, 2010),  and the well established Burkitt’s lymphoma cell line Ramos (an Epstein-
Barr virus negative human B-cell line originally established from a Caucasian male diagnosed 
with Burkitt’s lymphoma) purchased from the American Type Culture Collection, (ATCC®, 
Virgina, USA). Cells were cultured and exposed to aldrithiol – 2.2 dithiopyridine (AT-2) 
inactivated HIV-1 X4/R5 virus. Cells that were left untreated, as well as treated with matched 
microvesicles served as controls. Both cell lines were cryopreserved with dimethyl sulfoxide 
(DMSO)/ glycerol and stored in liquid nitrogen until they were ready to be used.  
 
2.1.2 Cell thawing, expansion & freezing 
Following the culture conditions recommended by the creator of the cell lines, one vial of 
cryopreserved cells (Ramos (ATCC®, Virginia, USA)/L1439A (Freshney, 2010)) was 
removed from the liquid nitrogen stores and was thawed at room temperature. Once the vial 
was thawed (by hand for Ramos and at 37°C for L1439A) it was cleaned with 70% ethanol 
(EtOH) (Appendix A) and placed under the Biosafety Level two tissue culture fume hood. 
Prior to thawing, complete growth media was prepared using Roswell Park Memorial Institute 
(RPMI) media (Sigma-Aldrich, Missouri, USA) for Ramos cells and Dulbecco’s Modified 
Eagle Medium (DMEM) (Sigma-Aldrich, Missouri, USA) for L1439A cells, fetal bovine 
serum (FBS) and a penicillin/streptomycin (P/S) solution.  
 
Once all reagents were brought to room temperature, they were sterilised with 70% EtOH and 
placed under the fume hood. The complete growth media was prepared using RPMI (Ramos) 
and DMEM (L1439A), FBS (10% for Ramos; 20% for L1439A), and 1% P/S in a 50 mL 
Falcon tube (Appendix A). Upon completion, 5 mL of the growth media was added to a T25 
flask and placed in the CO2 incubator (5% CO2, at 37°C) to warm up and 4 mL of the media 
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was placed in a 15 mL Falcon tube. The contents of the cryovial were then added to this Falcon 
tube which was then centrifuged (MSE, London, UK) at 1000 revolutions per minute (rpm) 
for five minutes to remove the toxic DMSO/glycerol from the cells. Thereafter the supernatant 
was removed and the pelleted cells were resuspended in 1 mL of the warm media from the 
T25 flask that was in the incubator. The cells were then transferred to the T25 flask with the 
remainder of the warm media (4 mL) and placed back in the incubator to expand. 
 
Cells were maintained and expanded by the addition of fresh growth media (1-2 mL) every 
two to three days upon colour change of the media (Ramos: salmon to yellow; L1439A: red 
to orange) with depopulation occurring as required. These cells were counted and found to 
grow best at a density between 2 X 105 and 1 X 106 viable cells/mL and once the volume 
exceeded 20 mL in the T25 flask, the cells were transferred to a T75 flask.  
 
Cells were transferred to 15 mL Falcon tubes (10 mL in each) for freezing purposes which 
were centrifuged at 1000 rpm for 10 minutes (MSE, London, UK) with the removal of the 
supernatant thereafter followed by resuspension in 1 mL of freezing media. The freezing 
media was prepared in advance using RPMI/DMEM medium (Sigma-Aldrich, Missouri, 
USA), 10%/20% FBS and 10% DMSO/glycerol (enough to create a cell suspension of 1 X 
106 cells/mL) and was left on ice. Upon resuspension the cell suspension was added to each 
cryovial which were placed in a freezing container at -80°C overnight containing isopropanol 
to achieve a rate of cooling close to 1°C/minute. The isopropanol allows the process of slowly 
freezing the cells ensuring that fewer crystals are formed (Thermo Fisher Scientific™, 2010). 
The cryovials were then placed in liquid nitrogen the following day for long term storage. 
 
2.1.3 Mycoplasma testing 
Cells were tested for Mycoplasma contamination by plating cells (1 X 106 cells/mL) in P/S free 
culture medium for a minimum of three days in a 35 mm tissue culture dish to allow for any 
Mycoplasma present to proliferate to a detectable level (Chen, 1977). Approximately 3 µL of 
the suspension was placed directly onto a clean microscope slide and air dried until the film of 
cells were dried, fixed for two minutes by adding enough fixative (Appendix A) to cover the 
cells, washed with H2O and then stained with Hoechst 33342 stain (#H1399, Invitrogen, 
California, USA) (Appendix A) for eight minutes. The stain was then washed off with H2O 
and the cover slip placed onto the slide with a drop of mounting fluid (Appendix A). The cells 
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were then visualised using a fluorescent microscope at a magnification of 40x (Zeiss Axiovert 
200M, Carl Zeiss Microimaging, Germany).   
 
The principle behind the Hoechst stain is that it binds to all nuclear material and a positive 
Mycoplasma result will be indicated as fluorescent dots on the cellular membrane and in the 
cytoplasm of the cells. A negative result will have only the nucleus of the cell staining positive 
(Young et al., 2010).  
 
2.1.4 Cell treatment 
To enter its host cell and replicate effectively, HIV utilises two chemokine receptors, CCR5 
and CXCR4 (Moore et al., 1997). For the current project the HIV-1NL4-3 and HIV-1BAL dual 
based CXCR4-tropic (X4) and CCR5 (R5) viruses were utilised since both chemokine 
receptors are expressed on B-cells (Nie et al., 2004). The mild oxidising agent, AT-2 which 
has the ability to eliminate the infectivity of HIV, was used to modify the virus so that it was 
safe to handle in the laboratory. The AT-2 preferentially covalently modifies free sulfhydryl 
groups of the cysteines of internal virion proteins, particularly the nucleocapsid proteins 
(Rossio et al., 1998). In conjunction, it maintains the structural and functional integrity of the 
envelope glycoproteins on the surface of the virus. Therefore, the AT-2 inactivated virions are 
non-infectious and are able to interact with cell surface receptors. This system was first 
developed as a promising candidate vaccine, but is also useful and safe for use experimentally 
in the laboratory. Regardless, the cell treatments were carried out in a certified Biosafety Level 
two tissue culture facility for optimum safety. Although the virus preparations are highly 
purified, they do contain some non-virion material in the form of microvesicles (Rossio et al., 
1998). These microvesicles which were isolated from the supernatants of uninfected cell 
cultures in a manner identical to that used for virus preparation from infected cells was used 
as matched controls. AT-2 inactivated virions (HIV-1NL4-3 and HIV-1BAL; lot P4244) and 
matched control microvesicles (SUPT1-CCR5 (MV-CCR5; lot P4287) were kindly donated 
by Professor Jeff Lifson (and Dr. Wendy Burgers, Medical Virology, UCT) who pioneered 
the development of this method, through the Biological Products Core of the AIDS and Cancer 
Virus Program (Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, 
MD, USA).  
 
Once the amount of cells that was required was expanded (40 mL), the cell suspension was 
placed in 15 mL Falcon tubes (10 mL per tube) and was centrifuged at 1000 rpm (MSE, 
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London, UK). The supernatant was thereafter removed and resuspended in fresh medium. 
After the solution was mixed gently by resuspension, 10 µL was used for cell counting using 
a haemocytometer. A haemocytometer was used to determine the viable cell count number of 
both miRNA expressing and control cells for HIV-1 AT-2 treatment. Briefly, the cells present 
in a known volume were counted within four 1 mm2 squares and then the value was converted 
to a number per mL. 
 
For the treatment, cells (8 x 106/mL) were plated in 35 mm wells approximately 16 hours prior 
to treatment in low serum medium (0.5% FBS) (Appendix A). Three wells of cells were treated 
with 500 ng/mL of AT-2 inactivated HIV-1 or with the equivalent amount of microvesicle 
control or left untreated (Martinson et al., 2007), for a period of three hours (Guo et al., 2014). 
Each treatment was performed in triplicate and was covered with foil to prevent evaporation 
and influence by external variables.  
 
2.1.5 Viability assay 
To verify that the cells would remain viable after the three hour treatment, a viability assay 
was conducted for both cells using WST-1 (Roche Applied Science, Penzberg, Germany). The 
WST-1 reagent is designed to quantify cell viability spectrophotometrically. The reagent 
contains tetrazolium salts which are cleaved to formazan dye in the presence of cellular 
enzymes produced by metabolically active cells. The more salt that is cleaved, the great the 
colour change which indirectly indicates the viability of the cells (Riss et al., 2013). Viable 
cells were counted as above by use of a haemocytometer and plated in a 96 well plate followed 
by treatment with HIV-1 AT-2 virions in low serum media (Appendix A) for three hours. After 
exposure was completed, 10 µL of WST-1 reagent was added to the wells, covered with foil 
and then left to incubate for a further two hours (5% CO2 at 37°C). Upon completion, the 
absorbance of the samples was measured against a background control as a blank using a Glo-
Max®-Multi+ multiplate reader (Promega, Wisconsin, USA) at a wavelength between 420-
480 nm.  
 
2.2  RNA EXTRACTION & QUANTIFICATION  
 
2.2.1 RNA extraction for miRNA PCR array 
Prior to working with RNA, the surface of working areas and reagents were wiped thoroughly 
with Decon (Thermo Fisher ScientificTM, Massachusetts, USA) and 70% EtOH followed by 
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using plasticware that was treated with 0.1% diethyl pyrocarbonate (DEPC) treated water 
(Appendix A). These preparations were performed in order to effectively remove any existing 
RNAses. Following treatment, the cells were harvested from the plate and placed in 15 mL 
Falcon tubes. Remaining cells were removed by rinsing the wells with cold 1X phosphate-
buffered saline (PBS) (Appendix A). The tubes were then centrifuged at 1000 rpm (MSE, 
London, UK) with the supernatant removed followed by resuspension in 1 mL cold 1X PBS 
and transfer into 1.5 mL centrifuge tubes. These tubes were thereafter centrifuged at 4°C for 
10 minutes at 2000 rpm (Beckman, California, USA). 
 
Extraction was performed using the mirVanaTM miRNA Isolation kit (Thermo Fisher 
ScientificTM, Massachusetts, USA) for total RNA isolation as per the protocol. This kit uses a 
three step procedure involving both organic and solid-phase extraction techniques to isolate 
high yields of pure RNA. Briefly, the cells were lysed by the addition of 600 µL of lysis/binding 
solution and was vortexed to obtain a homogenous lysate. Thereafter organic extraction was 
performed that included the addition of 30 µL of miRNA homogenate additive to the cells. The 
solution was mixed well by vortexing and left on ice for 10 minutes. A volume of 600 µL of 
acid-phenol: chloroform was added to the tubes followed by vortexing for 60 seconds to mix. 
The tubes were then centrifuged for five minutes at 10 000 rpm at room temperature to separate 
the aqueous and organic phases. On completion, the aqueous phase was transferred to a new 
1.5 mL tube with the addition of 100% EtOH before the lysate was passed through a filter 
cartridge. The mixture was passed through the filter by centrifuging the tubes for 15 seconds 
at 10 000 rpm (MSE, London, UK). Thereafter the flow-through was discarded and the step 
repeated until the lysate was passed through the filter. The wash solutions were then added 
separately to the filter cartridges, centrifuged for 10 seconds each with the flow-through 
discarded. Finally, the filter cartridges were added to a collection tube, spun for 30 seconds to 
elute the RNA with 15-18 µL of nuclease-free H2O (Thermo Fisher ScientificTM, 
Massachusetts, USA). The RNA was then quantified before storage at -80°C.  
 
2.2.2 RNA extraction for single-tube TaqMan® PCR assays  
The High Pure RNA Isolation Kit (Roche Applied Science, Penzberg, Germany) was used for 
total RNA extraction of cells, according to the manufacturers protocol. Briefly, cells were 
placed in a 1.5 mL Falcon tube and washed using 200 µL of 1X cold PBS. Thereafter 400 µL 
of lysis buffer was added to the cells and the tube was vortexed for 15 seconds. The cells were 
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then transferred into a High Pure Filter Tube and then placed into the collection tube. These 
tubes were then centrifuged for 15 seconds again at 8000 x g (Beckman, California, USA) The 
flow through was discarded and the RNA in the filter was treated with a DNase I treatment 
provided in the kit for 15 minutes at 25°C. Thereafter the filter was washed with 500 µL of 
Wash Buffer I. This step was repeated twice, first using 500 µL and then with 200 µL of Wash 
Buffer II. These were centrifuged for two minutes at 13 000 x g to remove all excess wash 
buffer (Beckman, California, USA). RNA was then eluted using 100 µL of elution buffer. The 
RNA was then quantified before storage at -80°C.  
 
2.2.3 RNA quantification 
Extracted RNA was quantified by two techniques, firstly by using the NanoDrop ND-1000 
Spectrophotometer (Thermo Fisher ScientificTM, Massachusetts, USA) and secondly by the 
QubitTM RNA Assay kit (Invitrogen, California, USA) as recommended by the manufacturer’s 
protocol. NanoDropTM analyses consists of spectrophotometrically determining the 
concentration of nucleotides in the samples as well as sample contamination by using 260/280 
and 260/230 ratios as a measure of sample purity. Briefly, 1 µL of each sample was analysed 
on the NanoDropTM using nuclease-free H2O (Thermo Fisher ScientificTM, Massachusetts, 
USA) as a blank between sample purity check. The QubitTM RNA Assays on the other hand is 
a more specific technique (Invitrogen, 2010) in detecting RNA that consists of a fluorescent 
dye that intercalates only with RNA present in the samples. Briefly, the QubitTM working 
solution was set up by diluting the QubitTM RNA reagent in a ratio of 1:200 in QubitTM RNA 
buffer. The working solution (190 µL) was then added to each of two 0.5 mL PCR tubes for 
the standards and the same amount for the individual RNA samples. Thereafter 10 µL of each 
QubitTM standard was added to the appropriately labelled standard tube and mixed by vortexing 
for two-three seconds without creating any bubbles. The RNA samples (10 µL) was then added 
to each individual assay tube and also mixed by vortexing for two-three seconds as before. All 
tubes were then allowed to incubate at room temperature for two minutes followed by 
quantification using the QubitTM 2.0 Fluorometer for RNA as per the manufacturer’s protocol.  
 
2.2.4 Gel electrophoresis of RNA samples 
To verify the integrity of the RNA samples, 1 µg of total RNA for each sample was separated 
on a 1% agarose gel. Prior to separation, the apparatus was treated with DEPC-treated H2O and 
~10% sodium hypochlorite for three hours preventing RNA degradation. Samples were 
prepared in DEPC treated RNase free dH2O with 5 µL of 2X RNA loading buffer (Appendix 
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A) in a total volume of 15 µL and denatured by heating at 55°C for five minutes. The samples 
were then briefly centrifuged and loaded onto an agarose gel containing ethidium bromide 
(EtBr) (0.5 µg/mL) using 1X Tris/Borate/EDTA buffer (Appendix A). The gel was 
electrophoresed at 100 volts/cm for 35 minutes and then visualised with an ultraviolet (UV) 
trans-illuminator (Uvitec, UK). 
 
2.3  ETHANOL PRECIPITATION USING AMMONIUM ACETATE 
 
The RNA for downstream differential expression of miRNAs using the microarray was 
concentrated using Ammonium Acetate which reduces the co-precipitation of oligosaccharides 
(Osterburg et al., 1975) (Figure 2.1). Briefly, 100% EtOH (2.5 volumes) was added to each 
RNA sample with 2.5M ammonium acetate (0.1 volumes). The samples were then incubated 
on ice for an hour followed by centrifugation at 12,000 x g for 30 minutes at 4°C (MSE, 
California, USA). The supernatant was thereafter discarded and the tubes were left to air dry 















2.4 TAQMAN® QUANTITATIVE REAL-TIME PCR LOW DENSITY ARRAY 
 
A comparative and comprehensive profiling analysis of miRNA expression was performed, 
using the Applied BiosystemsTM, custom 192a TaqMan® Quantitative real-time PCR low 
density array (TLDA) card (#4346802). This custom TaqMan® miRNA array platform 
(Applied BiosystemsTM, California, USA) was chosen and designed, as it was best suited in 
establishing a preliminary list of a number of differentially expressed miRNAs of interest for 
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the study. The 192a-card format was used, with each chosen miRNA target pre-spotted in 
duplicate on a 384 well plate array. 
 
The miRNAs contained within our customised array were chosen based on extensive literature 
searches focusing on differential expression studies of miRNAs in B-cell lymphomas (Lawrie 
et al., 2008; Lenz et al., 2008; Onnis et al., 2010; Robertus et al., 2010; Jima et al., 2010; 
Bueno et al., 2011; Lenze et al., 2011; Di Lisio et al., 2012). These reviews were then cross 
referenced with the available TaqMan® Assay Inventory pre-designed assays which are 
available for spotting onto the array card from Life Technologies, Applied BiosystemsTM. 
Additionally, online database resources such as miRBase (http://www.mirbase.org) and current 
literature were used to verify the number of mature miRNA sequences for an individual 
miRNA, as well as their target sequences. This comprehensive analysis resulted in 191 mature 
miRNAs including controls (RNU6B, RNU48, RNU44) (Malumbres et al., 2009; Linda et al., 
2010; Forte et al., 2012) (Appendix B –Table B1) which were then populated onto a Microsoft 
Excel spreadsheet for the array to be designed by the company. The custom TaqMan® miRNA 
array is a uniquely designed microfluidic card with 192 targeted miRNAs fitted with a reservoir 
of eight ports for loading.  It employs a novel target-specific stem loop reverse transcription 
primer that extends the 3’ end of the target to produce a template that can be used for 
quantification using real time PCR (qPCR) (Figure 2.2). The primer sequences for the 













Figure 2.2: Schematic overview of cDNA conversion from miRNA employing the unique stem-loop primer design  
(Reproduced from Chen et al., 2005). 
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Table 2.1: Primer sequences for endogenous controls 
snRNA – small nucleolar RNA 
 
 
2.4.1 Reverse transcription using custom multiplex stem-loop primers 
The first step involved in using the custom 192a TaqMan® miRNA array is to convert RNA 
into cDNA by reverse transcription (RT) using a custom pool of multiplex stem-loop primers 
(Appendix B – Table B2). These primers enable specific, efficient and simultaneous synthesis 
of single stranded cDNA for mature miRNAs from total RNA samples together with the 
TaqMan® miRNA Reverse Transcription kit (Applied BiosystemsTM, California, USA). The 
Ramos cell line was cultured and treated followed by RNA isolation. Briefly, the RT master 
mix was set-up (without preamplification) as stated in Table 2.2 in RNase free 1.5 mL 
centrifuge tubes. Prior to combination of solutions, the reagents were thawed on ice followed 
by set-up and thereafter centrifuged briefly (Beckman, London, UK). This mixture was then 
pipetted (4.5 µL) into DEPC treated PCR tubes with the addition of 3 µL of total RNA (350 
ng/µL). The samples were thereafter spun down and then incubated on ice for five minutes.   
 
Table 2.2: Components for the TaqMan® miRNA reverse transcription kit 
Reagent Volume (µL) 
Megaplex RT primers (10X) 0.80 
dNTPs with dTTP (100 mM) 0.20 
MultiScribe Reverse transcriptase (50 U/ µL) 1.50 
10X RT Buffer 0.80 
MgCl2 (25 mM) 0.90 
RNase Inhibitor (20 U/ µL) 0.10 
Nuclease-free water 0.20 
Total Volume 4.50 













The RT reaction was then run on the Applied BiosystemsTM 7900HT Real Time PCR (Applied 
BiosystemsTM, California, USA) with the following thermal cycling conditions outlined in 
Table 2.3 below (as per manufacturer’s protocol). Reaction tubes with cDNA were thereafter 
stored at -20°C until used for qPCR. 
 










2.4.2 Quantitative real-time PCR 
The second step involved in comparative miRNA analysis by microarray includes quantifying 
the RT product by qPCR. In this step the DNA polymerase from the TaqMan® Universal PCR 
Master Mix kit (No AmpErase®, UNG 2X) (Applied BiosystemsTM, California, USA) 
amplified the target cDNA using specific sequenced primers and probes on the TaqMan® 
miRNA microarray. The presence of this target is detected in real time through cleavage of the 
TaqMan® probe by the polymerase 5’ to 3’ exonuclease activity (Figure 2.3). Briefly, the 
qPCR reaction mix was set-up as stated in Table 2.4 in a 1.5 mL centrifuge tube for one array. 
A total of 100 µL was loaded into each port of the array followed by sealing, centrifuged at 
1200 rpm for two minutes (Eppendorf 5804, Hamburg, Germany) and then removal of the 
reservoir ports before loading onto the 7900HT Real-Time PCR System (Applied 
BiosystemsTM, California, USA) as per the manufacturer’s protocol (Table 2.5). A total of nine 










Stage Temp Time 
40 cycles 
16.0°C 2 min 
42.0°C 1 min 
50.0°C 1 sec 
Hold 85.0°C 5 min 
















Figure 2.3: Schematic overview of the TaqMan® probe-based assay chemistry  (Reproduced from 
http://www.lifetechnologies.com). 
 
Table 2.4: Components for qPCR in comparative miRNA analysis 
Reagent Volume (µL) 
TaqMan® Universal                      
PCR Master Mix 450.00 
RT Product 6.00 
Nuclease free water 444.00 
Total Volume 900.00 
 
Table 2.5: Cycling conditions for qPCR in comparative miRNA analysis 
Stage Temp Time Cycle 
Denaturation 94.5°C 10 min 
37 Cycles Annealing 97.9°C 5 sec 
Extension 59.7°C 45 sec 
 
2.4.3 Data Analysis 
Data and statistical analyses was conducted by a biostatistician, Dr. Wendy Kröger, from the 
Centre for Proteomic and Genomic Research (CPGR). The Ct values generated from the 384 
well plates (one plate per sample) were analysed with Bioconductor’s HTqPCR package 
(Dvinge & Bertone, 2009) in R (R Development Core Team, 2013) to determine differentially 
expressed miRNAs in the B-cell cancer cell Ramos treated with HIV-1 AT-2 compared to 
microvesicle treated controls. The quality of the raw data was assessed and normalised. The Ct 
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values are measured as the cycle number at which point the curve intersects a fluorescence 
threshold (set to exceed baseline noise). The amount of target template contained within a 
sample is therefore inversely proportional to the Ct value, i.e. lower Ct values are indicative of 
a large amount of target present and vice versa. In general, Ct values of below 29 are 
characteristic of strong positive amplifications suggesting abundant target molecule present in 
the sample. Those Ct values of between 30 and 37 are indicative of positive reactions 
characterising moderate levels of target molecule present in the sample. Ct values of above 38 
are characteristic of weak amplification suggesting minimal amounts or lack of target molecule 
present within the respective sample. 
 
Statistical analyses was conducted using student t-tests to determine significant differences 
between the treated samples and microvesicle treated controls. Significance was determined 
by using the Benjamini-Hochberg false discovery rate corrected for multiple testing (Benjamini 
& Hochberg, 1995) that was adjusted to p< 0.06. Given the limitation of the software 
mentioned above in being unable to eliminate failed replicates and samples with high Ct values, 
data was manually analysed. Each amplification plot was viewed using RQ Manager (Applied 
BiosystemsTM, California, USA) whereby the baseline and threshold values were set (account 
for noise) and failed replicates or replicates with high Ct values noted above were excluded. 
The data was then exported into the DataAssistTM software (version 3.01) (Applied 
BiosystemsTM, California, USA) to generate the Ct values for each replicate. miRNAs that 
exhibited a fold change of two or more were selected for further analysis.  
 
2.5  MIRNA SINGLE-TUBE TAQMAN® PCR ASSAYS 
 
To validate the differentially expressed miRNAs obtained from the miRNA microarray, qPCR 
using single-tube TaqMan® assays (Applied BiosystemsTM, California, USA) were performed. 
These included six assays for miR-200c-3p, miR-222-3p, miR-575, miR-363-3p and RNU48 
and RNU6B as endogenous control assays (Malumbres et al., 2009; Linda et al., 2010). 
 
These single-tube assays are more specific and sensitive at detecting miRNAs that have a one 
nucleotide difference than microarrays which are used mainly as a screening tool for further 
investigation. The TaqMan® assays contains two tubes, one containing specific stem loop 
primers for RT and the second tube containing the forward and reverse primers for qPCR and 
the miRNA specific MGB probe.  
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2.5.1 Reverse transcription using stem-loop primers 
The stem-loop primers of the miRNA assays are designed specifically for the mature miRNA 
sequences of the selected miRNAs. Briefly, after isolation, total RNA was diluted to 10 ng/µL, 
where after 1 µL was added to each reaction tube. Each RT conversion was performed for the 
six assays in DEPC treated PCR tubes for both cell lines. Briefly, a master mix reaction was 
set-up in a 1.5 mL centrifuge tube as per protocol (Table 2.6) using the TaqMan® miRNA 
Reverse Transcription kit (Applied BiosystemsTM, California, USA). The RT primers were 
added respectively to each tube for each sample (3 µL), followed by 7 µL of the master mix 
reaction, 1 µL of the RNA template and topped up to a total volume of 15 µL with nuclease-
free H2O (Thermo Fisher ScientificTM, Massachusetts, USA). 
 
Table 2.6: Components for the reverse transcription using stem-loop primers 
Reagent Volume (µL) 
10X RT Buffer 1.50 
RNase Inhibitor (20 U/µL) 0.19 
dNTPs with dTTP (100 mM) 0.15 
MultiScribe Reverse transcriptase 
(50 U/ µL) 1.00 
Nuclease-free water 4.16 
Total Volume 7.00 
 
The cycling conditions were set-up as per the protocol on the MultiGeneTM Gradient PCR 
Thermal Cycler (Labnet International, California, USA) (Table 2.7). Reaction tubes containing 
cDNA were thereafter stored at -20°C until they were used for qPCR. 
 
Table 2.7:  Cycling conditions for reverse transcription using stem-loop primers 
Stage Temp Time 
Hold 16.0°C 30 min 
Hold 42.0°C 30 min 
Hold 85.0°C 5 min 
Hold 4.0°C ∞ 
 
 
2.5.2 Quantitative real-time PCR 
A master mix reaction was prepared using the TaqMan® Universal PCR Master Mix kit (No 
AmpErase®, UNG 2X) (Applied BiosystemsTM, California, USA) for each miRNA in 
duplicate, a negative control (no-template) and two endogenous controls (RNU6B and 
RNU48). Briefly, reagents in Table 2.8 was added to 0.1 mL reaction tubes supplied by the 
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manufacturer (Qiagen, Hilden, Germany) in a total volume of 20 µL. The reaction tubes were 
then loaded onto the Rotor Gene-Q machine (Qiagen, Hilden, Germany) following the cycling 
conditions outlined in Table 2.9 as per the manufacturers protocol. 
 
Table 2.8: Components for single tube TaqMan® miRNA assays 
Reagent Volume (µL) 
TaqMan®  miRNA Assay 0.50 
TaqMan®  Universal Master Mix X2 5.00 
Nuclease-free water 3.90 
cDNA product 0.60 
Total Volume 10.00 
 
Table 2.9: Cycling conditions for single tube TaqMan® miRNA assays 
Stage Temp Time 
Hold 95.0°C 10 min 
40 Cycles 
95.0°C 15 sec 
60.0°C 45  sec 
 
 
2.5.3 Data Analysis  
The quantification data for all experiments were analysed using the comparative critical 
threshold (∆∆Ct) method to calculate the fold change expression of the miRNAs. Before this 
could be performed, each amplification plot was viewed using RQ Manager (Applied 
BiosystemsTM, California, USA) whereby the baseline and threshold values were set. The data 
were exported into the DataAssistTM software (version 3.01) (Applied BiosystemsTM, 
California, USA) to generate the Ct values for each replicate and to determine which 
endogenous control was consistent amongst the data. The Ct values are then used to calculate 
the fold change by first excluding any outliers in the data set (Ct >35; Change in Ct >1 amongst 
technical replicates) then the miRNA of interest was normalised to the endogenous control 
relative to the microvesicle treated control samples. The fold induction was thereafter 
calculated using the equation 2-ΔΔCt. Finally, the average fold changes were represented as 
means and standard deviations relative to the microvesicle treated control normalised to 1. 
Student t-tests were performed using Microsoft® Excel for Mac (version 15.2.3) to determine 
any significant differences between the treated samples relative to the microvesicle treated 




2.6  BIOINFORMATICS ANALYSIS AND TARGET SELECTION 
 
Once the data were analysed, one miRNA was selected for further characterisation. 
Bioinformatic databases such as miRBase (http://www.mirbase.org), miRNADB 
(http://www.mirdb.org), microRNA.org (http://www.microrna.org) and miRTarBase 
(http://mirtarbase.mbc.nctu.edu.tw/index.php) was used to identify putative gene targets. 
Target selection was determined by similar search results across all databases (Kuhn et al., 
2008). In addition, literature was consulted to identify validated targets in other cancers. These 
target prediction tools employ complementarity binding of the seed region (6-8 nucleotides in 
length within the structure of the 5’ miRNA end) and its target mRNA (Kuhn et al., 2008). 
They also employ partial complementarity to the 5’ miRNA end compensated by additional 
base pairings in the 3’ end (Liu et al., 2012).  
 
2.7  DNASE I TREATMENT OF RNA SAMPLES 
 
RNA samples were DNase treated prior to qPCR of selected gene targets to eliminate any 
genomic DNA (gDNA) contamination that would affect downstream qPCR experiments. Total 
RNA that had been previously isolated (Section 2.2.1) (used mirVana kit that lacked a DNase 
treatment step) were treated with DNase I and concentrated using the RNA Clean & 
ConcentratorTM -5 Kit (Zymo Research, California, USA).  Briefly, 10 µL of RNA from each 
sample was treated with nuclease-free H2O, 5 µL of DNase I in 5 µL of DNA digestion buffer 
in a total volume of 50 µL. The reactions were incubated at 25°C for 15 minutes and thereafter 
RNA binding buffer and 100% EtOH was added. Consequent steps of washing with the RNA 
prep and wash buffers was then performed in corresponding column tubes. After each wash, 
the flow-through was discarded until the final step, whereby the columns were transferred to 
DEPC treated 1.5 mL centrifuge tubes. The RNA was eluted in 8-10 µL of RNase free H2O 
(Zymo Research, California, USA) followed by quantification by NanoDropTM (Thermo Fisher 
ScientificTM, Massachusetts, USA) analysis, QubitTM RNA Assays and visualised by agarose 






2.8  REVERSE TRANSCRIPTION AND PCR OF SELECTED GENE TARGETS  
 
2.8.1 Primer design 
Primers specific for qPCR were designed for target genes using the Primer3Plus programme 
(http://www.bioinformatics.nl/cgi-bin/primer3plus.cgi) (Thornton & Basu, 2011). Two 
primers were designed, (forward and reverse) according to specific parameters. These 
parameters included the primer length of 18-25 base pairs (bp), melting temperature (Tm) of 
48-55°C, primer GC% of 40-60%. A potential primer pair was selected after the formation of 
secondary structures such as homodimers and heterodimers were analysed using 
OligoAnalyzer (Integrated DNA Technologies, Iowa, USA). Primers were avoided if the ∆G 
was more than 3 kcal/mole and the Tm of the hairpins exceeded 30°C. The primer pair was 
analysed to determine whether they would amplify other gDNA regions besides the target 
region using the Basic Local Alignment Search Tool (BLAST) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Primer pairs were included if they yielded 100% 
complementarity to the gene target and less than 75% to non-specific genes (Table 2.10).  
 













BLIDF 5’-CAGAGACCTTCCTATTTAACC-3’ 52.4 
91 
BLIDR 5’-CATCTGTCCTAACTCACTCC-3’ 52.0 
GAPDHF 5’-GAAGGCTGGGGCTCATTT-3’ 55.4 
133 
GAPDHR 5’-CAGGAGGCATTGCTGATGAT-3’ 55.2 
RPL27F 5’-ATCGCCAAGAGATCAAAGATAA-3’ 51.7 
123 
RPL27R 5’-TCTGAAGACATCCTTATTGACG-3’ 52.1 
bp – base pairs; BLID – BH3-like motif containing cell death inducer; F – forward; GAPDH – Glyceraldehyde-3-
Phosphate Dehydrogenase; R – reverse; RPL27 – 60S ribosomal protein 27; Tm – melting temperature 
 
2.8.2 Reverse transcription using oligoDT and random hexamer primers 
A master mix reaction was set-up by adding 4 µL of 5X iScript Reaction Mix and 1 µL of 
Reverse Transcriptase in a 1.5 mL centrifuge tube using the iScript cDNA Synthesis Kit (Bio 
Rad, California, USA). PCR reaction tubes were aliquotted with 5 µL of master mix, RNA 
template (500 ng/µL) and filled up to a total volume of 20 µL with nuclease-free H2O (Thermo 
Fisher ScientificTM, Massachusetts, USA). The reaction was run on the MultiGeneTM Gradient 
PCR Thermal Cycling System (Labnet International, California, USA) with the below cycling 




Table 2.11: Cycling Conditions for Reverse Transcription using oligoDT & Random Hexamer Primers 
Stage Temp Time 
Hold 25.0°C 5 min 
Hold 42.0°C 30 min 
Hold 85.0°C 5 min 
Hold 4.0°C ∞ 
 
 
2.8.3 PCR of selected gene targets  
To confirm the specificity of the qPCR primers, a conventional PCR was first performed for 
all primer pairs. The reaction was performed using the MyTaqTM DNA polymerase (Bioline, 
Tennessee, USA) in a total volume of 25 µL (Table 2.12) in a 1.5 mL centrifuge tube. 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) was used as an internal control 
(housekeeping gene) followed by a no-template control (NTC). The reaction was run on the 
MultiGeneTM Gradient PCR Thermal Cycling System (Labnet International, California, USA) 
as per cycling conditions in Table 2.13. 
 
Table 2.12: Components for Standard PCR using MyTaqTM DNA Polymerase 
Reagent Volume (µL) 
5X MyTaqTM Buffer 5.00 
MyTaqTM DNA polymerase (50 U/µL) 0.25 
Forward Primer (10 µM) 1.00 
Reverse Primer (10 µM) 1.00 
cDNA template 1.00 
Nuclease-free water 16.75 
Total Volume 25.00 
 
 
Table 2.13: Cycling Conditions for Standard PCR 
Stage Temp Time Cycle 
Initial Denaturation 95.0°C 1 min 1 Cycle 
Denaturation 95.0°C 15 sec 
30 Cycles Annealing 48.0°C 5 sec 
Extension 72.0°C 10 sec 
Hold 4.0°C ∞   
 
 
2.8.4 Gel electrophoresis of PCR products 
The PCR products were visualised by agarose gel electrophoresis. A 1.5% agarose gel was 
prepared with 1X TBE buffer (Appendix A) and EtBr (0.5 mg/mL). The samples were prepared 
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using 15 µL of PCR product and 2 µL of 5X DNA loading dye. Products were electrophoresed 
at 100 volts/cm for 35 minutes using 1X TBE as running buffer and 1kb DNA ladder (Appendix 
B – Figure B1). The gel was visualised under a UV trans-illuminator (Uvitec, UK). 
 
2.8.5 Quantitative real time PCR of miRNA gene targets 
Upon confirmation of the specificity of qPCR primers, qPCR was performed using the KAPA 
SYBR® FAST qPCR Kit (Kapa Biosystems, Cape Town, SA). Reactions were carried out in 
triplicate with GAPDH and 60S ribosomal protein L27 (RPL27) used as validated 
housekeeping genes. A master mix reaction (Table 2.14) was set-up in 0.1 mL reaction tubes 
in a total volume of 20 µL and was run on a Rotor Gene-Q (Qiagen, Hilden, Germany) machine 
(Table 2.15). Quantified data was exported and statistically analysed using the comparative 
∆∆Ct method and student t-test as described in Section 2.5.3. 
 
Table 2.14: Components for qPCR for expression of gene targets 
Reagent Volume (µL) 
SYBR Green qPCR Reaction Mix 5.00 
Forward Primer (10 µM) 0.20 
Reverse Primer (10 µM) 0.20 
cDNA template 1.00 
Nuclease-free water 3.60 
Total Volume 10.00 
 
 












2.9  FUNCTIONAL ANALYSIS & CHARACTERISATION OF MIRNA 
 
2.9.1 Protein extraction using RIPA buffer 
Protein were extracted using the Radio-Immunoprecipitation Assay (RIPA) buffer which 
utilises three non–ionic and ionic detergents to efficiently lyse and permeabilise the cells. The 
RIPA buffer was prepared (Appendix A) and combined with 7X cOmplete™, Mini, EDTA-
Stage Temp Time Cycle 
Pre-Incubation 95.0°C 3 min 1 Cycle 
Amplification 
95.0°C 10 sec 
40 Cycles 48.0°C 20 sec 
72.0°C 1 sec 
Hold 4.0°C ∞   
 36 
free, Protease Inhibitor (Appendix A) (Roche Applied Science, Penzberg, Germany). The 
protease inhibitor protects the extracted protein sample from degradation by proteases present 
in the cell lysate. The above principle applies to both the suspension (L1439A) and adhesion 
cell lines. The breast cancer adhesion cell lines T47D (ATCC®, Virginia, USA) and MDA-
MB231 (ATCC®, Virginia, USA) were used as positive controls since the cell lines have been 
reported to express endogenous BLID. These were not cultured (kindly donated by the Sharon 
Prince Lab) and protein was received for MDA-MB231 whilst protein was extracted for T47D 
cells. 
 
2.9.1.1 Suspension Cells 
Fresh RIPA solution was made (Appendix A) and kept on ice under the hood. The cell 
suspension was transferred into 15 mL Falcon tubes and was centrifuged for five minutes at 
2000 rpm (MSE, California, USA). The supernatant was removed and the pellet was washed 
three times in ice cold 1X PBS (Appendix A) followed by repeating the above centrifugation 
and removal of the supernatant. Sufficient RIPA solution was added (200-500 µL depending 
on pellet size) to the cells until it became viscous and was stored overnight at -80°C for 
optimum lysis. The cells were then thawed on ice and then centrifuged at 4°C at 12 000 rpm 
for 20 minutes to remove cell debris (Beckman, London, UK). The supernatant was aliquotted 
and stored at -80°C. 
 
2.9.1.2 Adherent Cells 
As before, fresh RIPA solution was made and kept on ice under the hood. The culture plate 
containing the cells were placed on ice and the medium was removed and cells were washed 
three times with ice cold 1X PBS (Appendix A). RIPA solution (500 µL) was added to the 
culture plate and the cells were scraped using a 1 mL syringe plunger as a cell scraper, 
transferred into a 1.5 mL Eppendorf tube and stored at -80°C overnight. The procedure 
thereafter was the same as noted above.  
2.9.2 Protein quantification using the BCA reagent 
The bicinchoninic acid (BCA) reagent was used to determine the protein concentrations, using 
the Pierce™ BCA Assay kit (Thermo Fisher Scientific™, Massachusetts, USA). The assay 
uses a sensitive and selective colourimetric detection system where a unique reagent containing 
BCA detects the reduction of Cu2+ to Cu1+ (biuret reaction) in an alkaline medium. The color 
produced from this reaction is stable and increases in a proportional pattern over a broad range 
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of increasing protein concentrations. A standard curve is generated using bovine serum 
albumin (BSA) at a range of concentrations (2000 µg/mL, 1000 µg/mL, 500 µg/mL, 125 
µg/mL and 0 µg/mL) (Smith et al., 1985). Briefly protein is thawed on ice and then is diluted 
(1:5; 1:2) in the RIPA buffer in a total volume of a minimum of 25 µL. The BCA standards are 
prepared as per the manufacturers protocol by combining Reagent A and B in a ration of 50:1 
to produce the working reagent. In a 96-well plate, 10 µL of the protein sample (diluted with 
RIPA buffer) is added to each well with 200 µL of working reagent in duplicate. The plate is 
then incubated at 37°C for 30 minutes and the colour change is measured using the Glo-Max®-
Multi+ multiplate reader (Promega, Wisconsin, USA) at a wavelength of 560 nm. The 
concentration of the protein is extrapolated from the generated standard curve.  
 
2.9.3 SDS-PAGE & Western blotting to determine protein expression 
 
2.9.3.1 SDS-PAGE 
To visualise proteins, a polyacrylamide gel electrophoresis (PAGE) was performed using an 
anionic detergent, sodium dodecyl sulphate (SDS), to linearise and negatively charge proteins. 
A 7.5 mL 15% resolving gel and a 5% stacking gel (Appendix A) as per the manufacturers 
protocol was made using the Mini-PROTEAN 3 casting apparatus (Bio-Rad, California, USA) 
(Table 2.16). The dithiothreitol (DTT) was used as a small redox reagent to reduce the 
disulphide bridges present in the proteins.  
 
Table 2.16: Components for protein sample preparation for SDS-PAGE  
Reagent Volume (µL) 
Protein sample (14-20 µg)* x 
100 mM DTT 1,00 
1X RIPA Buffer 30 – x 
5X SDS loading dye 4.00 
Total Volume 30.00 
*Protein concentration varied in order to determine the optimal detection of the protein for western blotting 
 
 
Prior to loading, samples were denatured at 95°C for five minutes, spun down and kept on ice. 
The polyacrylamide gel was assembled in the electrophoresis apparatus (Bio-Rad, California, 
USA) and 1X running buffer was added until it was overflowing (Appendix A). The comb was 
then removed and was washed with the buffer. Samples were added (30 µL) with 5 µL of the 
BenchMark™ Pre-Stained Protein Ladder (Appendix B – Figure B2) and 1 µL of 5X SDS 
loading dye to the empty wells (Appendix A) to ensure the proteins electrophorese vertically. 
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The apparatus was connected to the Bio-Rad power pack and electrophoresed for two hours, 
five minutes at 100 volts. 
2.9.3.2 Protein Transfer 
After the proteins were separated by SDS-PAGE, they were then transferred to a nitrocellulose 
membrane (Bio-Rad, California, USA). The transfer was set-up in a cassette by placing the gel, 
filter paper and membrane in a specific order as illustrated in Figure 2.3. This cassette was then 
placed back into the Mini-PROTEAN 3 casting apparatus (Bio-Rad, California, USA) and cold 
1X transfer buffer (Appendix A) was added along with an ice pack. The transfer was conducted 














Figure 2.4: The western blot cassette orientation for transfer of proteins (Reproduced from 
http://www.radio.cuci.udg.mx/bch/EN/Western.html). 
	
2.9.3.3 Antibody incubation & visualisation  
Upon completion of the transfer, the membrane was stained with Ponceau S (Sigma Aldrich, 
Missouri, USA) to visualise the protein bands (Appendix A) and confirm a successful transfer. 
Thereafter the membrane was washed with deionized water followed by PBS/Tween 
(Appendix A) and then blocked in PBS/Tween containing 5% of fat-free milk powder for one 
hour (Appendix A) with gentle shaking at room temperature. After blocking was completed, 
the membrane was incubated with primary antibody diluted to the desired concentration (BLID 
(Novus Technologies, Singapore, Malaysia); p38 (Bio-Rad, California, USA)) (Table 2.17) 
and was incubated overnight at 4°C in blocking solution with gentle shaking. The membrane 
was then washed with PBS/Tween (2X quick washes; 2X five minutes; 2X ten minutes) with 
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gentle shaking. The membrane was then incubated with the appropriate HRP-conjugated 
secondary antibody diluted in blocking solution for one hour at room temperature with gentle 
shaking (Table 2.17). Thereafter the membrane was washed as before and then visualised by 
enhanced chemiluminescence using the Clarity™ Western ECL Substrate (Bio-Rad, 
California, USA) as per the manufacturers protocol. The membrane was exposed to X-ray film 
and the resulting signal was captured by developing and fixing the film.   
 
Table 2.17: Primary and secondary antibody concentrations used for western blot analyses 
Protein Primary antibody Secondary antibody 
BLID 1:500 1:5000 (goat anti-mouse) 
p38  1:5000 1:5000 (goat anti-rabbit)  
BH3-like motif containing cell death inducer 
 
2.9.3.4 Membrane stripping 
Antibodies were removed from the blot by incubating in 55°C pre-warmed stripping buffer 
(Appendix A) at 55°C for one hour, with brief agitation every ten minutes. The membrane was 
then washed twice for ten minutes with PBS/Tween and the blot was reused from the blocking 


















CHAPTER 3: IDENTIFICATION OF DIFFERENTIALLY 
EXPRESSED MIRNAS IN B-CELLS EXPOSED TO HIV 
USING MICROARRAY ANALYSIS 
___________________________________________________________________________ 
 
3.1 INTRODUCTION  
 
miRNA microarray analysis has gained momentum as a discovery tool for identifying miRNA 
signatures especially for different cancers (Wang & Xi, 2013). Given the dearth of evidence 
linking HIV, miRNAs and NHLs, we aimed firstly to identify miRNAs that are differentially 
expressed in B-cells when they are exposed to HIV. To do this we designed a custom miRNA 
microarray to profile the expression of miRNAs which are either linked to the development of 
BL and DLBCL, as well as those which have been described as miRNA signatures for these 
cancers. This extensive search also expanded towards the addition of deregulated miRNAs that 
are involved in known cancer pathways. The results of the search for the chosen miRNAs and 
the microarray analysis are presented below followed by a discussion of these results. 
 
3.2 RESULTS  
 
3.2.1 Extensive literature searches to identify a panel of miRNAs for the design of a 
customised PCR array 
As mentioned in Section 2.4, an extensive literature search was conducted to identify and select 
miRNAs for inclusion in the customised microarray card to be used for profiling. Search 
engines, GoogleTM Scholar (http://scholar.google.com) and PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed/) were used to search for relevant literature with the 
keywords Diffuse Large B-cell lymphoma, Burkitt’s lymphoma and microRNAs. Secondly, to 
select suitable miRNAs, published miRNA signatures for DLBCL and BL were reviewed and 
used to select the panel (Table 3.1 and Table 3.2). In addition, commercially available arrays 
(from SABiosciences http://www.sabiosciences.com/mirna_pcr_product/HTML/MIHS-
102Z.html) were consulted that featured miRNAs that are implicated in cancer pathways or 
differentially expressed in other cancers (Human Cancer PathwayFinder miRNA PCR Array: 
MIHS-102Z) were also selected.  
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The selected miRNAs were then cross referenced with the TaqMan® Inventory database 
available from Applied Biosystems™ (California, USA) which are based on the miRBase 
platform (https://www.thermofisher.com/za/en/home/life-science/pcr/real-time-pcr/real-time-
pcr-assays/mirna-ncrna-taqman-assays/taqman-microrna-assays-educational-
resources.html). In conjunction, controls (RNU44, RNU48, RNU6B) were chosen based on 
literature and also cross referenced with the list to check on their availability (Malumbres et 
al., 2009; Linda et al., 2010; Forte et al., 2012). The selected miRNAs were then finalised (n 
= 188) (Table 3.3) to fit onto a 192a array format assay in duplicate with controls in 
quadruplicate and two wells unspotted as negative controls (blank). 
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Table 3.1: A summary of miRNAs reported to be deregulated in Diffuse Large B-cell lymphoma 
 






miR-10398-3p, NOVEL00260M, NOVELM00010M, miR-10b-5p, miR-423-3p, miR-301a-5p, miR-598, miR-
181a-5p, miR-30e-3p, miR-744-5p, miR-4746-5p, miR-1270, miR-3074-5p, miR-589-3p, miR-151a-3p, miR-331-
3p, miR-3934-3p, miR-589-5p, miR-210, miR-138-1-3p, miR-28-5p, miR-339-3p, miR-196b-5p, miR-151b, miR-




* Lim et al., 2015 
* miR-28 Schneider et al., 2014 
miR-18a * Alencar et al., 2011 
miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a * Fassina et al., 2012 
miR-17-5p, miR-150, miR-145, miR-328 * Roehle et al., 2008 
miR-17/92, miR-181a, miR-221 * Lawrie et al., 2008 
miR-17, miR-19b, miR-20a * Culpin et al., 2010 




miR-10397-5p, NOVELM00288M, miR-155-3p, miR-222-5p, miR-148a-5p, miR-222-3p,  miR-625-3p, miR-363-
3p, miR-30d-3p, miR-30b-3p, miR-221-3p, miR-92a-1-5p, miR-21-3p, miR155-5p, miR625-5p, miR-29b-1-5p, 




Lim et al., 2015 
miR-181, miR-222 * Alencar et al., 2011 
* miR-34a Craig et al., 2012 
miR-155,  miR-29b, miR-146a, miR-365, miR-30b, miR-26b, miR-374, let-7f, miR-9, miR-9-3p, miR-34b * Di Lisio et al., 2012 
miR-23a, miR-24-2, miR-27a * Kong et al., 2010 
miR-150, miR-145, miR-328 * Roehle et al., 2008 
miR-155, miR-21, miR-210, miR-221 * Lenz et al., 2008 
miR-155,  miR-21,  miR-22, miR-146a, miR-146b, miR-500, miR-363, miR-574-3p, miR-547-5p, miR-222 * Malumbres et al., 2009 
miR-29a, miR-92a, miR-106a, miR-720, miR-1260, miR-1280 * Culpin et al., 2010 
miR-155, miR-542-3p * Iqbal et al., 2015 
* no miRNAs were reported as downregulated/upregulated in this study (miR-microRNA) 
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Table 3.2: A summary of miRNAs as reported to be deregulated in Burkitt’s lymphoma 
* no miRNAs were reported as downregulated in this study  








Upregulated miRNAs Downregulated miRNAs Reference 
miR-371, miR-185, miR-93, miR-326, miR-339, miR-485, miR-193a, 
miR-448, miR-202, miR-483, miR-26a, miR-328, miR-192, miR-429, 
miR-324, miR-340, miR-105, miR-124 
miR-221, miR-30a, miR-146a, miR-146b, miR-26b, miR-23a, miR-
30d, miR-107, miR-103, miR-222, miR-26a, miR-30a, miR-142, 
miR-23b, miR-342, miR-29b, miR-34b, miR-9 
Lenze et al., 2011 
miR-19a, miR-18a, miR-19b, miR-20a, miR-17-3p, miR-17-5p, miR-92, 
miR-106a, miR-130b, miR-128b, miR-7, miR-206, miR-370, miR-494, 
miR-148a, miR- 20b 
miR- 210, let-7e, miR-215, miR-144, miR-451, miR-101, miR-
125b, miR-139, miR-140, miR-142-3p, miR-146a, miR15a, miR-
150, miR-16, miR-195, miR-22, miR-223, miR-23a, miR-23b, miR-
24, miR-26a, miR-26b, miR-29a, miR-29b, miR-29c, miR-30c, 
miR-30e-3p, miR-30e-5p, miR-34a, miR-99b, let-7a, miR-155, 
miR-196a, miR-342 
Robertus et al., 2010 
miR-17-5p, miR-20a, miR-9-3p * Onnis et al., 2010 
miR-210, miR-494, miR-575, miR-202, miR-801, miR-370, miR-765, 
miR-188, miR-296, miR-560, miR-663, miR-181, miR-574, miR-197, 
miR-92, miR-20b, miR-20a, miR-17-5p, miR-106, miR-93, miR- 422, 
miR-17-3p, miR-18a, miR-130, miR-19b, miR-19a 
miR-29b, let-7d, miR-155, miR-15a, let-7e, miR-23b, miR-768-5p, 
miR-148a, miR-331, miR-27b, miR-28, miR-363, miR-98, let-7a, 
let-7f, let-7g, miR-29a 
Bueno et al., 2011 
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*No reported differential expression in B-cell lymphomas and/or cancer (added onto array for miRNA family involvement) 
 
References: See Bueno et al., (2011); Chang et al., (2008); Chiang et al., (2013); Di Lisio et al., (2012); Forte et al., (2012); Imig et al., (2010); Jima et al., (2010); 






























































































































































































































































































































































































































































































































































































































































































































POSITIVE CONTROLS  DOWNREGULATED UPREGULATED BOTH UP & DOWN 
DOWNREGULATED 
NO RESULT* NEGATIVE CONTROL 
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3.2.2 Cells remained viable after the selected treatment period  
Following expansion of the two B-cell lines namely a lymphoblastoid cell line derived from a 
healthy donor (L1439A), and the commercially available BL cell line Ramos, a sample from 
each culture was tested for Mycoplasma infection (Section 2.1.3) and was found to be free of 
the contaminant (data not shown). The length of time chosen to expose the cells to HIV, as 
well as the amount of virions, were chosen based on what has been reported in the literature 
for various cell types such as dendritic cells and monocytes (Lapenta et al., 2003; Martinson et 
al., 2007; Moir et al., 2000; Mureth et al., 2010; Perise-Barrios et al., 2012; Nicholas et al., 
2013; Guo et al., 2014; Mdletshe, 2015). Based on these studies, as well as consultation with 
colleagues working with HIV virions (Dr. Andrea Soares, Dr. Wendy Burgers – Department 
of Virology, UCT) a treatment time of three hours was selected, using a concentration of 500 
ng/mL.  
 
It was important to verify that the cells remained viable after the three hour treatment, and 
therefore a viability assay was conducted for both cells using WST-1 (Section 2.1.5). No 
significant differences in cell viability was observed between microvesicle-treated and HIV-1 
















Figure 3.1: WST-1 assay assessing cell viability after HIV-1 AT-2 treatment in the Ramos and L1439A cell lines. No 
significant differences were observed between HIV-1 treated cells and microvesicle-treated controls for both cell 
lines. The assay was performed in triplicate for both cell lines with the means displayed for each treatment relative 
to the untreated samples. Absorbance was read at a wavelength between 420-480nm. The error bars represent the 
standard deviation (Prism 7, Graphpad, USA).  
 
Due to the extremely slow growth of the lymphoblastoid cell line L1439A, the Ramos cell line 
was chosen for the microarray screening with the intention to perform downstream validity 
studies in both cell lines.  
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3.2.3 RNA for miRNA profiling was contaminated with genomic DNA  
Following treatment which is described in Section 2.1.4 of Chapter two, total RNA was 
extracted using the mirVana system (Section 2.2.1). Thereafter, an aliquot of RNA from each 
dish was separated using gel electrophoresis (Section 2.7.5) to analyse integrity (Figure 3.2). 
The RNA was found to be contaminated with genomic DNA (gDNA) indicated by the bands 
at the top of the gel picture (indicated as gDNA in Figure 3.2 below). Importantly, the 
ribosomal RNA (rRNA) bands 18S and 28S were intact.    
  
                                        
                                             UT                                 MV                          HIV 









Figure 3.2: RNA integrity gel displaying RNA extracted from Ramos cells for miRNA profiling. A 1.5% agarose gel 
visualised with 6 µL/100 mL EtBr, was used to separate (electrophoresed for 35 minutes at 100 volts/cm) 10 µL 
of RNA mixed with 5 µL of 5X RNA loading dye and heat denatured at 55°C for 5 minutes in a total volume of 
15 µL. Lanes 1-3 represents the untreated (UT) cells; Lanes 4-6 represents the HIV-1 (HIV) treated cells and 
Lanes 7-9 represents the microvesicle treated (MV) control cells. Two bands were identified for ribosomal RNA, 
28S and 18S whilst genomic DNA contamination was also present at the top of the gel image (gDNA). 
 
 
Following gel electrophoresis, the RNA was quantified (Table 3.4) spectrophotometrically 
using the NanoDropTM. The concentrations varied from 91.47 to 211.23 ng/µL. The purity of 
the RNA as denoted by the 260/280 ratio was of high purity as it was close to 2.00. The 
secondary measurement, the 260/230 ratio which indicates the presence of contaminants was 
found to be within acceptable range (2.0-2.2) except for samples, UT3 and HIV3 which are 
flagged in the table (Table 3.4) (Thermo Fisher ScientificTM, 2008). 
 
Since we required RNA of good quality and to ensure the correct concentration for downsteam 
experiments, it was decided that a second and more sensitive method of quantification was 
necessary. This was done using the QubitTM RNA assay as described in Section 2.2.3 of 
Chapter two. The assay revealed extremely low RNA levels which were less than the 
recommended amount required (per total volume allocated i.e., 120 ng/µL in a total volume of 
15 µL) in order to perform the array. Therefore we attempted to concentrate the RNA by 
ethanol precipitation (Section 2.3).  The QubitTM RNA assay was then performed again and 
               gDNA  
                 
                  28S 
 
                  18S 
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showed a five-fold increase in RNA concentrations (Table 3.5). However, upon 
communication with technicians from Life TechnologiesTM we were subsequently advised that 
concentrating the RNA in this way may have favoured the precipitation of some miRNAs over 
others (size dependent). We then performed single-tube miScript SYBR green assays (Qiagen, 
Hilden, Germany) (Appendix A) to determine whether the experiment would be successful 
using the lower than recommended amount of RNA. We found the Ct values to be within 
acceptable range (20-25) and comparable to the result obtained when a higher concentration of 
RNA is used (Figure 3.3) and we therefore proceeded with the experiment using un-
precipitated (non-concentrated) RNA. We used the QubitTM readings to calculate the 
concentration of RNA required since this method is a more sensitive approach which can 
quantify RNA or DNA only in the sample whilst the NanodropTM quantifies all nucleic acids 
in the sample and cannot distinguish between the two acids (O‘Neill et al., 2011).  
 








UT1 211.23 1.98 2.20 
UT2 91.47 1.97 2.13 
UT3 141.20 1.95   2.26* 
MV1 176.70 1.98 2.19 
MV2 157.77 1.96 2.12 
MV3 142.02 1.98 2.11 
HIV1 199.14 1.96 2.15 
HIV2 141.72 2.00 2.03 
HIV3 194.76 1.97   2.26* 
HIV – HIV-1 Aldriothiol-2.2 treated cells; MV – microvesicle treated control; UT – untreated cells 
*Out of acceptable range; #eluted in a volume of 15-18 µL 
 
 
Table 3.5: RNA quantification as analysed by QubitTM RNA assay before and after ethanol precipitation  
Sample 
Concentration (ng/ µL) 
BEFORE AFTER 
UT1 34.50 142.00 
UT2 32.00 124.00 
UT3 37.50 148.00 
MV1 42.50 126.00 
MV2 27.00 122.00 
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MV3 41.00 162.00 
HIV1 31.50 122.00 
HIV2 35.50 172.00 
HIV3 34.00 163.00 









(a)                                                                                                   (b) 
Figure 3.3: Amplification plots (in log scale) of single tube qPCR using a low RNA sample compared to higher amount 
of RNA. Single-tube SYBR Green PCR experiments were performed in triplicate using the lowest RNA sample 
from our studies and a higher concentration of RNA sample as a control for the RNU6B assay. (a) The cycle 
threshold value of the lowest RNA sample (91.47 ng/µL) was found at 25 whilst (b) at 23 for the control RNA 
sample (500 ng/µL). 
 
3.2.4 Expression profiling reveals 16 upregulated & 16 downregulated miRNAs in 
Burkitt’s lymphoma cells  
Preliminary statistics and data analysis was conducted by the Centre for Proteomic & Genomic 
Research (CPGR) (Section 2.4.3). Their report revealed no significant differential expression 
of miRNAs for HIV-1 AT-2 treated samples when compared to microvesicle treated controls, 
but they recommended two miRNAs (miR-532 (p=0.0584; FC = 0.432) and miR-342-3p 
(p=0.0584; FC = 1.630) for further analysis (The complete report is included in Appendix C) 
(Heat map in Appendix B – Table B6). This finding was surprising, however upon interrogation 
of the methodology they used, it was revealed that a crucial limitation existed. The limitation 
resided in the software package they used, provided by Thermo Fisher ScientificTM 
(Massachusetts, USA) for the miRNA microarray, which did not allow for exclusion of failed 
replicates, or those which were obviously out of range and showed a large variation between 




















Figure 3.4: Boxplot comparisons of standard deviation between raw replicated features within samples from the miRNA 
microarray experiment. A number of feature replicates indicated large variation between replicates with more than 
30% difference from their means. (Full report in Appendix C).  
 
Therefore, an in depth manual analysis of each amplification plot for 192 miRNAs was 
performed, then the DataAssistTM software (version 3.01) (Applied BiosystemsTM, California, 
USA) was used so that we could exclude failed replicates (Section 2.4.3). After this more 
comprehensive and intensive analysis, the result revealed that 32 miRNAs were either 
upregulated or downregulated by two or more fold changes. This is summarised below (Table 
3.6). 
 
Table 3.6: miRNAs differentially expressed in Ramos cells exposed to HIV-1 AT-2 compared to microvesicle treated 
controls 
miRNAs p.value FC 
UPREGULATED 
miR-520d-3p 0.030 13.268 
miR-342-5p 0.223 9.523 
miR-513-3p 0.074 7.907 
miR-222-3p 0.042 6.735 
let-7a-2-3p 0.180 5.546 
miR-575 0.211 4.519 
miR-520f-3p 0.378 4.268 
miR-30b-5p 0.420 3.566 
miR-363-3p 0.248 3.496 
miR-100-5p 0.328 3.308 
let7c-5p 0.532 3.247 
miR-485-3p 0.110 3.006 
miR-132-3p 0.282 2.807 
miR-563 0.273 2.790 
miR-101-3p 0.408 2.604 
miR-365-3p 0.250 2.046 
DOWN-REGULATED 
miR-27a-3p 0.132 0.171 
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miR-200c-3p 0.367 0.151 
miR-769-5p 0.071 0.084 
miR-29c-3p 0.567 0.144 
miR-628-5p 0.210 0.224 
let-7b-5p 0.151 0.297 
miR-199a-3p 0.468 0.272 
miR-188-5p 0.102 0.263 
miR-27b-3p 0.487 0.204 
miR-30e-3p 0.173 0.201 
let-7b-3p 0.203 0.197 
miR-324-3p 0.320 0.194 
let-7f-1-3p 0.100 0.185 
miR-30e-5p 0.119 0.171 
miR-9-3p 0.378 0.030 
miR-9-5p 0.315 0.020 
FC – fold change; miRNAs – microRNA 
 
 
3.3 DISCUSSION  
 
We report the first study on the investigation of differentially expressed miRNAs in B-cells 
exposed to HIV. B-cells are the cell of origin of two highly aggressive cancers namely DLBCL 
and BL, which preferentially affect HIV positive people (Abayomi et al., 2011). It has become 
clear that HIV does not merely promote cancer development through a compromised immune 
system, but more directly through the alteration of host cellular pathways (Seddiki et al., 2013; 
Guha et al., 2016). Thus far, this has been mostly demonstrated in HIV-associated Karposi 
Sarcoma (Zhou et al., 2013b; Xue et al., 2014; Yan et al., 2014). In this study, B-cells were 
exposed to an attenuated form of HIV, and changes in miRNA expression was assessed.  
 
Firstly, the viability of our cells under our treatment conditions were assessed. This is important 
because HIV has been shown to promote apoptosis (Moir & Fauci, 2009; Perise-Barrios et al., 
2012) and our aim was to use treatment conditions which are physiologically relevant, and able 
to affect cell functions, but at the same time not kill the cells. We found no significant changes 
in cell viability (Figure 3.1) when exposing cells to 500 ng/mL of HIV-1 AT-2 for 3 hours. 
Previously, Perise-Barrios et al., (2012) exposed B-cells to 125 ng/mL of HIV-1 and significant 
changes in cell surface markers was only seen upon day four of treatment. In contrast, Nazli et 
al., (2010), was able to show no viability change in primary genital epithelial and intestinal 
cells after 24 hours exposure to HIV-1 (49-773 ng/mL). It would seem that HIV exposure and 
viability depends on the tissue type however for our experiments, our conditions were adequate 
as they did not result in significant viability changes in the cells during treatment.  
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Microarray analysis (DNA, protein, antibody or for tissue application) is a powerful high 
throughput tool for standardised genome-wide assays since it can monitor the expression of 
thousands of targets in an organism at the same time (Ekins & Chu, 1999; Git et al., 2010; 
Hernandez et al., 2012). Though initially used for gene expression analysis it has become 
increasingly utilised for investigating complex molecular interactions involving miRNAs. Like 
any other platform in biomedical research, array profiling has its disadvantages which include 
acquiring and analysing data, sample preparation, hybridisation of the probes (basis for 
determining relative abundance of miRNAs) and equipment errors (Benes & Castoldi, 2010; 
reviewed by Wang & Xi, 2013). We opted to use a TLDA platform from Life TechnologiesTM 
for various reasons. Firstly, the system is well cited in the literature, and furthermore a 
colleague at Stellenbosch University (Lani Thiart, personal communication) had used the same 
platform and had associated technical expertise and attested to a satisfactory overall outcome 
for her experiment. She used a readily available miRNA array, as opposed to a custom array. 
Secondly, the equipment needed for the array (setting up of plate, qPCR machine and data 
analyses expertise) was available at CPGR, which provided the service at no cost as long as 
their platform was used. This array also allowed us to customise the miRNAs that we were 
interested in and previous literature reported no significant differences for intra-platform 
reproducibility when the TaqMan® Low Density Array was compared to Locked Nucleic Acid 
or beads array and was an effective solution for miRNA profiling (Wang et al., 2011) whilst 
Baker, (2010) reported various platforms can provide different answers.  
 
The challenges however with miRNA microarray analysis is that variability can occur in both 
biological and technical procedures which makes experimental design essential to minimise 
irregularities (Chuaqui et al., 2002; Wang & Xi, 2013). We ensured that adequate time was 
spent on the design by consulting other array platforms since strengths of others should be 
referred to when performing these experiments (Mestdagh et al., 2009). In addition, we had 
several positive controls and a negative control (Git et al., 2010) since normalisation is an 
essential step in this process that helps reduce non-biological errors and converts the raw data 
into valid results (Wang & Xi, 2013).  The use of different controls and their expression varies 
from tissue samples and it is challenging to find controls that are stable in different cell lines 
but they should have properties similar to miRNAs in size, biogenesis and stability (Wang et 
al., 2010). We could not however validate these controls since we did not have spare array 
cards to do so but relied on literature to make our choice (Wang et al., 2011).  
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Our microarray experiments were performed at the CPGR to ensure efficiency of sample 
preparation. Good quality RNA is required for efficient miRNA microarray analysis (Baker, 
2010; Becker et al., 2010) especially when it comes to the design of the Taqman® microarray 
cards (Figure 3.4). Though it eliminates the need to aliquot and track large numbers of assays, 
it has eight ports in which the recommended RNA concentration (350 ng/µL) must disperse 
evenly to 384 wells. Our RNA levels were below this range but previous literature reported 
using less than the recommended amount and the experiments were successful (Chen et al., 
2005) and our experiments using single-tube SYBR green PCR assays were also successful 
(Figure 3.3). In addition, the use of the stem-loop primers enables accurate detection of larger 
number of miRNAs with small amounts of RNA sample (Hurley et al., 2011). Nevertheless an 
important step is validating this RNA yield with an initial array card which we unfortunately 












Figure 3.5: Schematic of TaqMan® Array Card from Life TechnologiesTM. TaqMan® Array Card is a 384-well 
microfluidic card, designed for performing 384 simultaneous real-time PCR reactions without the need for 
expensive liquid-handling automation. TaqMan® Array Cards are preloaded with dried-down, high-quality 
TaqMan® Assays (TaqMan® probes and PCR primer sets), ready for 1 to 8 samples to be run in parallel against 
12 to 384 TaqMan® Gene Assay targets. (Reproduced from https://www.thermofisher.com). 
 
 
Analysis of microarray data is another challenge that arises after profiling and this is well 
documented in the literature (Reviewed by Pritchard et al., 2012; reviewed by Chugh & 
Dittmer, 2012; reviewed by Wang & Xi, 2013; Backes et al., 2016). Our data analysis revealed 
high Ct values with large variation (Pearson correlation clustering) between technical replicates 
with 18.75% flagged as unreliable data (Appendix C). Specific normalisation methods for 
miRNA profiling analysis are relatively few (Wang et al., 2010) but proper normalisation 




Pre-spotted TaqMan® Assays  
(192 in duplicate) 
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miRNAs (Wang et al., 2011). For our data (treated samples (HIV-1 AT-2) were normalised 
with the matched microvesicle treated control samples) we used three different methods, 
geometric mean (Mestdagh et al., 2009), delta Ct, and quantile methods (Bolstad et al., 2003). 
Each method has its own advantages and disadvantages but it is better to use more than one 
method to observe how the data best fits a normalisation algorithm (Meyer et al., 2010; Wang 
& Xi, 2013). In addition, these methods worked well for our larger Ct values with the geometric 
mean and delta Ct methods displaying the most similar patterns to the raw data for all Ct values. 
Though the quantile method is reported as one of the best performed normalisation methods 
for miRNA data (Hua et al., 2008), the method showed large deviations suggesting a possible 
over-normalisation so we omitted this method when determining differential expression. 
However the geometric mean normalisation has some advantages over others particularly for 
miRNA studies (Dvinge & Bertone, 2009; Mestdagh et al., 2009) which is the method we 
particularly focused on.  
 
The focus for miRNA profiling data is on ‘differentially expressed’ miRNAs between two cell 
populations, but this term is not well-defined. The fold change (FC) is the main means for 
assessing a difference but it is also not clear on what the difference should be to regard treated 
samples as differentially expressed (FC = 1< upregulation; =1 no change; 1>downregulation). 
For gene expression analyses it is widely accepted that a difference can be regarded as 
significant when there is a FC of two or more (Rays et al., 1996) however for miRNA studies 
this is not clear. When adhering strictly to the software analysis, we observed no significant 
differences in our samples. Wang & Xi, (2013) recommend both the FC and the basal level of 
the miRNA to be taken into consideration since a miRNA can be highly expressed with a 
practical meaning whilst another miRNA can be weakly expressed and lack a measurable 
biological phenotype (Chugh & Dittmer, 2012). The FC needs to be used cautiously and should 
be used only for miRNAs that are expressed in both samples. In practice, many laboratories do 
not repeat array experiments and lack replicates. After the preliminary analysis by CPGR, no 
miRNAs were found to be significantly differentially expressed due to the software limitation 
and being unable to eliminate replicates with large deviation amongst samples which may have 
introduced significant bias to the detection of differentially expressed miRNAs (Wang & Xi, 
2013). Raw data was therefore comprehensively consulted by manual analysis before we made 
a final decision on the list of 32 (Table 3.6) since the importance of low abundance miRNAs 
may still serve as specific biomarkers and should not be omitted from determining differential 
expression (Chugh & Dittmer, 2012; Wang & Xi, 2013). 
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As noted above, proper normalisation methods (Hua et al., 2008; reviewed by Meyer et al., 
2010) are crucial to determining differentially expressed miRNAs but validation is also a 
critical factor when it comes to profiling (Wang et al., 2011). Validation by qPCR is favoured 
(Meyer et al., 2010) and future work should validate the above results by efficient and accurate 
methods. Since miRNAs are often clustered in families (such as let-7; miR-17-92) that can 
differ by only one nucleotide; validation by qPCR allows one to quantify these precise changes 


























CHAPTER 4: MIRNA VALIDATION BY SINGLE-TUBE 
TAQMAN® QPCR ASSAYS 
___________________________________________________________________________ 
 
4.1  INTRODUCTION  
 
Studying miRNAs in situ and validation are two important steps for miRNA investigation 
(Baker, 2010). The standard method for validation of results is by using an efficient method 
(such as qPCR) in order to either confirm or reject the result as observed from the microarray 
analysis (Wang & Xi, 2013). It is a more reliable and accurate method since it focuses on 
quantifying one miRNA per assay and can detect low amounts of miRNA (Chugh & Dittmer, 
2012). The aim of this part of the study was to validate selected miRNAs identified in the 
microarray in Chapter three. Following a comprehensive analysis of the miRNA microarray 
results, 32 differentially expressed miRNAs were selected for further investigation. In this 
chapter, we describe the validation of four miRNAs namely miR-200c-3p, miR-363-3p, miR-
222-3p and miR-575. The chapter starts with a summary of relevant literature on each of these 
miRNAs followed by the results of the validation using single-tube miRNA Taqman® qPCR 
assays. Thereafter the results are discussed. 
 
4.2 RESULTS  
 
4.2.1 Selection of miRNAs for validation 
The four miRNAs that were selected for further analysis from the 32 were based on existing 
literature reporting their involvement in cancer, particularly in B-cell lymphomas (Figure 4.1). 
Furthermore, reports on any gene targets (whether identified or validated) was also searched 


























Figure 4.1: Flow diagram illustrating the selection process of four miRNAs for validation in this part of the study. 




Table 4.1: Literature on miRNAs selected for validation  
miRNA B-cell lymphoma Other cancers References 
miR-200c-3p 
Survival marker for DLBCL 
(downregulation results in 
more aggressive cancer 
through de-repression of 
ZEB1) 
 
Downregulated in BL when 
compared to CLL (profiling 
data) 
Tumour suppressor miR in 
breast, ovarian and endometrial 
cancers (ZEB1/2 -promotes 




Cochrane et al., 2010 




Lim et al., 2015 
Robertus et al., 2010 
miR-222-3p 
Upregulated in DLBCL 
(p<0.05) 
 
Long term prognostic value 
for DLBCL  
 
Downregulated in BL 
compared to DLBCL 
(profiling data) 
Tumour suppressor miR in breast 
cancer (TRPS1 - promotes 
epithelial to mesenchymal 
transition), squamous cell 
carcinoma, thyroid papillary 
carcinomas  
 
OncomiR in glioblastoma (p27 - 
cell cycle inhibitor & tumour 
suppressor; PUMA - induces cell 
survival) 
Le Sage et al., 2007 
Zhang et al., 2010 
Stinson et al., 2011 
 
 
Malumbres et al., 2009 
Lenze et al., 2011 
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miR-363-3p 




Downregulated in BL 
compared to lymph nodes 
(p<0.05) 
Tumour suppressor miR in head 
and neck cancer (HNSCC) 
(PDPN (podoplannin) – 
contributes towards invasion and 
metastasis) and neuroblastoma 
 
OncomiR in colorectal cancer 
GATA6 (suppresses 
tumourigenecity) 
Tsuji et al., 2014 
Qiao et al., 2013 
Sun et al., 2013 
 
Jorgensen et al., 2014 
Bueno et al., 2011 
 
miR-575 Upregulated in BL compared to lymph nodes (p<0.05) 
OncomiR in non small cell lung 
cancer (NSCLC) (BLID  - 
promotes growth and invasion) 
 
Downregulated in bladder cancer 
(profiling data) 
 
Upregulated in gastric cancer 
(p<0.05) 
Wang et al., 2015 
Tatarano et al., 2011 
 
Bueno et al., 2011 
 
 
Yao et al., 2009 
BL – Burkitt’s lymphoma; BLID – BH3-like motif containing cell death inducer; CLL – chronic lymphocytic 
leukaemia; DLBCL – Diffuse large B-cell lymphoma; GATA6 - GATA Binding Protein 6; HNSCC – head and 
neck cancer; miR- microRNA; NSCLC – non small cell lung cancer; PDPN – podoplannin; TRPS1 – 
Transcriptional Repressor GATA Binding 1 
 
4.2.2 RNA for miRNA validation was of good quality 
Cells were plated and treated as before with attenuated HIV and microvesicle treated controls 
(Section 2.1.4). This time, in addition to the Ramos cells, the B-lymphoblastoid cell line 
L1439A, derived from a healthy individual, was also treated.  Following RNA extraction, the 
samples were separated on an agarose gel to analyse integrity (Figure 4.1 and Figure 4.2). The 
RNA was found to be of good quality indicated by the clear intact rRNA bands, 18S and 28S. 
Furthermore, contrary to previous extraction, there was no evidence of genomic DNA 
contamination. This is because the kit used for extraction (Roche Applied Science, Germany) 
has a gDNA elimination step (Section 2.2.2). 
 








Figure 4.2: RNA integrity gel of L1439A cells for miRNA validation. A 1% agarose gel visualised with 6	µL/100 mL 
EtBr, was electrophoresed for 45 minutes at 100 volts/cm and used to analyse the integrity of 10 µL of extracted 
                 28S 
 
                 18S 
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  1        2         3        4        5         6 
                 28S 
 
                 18S 
RNA combined with 5 µL of 5X RNA loading dye heat denatured at 55°C for 5 minutes in a total volume of 15 
µL. Lanes 1-2 represents the untreated (UT) cells; Lanes 3-4 represents microvesicle treated (MV) control cells 
and Lanes 5-6 represents the the HIV-1 (HIV) treated cells. Two bands were identified for ribosomal RNA, 28S 
and 18S. 
 








Figure 4.3: RNA integrity gel of Ramos cells for miRNA validation. A 1% agarose gel visualised with 6	µL/100 mL 
EtBr, was electrophoresed for 45 minutes at 100 volts/cm and used to analyse the integrity of 10 µL of RNA and 
5 µL of 5X RNA loading dye heat denatured at 55°C for 5 minutes in a total volume of 15 µL. Lanes 1-2 
represents the untreated (UT) cells; Lanes 3-4 represents microvesicle treated (MV) control cells and Lanes 5-6 
represents the the HIV-1 (HIV) treated cells. Two bands were identified for ribosomal RNA, 28S and 18S. 
 
 
Quantification by spectrophotometry using the NanoDropTM and QubitTM assay revealed much 
higher RNA yields than obtained previously using the mirVana kit (Table 4.2 and 4.3) for both 
cell lines. The 260/280 ratio revealed that the RNA contained a small amount of contaminants 
(>2,0) whilst the 260/230 ratios further confirmed this as the levels were slightly below normal 
range (0.90-1.97) (Thermo Fisher ScientificTM, 2008). Since there is no consensus on the lower 
range of the latter ratio, we continued with downstream validation (Von Ahlfen & 
Schlumpberger, 2010).  
 











UT1 253.29 2.05 1.75 712.00 
UT2 371.71 2.06 1.96 716.00 
MV1 377.64 2.05 1.48 724.00 
MV2 251.16 2.10 1.85 648.00 
HIV1 463.45 2.04 1.74 682.00 
HIV2 317.21 2.07 1.45 480.00 
HIV – HIV-1 Aldriothiol-2.2 treated cells; MV – microvesicle treated control; UT – untreated cells 

























HIV – HIV-1 Aldriothiol-2.2 treated cells; MV – microvesicle treated control; UT – untreated cells 
       * eluted in a volume of 100 µL 
4.2.3 miRNA-575 is significantly downregulated in Ramos cells  
To ensure that the results obtained are true for qPCR, two endogenous controls were used 
namely the small nucleolar RNAs, RNU48 and RNU6B (Section 2.5). It was found that 
RNU48 produced the most consistent result amongst replicates and across experiments and 
was therefore used to report on expression of the miRNAs of interest (Data for RNU6B 
presented in Appendix B – Table B3). The expression of miR-575 was found to be 
significantly downregulated (p=0.001) in the Ramos cells when treated with HIV-1 AT-2, 
relative to microvesicle treated control cells (Figure 4.3). A significant fold change was 















Figure 4.4: miR-575 is downregulated after HIV-1 AT-2 treatment in Ramos cells relative to microvesicle treated control 
cells. Downregulated expression of miR-575 expressed as the average fold change in HIV-treated cells relative to 
microvesicle-treated control cells, which has been normalised to one. The small RNA molecule RNU48 was used 











UT1 235.50 2.06 0.90 504.00 
UT2 211.26 2.10 1.71 400.00 
MV1 244.54 2.08 1.80 732.00 
MV2 285.66 2.10 1.77 608.00 
HIV1 206.10 2.12 1.97 656.00 
HIV2 269.40 2.11 1.84 610.00 
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triplicate. Error bars represent the standard deviation. A consistent and significant downregulated expression was 




The results for miR-363-3p, miR-200c-3p and miR-222-3p were inconsistent (Data presented 
in Appendix B – Table B4), and were not repeated. Since at this stage the validation and 
characterisation of those miRNAs in the Ramos cells became part of a separate project, the 
role of the miRNAs in the normal lymphoblastoid cell line, L1439A became the focus in this 
study.  
 
4.2.4 miRNA-575 is significantly upregulated in normal B-cells L1439A whilst miR-
363-3p, miR-200c-3p and miR-222-3p are significantly downregulated 
Validation for miR-575 showed a consistent and significant upregulation (p=0.003) in the 
normal B-cells when treated with HIV-1 AT-2, relative to microvesicle treated control cells 
(Figure 4.4). A significant fold change was observed with the highest found at 3.31 and the 




                                                              * 






Figure 4.5: miR-575 is consistently upregulated after HIV-1 AT-2 treatment in normal B-cells relative to microvesicle 
treated control cells. Upregulation of miR-575 expressed as fold changes in two independent experiments in HIV-
treated cells relative to microvesicle treated control cells, which has been normalised to one. The small RNA 
molecule RNU48 was used as the endogenous control. Two independent experiments was performed with 
samples performed in triplicate. Error bars represent the standard deviation. An upregulated fold change was 
observed ranging from 1.54-3.31. p<0.05* when compared to microvesicle treated control cells (Prism 7, 
Graphpad, USA).  
 
 
The expression of miR-363-3p, miR-200c-3p and miR-222-3p were all found to be 
significantly downregulated (p=0.003; p=0.001; p=0.027 respectively) in normal B-cells when 
treated with HIV-1 AT-2 relative to microvesicle treated cells (Figure 4.5a) (Data for RNU6B 
presented in Appendix B – Table B5). The highest downregulated average fold change for  
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miR-363-3p was 0,837 and the lowest fold change was for miR-222-3p (0.551) whilst the 
average fold change for miR-575 was 2.410 (Figure 4.5b). 
 
                                                                                                                                                                                        * 






      
 
                                                                                             *       *    *    *             *            *                                                                                 *       *        *                                                                                                                         
 
(a) (b)    
Figure 4.6: Downregulation of miR-363-3p, miR-222-3p and miR-200c-3p after HIV-1 AT-2 treatment in the normal 
B-cell line L1439A relative to microvesicle treated control cells (a) Average fold change of all miRNAs chosen for 
validation (b). (a) miR-363-3p, miR-200c-3p and miR-222-3p are significantly downregulated. Fold changes 
displayed in HIV-treated cells relative to microvesicle treated cells, which has been normalised to one. The small 
nucleolar RNA molecule RNU48 was used as the endogenous control. Two independent experiments were 
performed with each sample performed in triplicate. A significant downregulation was observed for miR-363-3p 
ranging from 0.830- 0.939; miR-200c-3p ranging from 0.669-0.754 and for miR-222-3p ranging from 0.448-
0.912. (b) Average fold change displayed in HIV treated cells relative to microvesicle treated cells for miR-363-
3p, miR-200c-3p, miR-222-3p and miR-575. The average downregulated fold changes for miR-363-3p, miR-
200c-3p and miR-222-3p was 0.837; 0.707 and 0.551 respectively. Error bars represent the standard deviation. 
p<0.05* when compared to microvesicle treated control cells (Prism 7, Graphpad, USA). 
 
4.2.5 Comparison of array results with validation studies 
The findings from the validation experiments were compared with results from the miRNA 
array. We found consistent results with two of the miRNAs namely miR-200c-3p 
(downregulated) and miR-575 (upregulated) when compared with the array data whilst the 
opposite trend was found for the rest of the miRNAs (Table 4.4).  
 












miR-363-3p 3.496 0.837* 
miR-200c-3p 0.151* 0.707* 
miR-222-3p 6.735 0.551* 
miR-575 4.519 2.410 
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As mentioned in the previous chapter, validation is a critical component of microarray 
profiling (Wang et al., 2010) since profiling is limited in terms of sensitivity and specificity 
and is used as a screening tool (Krichevsky, et al., 2003). Currently, no standard definition of 
validation exists however it can be described as either confirming or rejecting a result so that 
the result can be considered genuine or not (Chen et al., 2005; Morey et al., 2006). As such 
we chose four miRNAs to validate in this study by single-tube TaqMan® qPCR assays which 
is a sensitive and accurate technique to validate profiling data (Meyer et al., 2010). This is 
necessary in order to attach biological plausibility and significance to a profiling result 
presented in the previous chapter (Chugh & Dittmer, 2012).  
 
Traditionally, northern blot analysis was used for validation of miRNAs but given their small 
nature, they escape by this method (Lagos-Quintana et al., 2001) and so the gold standard 
currently in use for gene expression is real time qPCR but a novel scheme was thereafter 
developed that accurately detects miRNAs. This system, the TaqMan® PCR assay contains 
stem loop primers which is widely accepted to specifically quantify miRNA expression levels 
with superior performance over existing conventional detection methods (Hurley et al., 2011). 
In addition, these assays are much more efficient at detecting a one nucleotide difference 
between family members of miRNAs (Chen et al., 2005). It also has a dynamic range and can 
detect as low as seven copies in the PCR reaction. It was also found that this novel assay has 
a high precision and specificity to mature miRNAs with the stem-loop primers being as much 
as 100 times more efficient than conventional primers (Chen et al., 2005). We therefore chose 
this platform in which to validate our microarray data for the four chosen miRNAs. Choosing 
miRNAs for validation are primarily based on the FC however we based our selection on the 
context of our investigation namely, potential involvement in B-cell lymphomas but also 
cancers (Table 4.1).  
 
High quality RNA is essential for single-tube TaqMan® assays and though a small amount of 
genomic DNA maybe present in the sample (this is dependent on the kit used) it has been 
found that it does not readily affect the reaction suggesting that the assays are highly specific 
for RNA targets (Chen et al., 2005). In our study, we used two kits for total RNA isolation, 
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the mirVanaTM miRNA Isolation kit (Thermo Fisher ScientificTM, Massachusetts, USA), 
which lacks a gDNA elimination step (Section 2.2.1), and revealed the presence of gDNA in 
the sample (Figure 3.2); as well as the Roche kit (Roche Applied Science, Penzberg, Germany) 
that contains a gDNA removal step (Section 2.2.2) which resulted in the absence of gDNA 
(Figure 4.1 and 4.2). The mirVanaTM miRNA Isolation kit (Thermo Fisher ScientificTM, 
Massachusetts, USA) was used when extracting RNA for use in the miRNA microarray, as it 
is the recommended kit for that purpose. For single-tube validation, we shifted to the use of 
the Roche kit since the isolated RNA was to be used for investigating both changes in miRNA 
expression, as well as miRNA gene target expression. For the latter purpose, it was important 
that genomic DNA is not present in the sample.  
 
We could not draw conclusions on the differential expression of miR-363-3p, miR-200c-3p 
and miR-222-3p in the Ramos cell line (Appendix B – Table B3). Reasons for this include 
large variation between technical replicates as well as high Ct values (>35). These particular 
experiments were subsequently repeated by another Masters student in the laboratory and will 
therefore not be reported here. Instead, the focus is on validation in the B-lymphoblastoid cell 
line L1439A, which was derived from a healthy individual.  It is important to make a 
distinction between the two, as previous work in the laboratory has shown that a normal B-
cell line, and a Burkitt’s lymphoma cell line respond differently to exposure to HIV particles 
(Mdletshe, 2015). This wil be discussed in more detail in the sections below. However, before 
shifting our focus entirely to responses in L1439A, it is worth reporting that the single-tube 
assays revealed that miR-575 is downregulated in Ramos cells (Figure 4.3) which is contrary 
to the result obtained in the microarray (Table 4.4). Since validation experiments hold more 
credibility, this result is taken as being more reliable than the microarray result for miR-575. 
Yet again, this highlights the importance of validation of microarray data (Allison et al., 2006). 
Often in microarrays, the cost involved limits the number of times the experiment can be 
performed, and therefore relies on validation studies for confirmation (Kerr, 2003).  
 
As mentioned above, previous work in the laboratory has revealed that ‘normal’ B-cells 
respond differently to the same treatment conditions compared to cancer cells, such as the 
Burkitt’s lymphoma cell line Ramos (Mdletshe, 2015). In the latter study, opposite effects 
were found on changes in the expression of two genes involved in BL development, when 
cells were exposed to HIV. This is the same as what has been found in the current study with 
regards to the expression of miR-575. This is likely due to the fact that there is a difference in 
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genomic integrity and signalling pathways in the two cell lines. Cancer cells tend to have more 
compromised stress response pathways than normal cells (reviewed by Hanahan & Weinberg, 
2011), and are more able to mitigate the negative effects of stress agents, such as exposure to 
HIV, by bypassing cell death mechanisms. It is therefore important to investigate both 
scenarios i.e., effect on ‘normal’ and cancer cells. This is because, in vivo, the former 
represents an HIV infected individual who has not yet developed NHL, and the latter 
represents an HIV infected individual who has developed NHL and continues to harbour the 
virus.  
 
The role of miR-222-3p has been studied as a survival marker of prognostic value for DLBCL 
with high tissue expression associated with progression free survival (Malumbres et al., 2009; 
Montes-Moreno et al., 2011; Alencar et al., 2011) however this could not be significantly 
distinguished between patient cohorts in a later study by Shepshelovitch et al., (2015). In 
addition, the evidence from these studies above have been from profiling array data and while 
Lenze et al., (2011) attempted validation of this downregulated miRNA from their BL/DLBCL 
array data, the sample demonstrated reproducible signals in the NTC and was therefore 
omitted. In our study, we found the expression of miR-222-3p to be significantly 
downregulated when normal B-cells were treated with HIV-1 relative to microvesicle treated 
cells (Figure 4.5a). The literature indicates that mRNA targets for this miRNA include Era, 
MYC, CDKN1B/p27, c-KIT, p57, PUMA and TRPS1 (Poliseno et al., 2006; Visione et al., 
2007; Le Sage et al., 2007; Zhao et al., 2008; Sun et al., 2008; Miller et al., 2008; Felicetti et 
al., 2008; Medina et al., 2008; Zhang et al., 2010; Stinson et al., 2011) (Table 4.1). Research 
characterising the precise role of miR-222-3p in cancer is still emerging.   
 
The expression of miR-200c-3p was also found to be downregulated in L1439A cells, when 
exposed to attenuated HIV-1 (Figure 4.5a). This not only confirmed what was observed in our 
microarray (using Ramos cells) (Table 4.4), but other studies that profiled miRNAs for 
DLBCL and BL also support this finding (Lim et al., 2015). Furthermore, miR-200c-3p levels 
in BL tissues were found to be downregulated when compared to chronic lymphocytic 
leukaemia (CLL) and mantle cell lymphoma (MCL) tissues (Robertus et al., 2010). However, 
the prognostic value in DLBCL is unclear (Malumbres et al., 2009) since Berglund et al., 
(2013) found the miRNA expression to be upregulated with an association with poor overall 
survival but Yamagishi et al., (2015) found the opposite conclusion associated with overall 
survival. In serous ovarian cancer however, profiling data revealed that the expression was 
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upregulated (Ibrahim et al., 2015). There is strong evidence supporting the fact that the two 
transcription factors ZEB1/ZEB2 are targets of miR-200c-3p. These ZEB proteins are involved 
in epithelial to mesenchymal transition in breast, ovarian and endometrial cancers (Cochrane 
et al., 2010; Hill et al., 2013) as well as ZEB1 characterised for gastric DLBCL (Huang et al., 
2014). Furthermore, using miRNA-seq to profile DLBCL patient samples, a significant 
decreased expression was observed when compared to other cancers (Lim et al., 2015) 
resulting in a more aggressive DLBCL through the de-repression of ZEB1 (Huang et al., 2014). 
Other targets have been validated for other cancers such as E-cadherin (Hurteau et al., 2007) 
and TGFβ2 (Bai et al., 2014).  
 
The expression of miR-363-3p on the other hand is one that has been quite controversial in 
our laboratory since several independent experiments have yielded inconclusive results 
suggesting that the basal levels may be too low to be detected. Validation in the normal B-cell 
line however revealed a downregulation (Figure 4.5a) which is consistent with the findings by 
Bueno and colleagues (2011). In a study investigating the expression of miRNAs, miR-363-
3p was found to be significantly downregulated in BL when compared to lymph nodes (Bueno 
et al., 2011) and when compared to MCL (Robertus et al., 2010). In DLBCL, its 
downregulation (p<0.05) has been reported as a diagnostic marker predicting B-cell 
lymphoma up to 12 months before diagnosis (Jorgensen et al., 2014). Therefore the experiment 
should be repeated in other BL cell lines as well as in the context of DLBCL to elucidate its 
expression.  
 
As stated earlier, the expression of miR-575 was found to be downregulated in Ramos cells; 
whilst we found that in the normal B-cell, miR-575 was found to be significantly upregulated 
(Figure 4.4). The result obtained in the normal B-cell line is consistent to what was observed 
in our PCR array, although the cell line is different (Table 4.4). It has been found by microarray 
analysis to be significantly upregulated in BL by Bueno et al., (2011) and our finding is also 
supported by other studies focusing on other cancers such as gastric cancer (p<0.05) (Yao et 
al., 2009), breast cancer (Fisher et al., 2015), oesophageal adenocarcinoma (Drahos et al., 
2015) and recurrent serous ovarian carcinoma (p<0.05) (Nam et al., 2016). The finding is 
however in contrast to other cancers such as leukaemia, (downregulation) (Pizzimenti et al., 
2009) and lymphoblastic cancer (downregulation) (Lee et al., 2012) whilst it has also been 
identified as a biomarker for the prediction of colorectal cancer responses to chemotherapy 
(Zhu et al., 2017). The miR has however been comprehensively studied in bladder cancer.  
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Using cell lines and tissues samples, miR-575 was reported as downregulated and validated 
upon using TaqMan® assays as well as conducting gain of function studies. It was interesting 
to note that they determined differential expression by a FC of >0.01 and their results ranged 
consistently between 0.01-0.09 for miR-575 expression (Tatarano et al., 2011).  Recently 
Wang et al., (2015) investigated the role of miR-575 and found that it promotes growth and 
invasion of non small cell lung cancer by functioning as an oncogene by directly targeting 
BH3-like motif containing inducer of cell death (BLID). A significant inverse correlation was 
found between miR-575 (upregulation) and BLID mRNA (downregulation) and lower levels 
of protein was found by western blotting. In the next chapter, experiments are performed in 























CHAPTER 5: THE CHARACTERISATION OF MIR-575 IN 
THE PATHOGENESIS OF HIV-ASSOCIATED NHL 
__________________________________________________________________________ 
 
5.1  INTRODUCTION  
 
In this chapter, we report on further characterisation of miR-575, which was found to be 
significantly upregulated during the validation studies (Figure 4.4). A literature search 
revealed that, although miR-575 has been found to be deregulated in cancer, its role is not well 
described. Therefore the aim of this part of the study was to conduct functional analyses to 
characterise the role of miR-575 in the pathogenesis of HIV-associated NHLs. We first used 
bioinformatic tools to predict its mRNA gene targets of which the BH3-like motif containing 
inducer of cell death (BLID) was chosen for expression analysis at the mRNA level (by qPCR) 
and at the protein level (by western blotting). These results are presented below followed by a 
discussion. 
5.1.1 The role of the BH3-like motif containing inducer of cell death (BLID) 
A tumour suppressor function for BLID also known as breast cancer cell type 2 (BRCC2) has 
been proposed by a Yu & Li (2015) for breast cancer but it is unclear for other cancers. 
Previous literature does however elude BLID, a member of the Bcl-2 family of cell death 
controllers to a possible interaction or function in B-cell NHLs. BLID can control gene 
transcription in cancer and overexpression has been shown to significantly inhibit the 
phosphorylation of the AKT pathway (Li et al., 2013), and shown to induce apoptosis by 
correlation with the activation of caspase-3 and caspase-9 (Broustas et al., 2004) both of which 
play an important role in the proliferation, migration and invasion of cancer. In addition, 
Broustas et al., (2010) identified BLID as a new binding partner of BCL-XL and showed that 
BLID-induced apoptosis was associated with the activation of BAX and an increase in 
cytosolic cytochrome c. Furthermore, MMP-2 and MMP-9 that degrade type I and IV collagen 
and breakdown of the extracellular matrix contributing to cancer metastasis, was found to be 
significantly decreased when BLID was overexpressed (Li et al., 2013). Despite the above 
evidence, the mechanism by which BLID is deregulated remains unknown and this is also 
currently largely unknown for its role in HIV-associated NHLs. However, unlike other tumour 
suppressor genes of its family, it is unique in that it is emerging as a prognostic and therapeutic 
target especially for breast cancer (Cavalli et al., 2011; Li et al., 2014).  
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5.2 RESULTS  
 
5.2.1 An assessment of the role of miR-575 in cancer 
The table below is a summary of the current published literature (as of March 2017) on the 
involvement of miR-575 in cancer.  
 
Table 5.1: Summary of existing literature on the role of miR-575 
Findings Reference 
Significantly upregulated in gastric cancer 
(p<0.05) 
No mRNA target identified 
 
Yao et al., (2009) 
Upregulated in B-cell lymphoma  
No mRNA target validated  
Bueno et al., (2011) 
  
Upregulation promotes increased cell 
proliferation, migration and invasion in non-
small cellular lung cancer cells.   
BLID identified and verified as a direct 
mRNA target 
 
Wang et al., (2015) 
Upregulation in breast cancer 
PLCXD1 identified as novel target 
Fisher et al., (2015) 
Upregulated in oesophageal adenocarcinoma 
No mRNA target identified 
Drahos et al., (2015) 
Significantly upregulated in recurrent ovarian 
carcinoma (p<0.05) 
No mRNA target identified 
Nam et al., (2016) 
Upregulated by administration of the human 
cathelicidin AMP, LL-37, and its analogue 
peptide, FF/CAP18, in the colon cancer cell 
line HCT116 
No mRNA target identified 
Kuroda et al., (2017) 
Upregulated in HT-29 cells as candidate 
biomarker for colorectal cancer response to 
chemoradiotherapy 
No mRNA target identified 
Zhu et al., (2017) 
BLID – BH3-like motif containing inducer of cell death; miRNA – microRNA; mRNA – messenger RNA; 
PLCXD1 - Phosphatidylinositol Specific Phospholipase C X Domain Containing 1 
 
Using recommended miRNA prediction tools (Witkos et al., 2011; Thomson et al., 2011; 
Ekimler & Sahin, 2014), hundreds of putative mRNA targets for miR-575 were identified with 
each respective programme. Recommendations from the literature suggests the use of three or 
more prediction programmes and that at least two methods must predict the same miRNA 
binding site before additional validation experiments can be conducted (Witkos et al., 2011; 
Ekimler & Sahin, 2014). To narrow down the search we combined the output of all the 
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programmes and selected the overlapped mRNA targets (Barbato et al., 2009; Thomson et al., 
2011) since they are largely build upon the same assumptions (Table 5.2). Due to the nature 
of these programmes providing possible interactions against a scoring method, we also 
searched the literature for reported and/or validated mRNA targets for miR-575. The only 
report of a validated target for miR-575 is by Wang and colleagues (2015), who showed, using 
luciferase reporter assays, that miR-575 directly targets sites in the 3’-UTR of the BLID gene 
(Wang et al., 2015). This was shown in the context of non small cell lung cancer where miR-
575 was found to be upregulated, as we have shown in our studies. 
 
Table 5.2: Predicted mRNA targets for miR-575 








NSCLC (Chang et 
al., 2015),  
 
Epithelial ovarian 
cancer (Xi et al., 
2015) 
DIANA microT DENND5A GTPase signalling 
pathway 
X 
miRTarBase ATAD5 ATPase Predisposition to 
cancer (Bell et al., 
2011) 
picTar Only has known miR 












Lung cancer (Butler 
et al., 2011) 
ATAD5 – ATPase Family, AAA domain containing 5; CDK1 – cyclin-dependent kinase 1; CSTA – cystatin-A 
DENND5A – DENN domain containing 5Al; NSCLC – non small cellular lung cancer; X – no result 
 
 
As mentioned earlier in Chapter one, classification of miRNA target sites are based on the 
complementarity within the seed region and 3’ UTR of the miRNA. There are different types 
of sites that can be distinguished and the majority of known targets have complete pairing in 
the canonical sites. There are three types of canonical sites of which BLID forms an 8mer site 






(Appendix B – Figure B8). Although poorly conserved, it warranted experimental validation 
of its interaction.  
 
Table 5.3: BLID and miR-575 interaction as predicted by the TargetScan software database  
mRNA: miRNA Predicted consequential pairing of target region (top) and miRNA (bottom) Site type 




                                               |  |  |  |  |  |  |  | 
3'             CGAGGACAGGUUGACCGAG 
8mer 
BLID – BH3-like motif containing inducer of cell death; mRNA – messenger RNA; miRNA – microRNA 
 
5.2.2 RNA for mRNA target analysis was of good quality 
The normal B-lymphoblastoid (L1439A) cells were treated as before (Section 2.1.4) and total 
RNA was extracted (Section 2.2.2), quantified (Section 2.2.3), separated on an agarose gel 
(Section 2.2.4) and assessed for integrity (Figure 5.1). The RNA was found to have reasonable 
purity (Table 5.4) and acceptable integrity as indicated by the intact rRNA bands, 18S and 28S 
shown in Figure 5.1. 
 









MV1 245.36 2.05 1.17 
MV2 208.69 1.97 1.17 
HIV1 228.77 2.05 1.42 
HIV2 191.18 2.03 1.58 
HIV – HIV-1 Aldriothiol-2,2 treated cells; MV – microvesicle treated control 
* eluted in a volume of 100 µL 
  









      1            2             3            4            
5             6           7            8 28S  
 
                 
18S 
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Figure 5.1: RNA integrity gel of L1439A cells for mRNA gene target analysis. A 1% agarose gel visualised with 6	
µL/100 mL EtBr, was electrophoresed for 45 minutes at 100 volts/cm and used to analyse the integrity of 10 µL 
of RNA and 5 µL of 5X RNA loading dye of heat denatured at 55°C for 5 minutes in a total volume of 15 µL. 
Lanes 1-2 represents microvesicle treated (MV) control cells and Lanes 3-4 represented the HIV-1 AT-2 treated 
cells. Two bands were identified for ribosomal RNA, 28S and 18S.  
 
5.2.3 Primer design and validation 
Despite validated primers for BLID found in the literature (Wang et al., 2015), upon analysis 
using BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi), we found that the primers had more 
than 75% amplification affinity to non-specific genes. We therefore designed our own primers 
using parameters as described in Section 2.8.1. As housekeeping genes, the validated GAPDH 
primer pair was used (Mowla et al., 2011), as well as the RPL27 primer pair (de Lima 
Reboucas et al., 2013) of which primer pairs were not designed for. 
 
5.2.3.1 Genomic DNA contamination affects downstream qPCR 
To verify the specificity of all primer pairs including the housekeeping genes, conventional 
PCR was performed (Section 2.8.3). As an initial test, the primers were used on cDNA which 
were generated from RNA isolated using the mirVana kit (Section 2.2.1) and which was used 
in the microarray. We were interested in investigating the expression of the gene targets 
present in these samples. As a control for the PCR, RNA was included as a template for one 
of the samples using primers specific to the control GAPDH. As shown in Figure 5.2 below it 
was found that the sample which included the RNA as template (Lane 1) produced a band of 
expected size (133 base pairs), indicating the presence of gDNA contamination in the sample 
which can potentially lead to false positive results. In Lane 2, the BLID primers were used, 
and the template was reverse transcribed using microvesicle treated RNA. As can be seen, the 
BLID primers successfully amplified a band of the expected size (91 base pairs). Lane 3 is a 










Figure 5.2: Agarose gel picture of PCR products. A 1.5% agarose gel visualised with 6 µL/100 mL EtBr, was 
electrophoresed for 45 minutes at 100 volts/cm and used to visualise 18 µL of PCR product, 2 µL of 10X 
DNA loading dye in a total volume of 25 µL with 5µL of 2X 1kb ladder. Lane 1 represents the RNA template 
control using GAPDH primers (133bp); Lane 2 represents the PCR products for BLID target gene (91bp); 
Lane 3 represents the no template (water) control whilst Lane 4 represents the 1kb DNA ladder. A single 
band was amplified for the BLID gene using the microvesicle treated control (MV) sample used for the 
microarray analysis however, a GADPH product was amplified for the RNA template control sample as 
noted in Lane 1. 
 
We proceeded to DNase I treat the RNA samples using the RNA Clean & ConcentratorTM 
-5 Kit (Zymo Research, USA) (Section 2.7) before downstream qPCR since the mirVanaTM 
Isolation Kit used for RNA extraction for the microarray does not contain a gDNA 
elimination step (Section 2.2.1). The DNase treatment led to a significant decrease in yield 
of RNA (Figure 5.3a), but succeeded in eliminating genomic DNA from the sample as 
found when the qPCR was repeated. When the DNase-treated RNA was used as template, 
no amplification took place (Figure 5.3b). A single amplified product was successfully 
observed for GAPDH in Lane 1 with no band in the water template control lane. 
 
 











                                        (a) (b) 
Figure 5.3: Agarose gel picture comparing PCR products before and after DNase treatment (a) and PCR products for 
target gene expression (b).  
(a) A 1% agarose gel visualised with 3 µL/50 mL EtBr, was electrophoresed for 45 minutes at 100 volts/cm and 
used to visualise 5 µL of RNA, 5 µL of 5X RNA loading dye heat denatured at 55°C for five minutes in a total 
volume of 10 µL. Lane 1 represents the non-DNase treated sample (microvesicle treated control sample) and 
Lane 2 represents the DNase treated sample. (b) A 1,5% agarose gel visualised with 3 µL/50 mL EtBr, was 
electrophoresed for 45 minutes at 100 volts/cm and used to visualise 18 µL of PCR product, 2 µL of 10X DNA 
loading dye in a total volume of 25 µL. Lane 1 represents the PCR product using GAPDH primers; Lane 2 
represents the RNA template control; Lane 3 represents the 1kb DNA ladder and Lane 4 represents the no 
template (water) control. A single band was amplified for GADPH using the microvesicle treated control sample. 
 
 
While the removal of gDNA was successful, it significantly reduced the concentration of 
the RNA to such an extent that there were insufficient amounts to be used for reverse 
transcription. Therefore our efforts for qPCR of the BLID target gene was focused on RNA 




5.2.4 BLID mRNA is downregulated upon HIV-1 AT-2 treatment in B-cells 
 
Once the primer pairs were successful in amplifying the BLID gene by conventional PCR, 
qPCR was performed using the cDNA reverse transcribed from the RNA isolated from the 
L1439A cells (Section 2.8.2) that were treated with HIV-1 AT-2 (Section 2.1.4). In line 
with what was observed for miR-575 expression in the L1439A, BLID mRNA expression 
was found to be downregulated (Figure 5.4). An average fold change of 0.588 was reported 
when normalised with GAPDH, the housekeeping gene, and although statistically not 
significant, the trend was consistent and reproducible. As noted in Chapter four, (Section 























Figure 5.4: BLID mRNA is consistently downregulated after HIV-1 AT-2 treatment in normal B-cells relative to 
microvesicle treated control cells. Downregulation of BLID mRNA expressed as fold changes in two 
independent experiments in HIV-treated cells relative to microvesicle-treated control cells, which has been 
normalised to one. The housekeeping gene, GAPDH was used as the endogenous control. Two independent 
experiments were performed with each sample performed in triplicate. Error bars represent the standard 
deviation. A downregulated fold change was observed ranging from 0.383-0.878 (Prism 7, Graphpad, USA). 
 
 
5.2.5 BLID protein was undetectable in both treated and untreated cells 
 
The next step was to assess the expression of the BLID protein in the cells. Cells were 
treated as before (Section 2.1.4) and total protein extracted as described in Section 2.9.1. 
The initial western blotting result produced unclear results, as a band of the correct size 
could not be detected (Appendix B – Figure B5). There were several possible explanations 
for this. To eliminate the possibility that the transfer of proteins onto the nitrocellulose 
membrane was unsuccessful, a Ponceau S stain (Sigma Aldrich, Missouri, USA) was 
performed (Section 2.9.3.3). This revealed that the transfer was successful (Appendix B – 
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Figure B3). A second possibility was that the anti-BLID antibody was not working 
optimally and/or the amount of protein loaded and transferred was insufficient. However, 
this problem was not solved even when the amount of protein was doubled (data not 
shown). We thereafter ran several western blots with the inclusion of a positive control 
from two different breast cancer cell lines, T47D and MDA-MB231, which have been 
reported to express endogenous BLID (Section 2.9.1) (Li et al., 2013) as well as making 
use of two different forms of the antibody from the manufacturer (monoclonal 
#H00414899-M05 and polyclonal #H00414899-B01; Novus Biologicals, Singapore, 
Malaysia) at varying concentrations (1:500 and 1:250). A band of the correct size was 
eventually detected in our positive control sample (Figure 5.5) for one of the analyses but 
this could not be detected in our L1439A protein samples even at high concentrations of 
the protein (Appendix B – Figures B7). 
 
 
                                                         MV     HIV       MDA-MB231+ 
 




Figure 5.5: BLID protein expression in normal B-cells relative to microvesicle treated control cells. 
Western blot analysis displaying BLID expression (~11.8 kDa) in the L1439A cell line. 5 µL of 5X SDS 
loading dye and 1 µL of DTT was added to 20 µg of protein (varying volumes) in RIPA buffer and denatured 
at 95 °C for five minutes before being loaded and separated on a 15 % SDS-PAGE gel at 100 V for two 
hours in 1X running buffer. The protein was then transferred onto a nitrocellulose membrane (Bio-Rad, 
USA) for one hour at 100 V in 1X transfer buffer. This was then detected using the Clarity™ Western ECL 
Blotting Substrate (Bio-Rad, USA). To detect BLID, mouse anti-BLID antibody (Novus Biologicals, 
Singapore, Malaysia) was used, with a HRP bound goat anti-mouse secondary antibody (Bio-Rad, 
California, USA). BLID – BH3-like motif containing inducer of cell death; HIV – HIV-1 AT-2 treated 






For this part of the study, we chose to characterise miR-575 given the minimal research 
investigating its role in cancer as well as in B-cell lymphomas. The next step for studying 
differential miRNAs in the context of disease is identifying and validating its potential 
mRNA target to understand its role in cellular pathways (Hamzeiy, et al., 2014). This is 
done by using online bioinformatic tools followed by experimental validation of the 
mRNA target for the miRNA of interest (Kuhn et al., 2008; Ekimler & Sahin, 2014; 
Palanichamy & Rao, 2014). 
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The effective prediction of mRNA:miRNA interactions remains a current challenge due to 
not only the complexity of miRNAs and their regulation of their targets (Reviewed by 
Pasquinelli, 2012; Vasudevan, 2011) but also to the limited criteria governing the process 
(Wikos et al., 2011). In addition, it has been shown both experimentally and predicted that 
a single miRNA can potentially regulate many gene targets (Zhou et al., 2013a) and several 
miRNAs may compete for the same mRNA (Krek et al., 2005; Wu et al., 2010). 
Computational methods that use target prediction algorithms have been the main catalyst 
assisting in finding possible interactions (Witkos et al., 2011) but there is a need for better 
approaches (Hamzeiy et al., 2014). Most of these prediction algorithms are focused on 
alignment of the complementary elements in the 3’ UTR with the seed sequence of the 
miRNA as well as the evolutionary conservation of this region amongst species (Hamzeiy, 
et al., 2014). Perfect complementarity of mRNA to miRNA are seen in plants, however for 
animals it is a rare phenomenon (Yekta et al., 2004). miRNA complementary elements can 
also be found sporadically in the 5’ UTR or open reading frames (ORF) of their target 
genes (Lytle et al., 2007). This means that some of the mRNA gene targets that the 
algorithms predict (that use the above criteria) can be non-functional and unreliable (Kuhn 
et al., 2008; Ekimler & Sahin, 2014). 
 
Besides sequence based approaches, other computational methods are homology based, 
and structure based. Many authors have reviewed the strengths and weaknesses of various 
algorithms and bioinformatic tools (Kuhn et al., 2008; Witkos et al., 2011; Pasquinelli, 
2012; Ekimler & Sakin, 2014; Hamzeiy et al., 2014; Peterson et al., 2014), but some 
recommend four tools that have high precision and sensitivity namely, TargetScan, picTar 
and Miranda and DIANA-microT (Witkos et al., 2011; Thomson et al., 2011; Ekimler & 
Sahin, 2014). We searched these online software databases for the gene target of miR-575 
(Table 5.2) followed by combining the output of all these programmes and selecting the 
overlapped mRNA targets (Barbato et al., 2009; Thomson et al., 2011). In our search, the 
target, DENND5A was found in three out of the four recommended methods to use but 
these tools are used as guides rather than confirmed results (Hamzeiy et al., 2014) as they 
produce scores based on searches of potential interactions (Witkos et al., 2011). Since there 
is also no consensus as to what criteria should be followed to determine miRNA targets 
and to confirm biological efficacy (Ekimler & Sahin, 2014), experimentally validated 
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mRNA targets are the most suitable approach for identifying mRNA:miRNA interactions 
(Witkos et al., 2011). Some online software databases store this information such as 
miRTarBase but the disadvantage is that novel interactions may not yet have been 
discovered or added on to the database (Hamzeiy et al., 2014) such as for miR-575. The 
reliance therefore is by manually searching the literature for evidence of interactions 
between mRNA targets and the miRNA of interest (Witkos et al., 2011). 
 
 
Recently, BLID was identified as a validated target of miR-575 in non small cell lung 
cancer (NSCLC) (Wang et al., 2015). This is the only study to date that has identified and 
validated a target for miR-575. However, BLID has been identified as a target for other 
miRNAs such as miR-125b-1 in childhood B-cell precursor acute lymphoblastic leukemia 
(Tassano et al., 2010), miR-17-5p (Wang et al., 2016) and miR-603 (Ma et al., 2016) in 
osteosarcoma. BLID (also known as breast cancer cell 2 (BRCC2)) was first reported in 
the MDA-MB-231 human breast cancer cell line in 2004 (Broustas et al., 2004) and has 
been recently identified as a novel tumour suppressor gene (Yu & Li, 2015). It is an 
intronless gene that has been mapped to chromosome 11q24.1 which is also a region that 
is characterised by extensive loss of heterozygosity in cancer. These include breast cancer 
with the loss associated with poor prognoses (Chunder et al., 2004; Climent et al., 2007), 
in chronic lymphocytic leukaemia (Crowther-Swanepoel et al., 2010) cervical cancer 
(Zhang et al., 2005) and many other diseaseas (Beneteau et al., 2011). Studies in human 
cancer cell lines reveal that BLID can inhibit cell growth and metastasis in breast cancer 
cells (Li et al., 2013) whilst overexpression can cause apoptotic cell death in three different 
cell lines (Broustas et al., 2004). 
 
It is important to experimentally validate the possible interaction of mRNA:miRNA 
produced by the predictive tools (Kuhn et al., 2008; reviewed by Thomson et al., 2011; 
Palanichamy & Rao, 2014). To do this we firstly analysed the mRNA level of BLID by 
qPCR. Since qPCR is a sensitive technique that amplifies small amounts of RNA, 
contaminants such as gDNA can affect the downstream application producing unreliable 
results (Bustin, 2000; Udvardi et al., 2008). We attempted to convert the RNA to cDNA 
isolated for use in the PCR array but after successful DNase treatment (Figure 5.3a) our 
volumes were not enough to conduct qPCR. We then treated our cells again and isolated 
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RNA using the Roche kit (Section 2.2.2) that contained a gDNA elimination step. Upon 
downstream qPCR we found that BLID mRNA was significantly downregulated in our 
normal B-cell line L1439A. Our findings are supported by other studies investigating other 
cancers such as NSCLC (Wang et al., 2015), and osteosarcoma (Ma et al., 2016; Wang et 
al., 2016). Importantly, we observed an inverse relationship between our validation data 
(expression of miR-575 in L1439A), and BLID mRNA expression in the same cells. If 
miR-575 targets BLID for degradation in our context, then this result supports this. 
However, this could not be further verified at the protein level as a band could not be 
detected in our samples (Appendix B – Figures B6 and B7). The longest predicted ORF of 
BLID is 862 base pairs and its mRNA encodes a protein that is 108 amino acids in length 
(~11.8 kDa) (GenBank accession numbers AF220061 and AF303179) (Li et al., 2013). It 
is possible that basal levels of the BLID protein may be too low to be detected using 
western blotting, even in microvesicle treated control cells (Li et al., 2013). 
 
Interestingly, BLID mRNA was found to be upregulated in the BL cell line Ramos (Figure 
B4 in Appendix B) upon treatment with HIV and once again, a reverse relationship 
between miRNA and its target is demonstrated. BLID was found to be upregulated in 
childhood B-cell precursor acute lymphoblastic leukeamia resulting from a novel IGH 
translocation which is a common abnormality in mature B-cell neoplasms (Tassano et al., 
2010) which is also seen in BL with the translocation of the transcription factor, c-MYC 
(Dang, 2012; Ott et al., 2013; Spender & Inman, 2014). These contrasting findings between 
the two cell lines support the notion that mRNA:miRNA interactions are tissue dependent 
(Palinichamy & Rao, 2014). Future studies should therefore probably focus on a different 





















CHAPTER 6: SUMMARY & CONCLUSION 
 
__________________________________________________________________________ 
6.1  SUMMARY 
 
Recently, it has emerged that HIV may play a direct role in the development of HIV-
associated NHLs. In this study, we propose that one of the mechanisms by which it can do 
this is via the modulation of miRNAs in B-cells. As such, the aim of our project was to to 
identify cellular miRNAs whose expressions are altered by HIV and which contribute to the 
development of HIV-associated NHLs. We sought to achieve this through three main 
objectives. 
 
In the first part of our study, we conducted a miRNA microarray analysis, using a custom 
made array plate, to identify miRNAs with altered expression in BL cells treated with HIV-1 
AT-2, compared to microvesicle treated control cells. No other study to date has identified 
expressed miRNAs in B-cells after HIV-1 exposure. Due to limitations in the original 
statistical analysis software, we conducted a comprehensive analysis and selected 32 
differentially expressed miRNAs that were not statistically significant, both upregulated and 
downregulated, with a fold change of two or more, for further validation. Not all dsyregulated 
miRNAs discovered by expression profiling are potentially pathogenetic and many do not 
have a clear mechanism of action in oncogenesis. As such, validation of these results is 
essential to add biological significance to the findings. 
 
In Chapter four we report on four miRNAs namely miR-363-3p, miR-200c-3p, miR-222-3p 
and miR-575, which were chosen based on their reported involvement in cancer. For the 
validation we used single-tube TaqMan® qPCR assays to assess their expression in both 
normal B-cells and the Ramos BL cell line. Unfortunately, we could not reach a conclusion 
for miR-222-3p, miR-200c-3p and miR-363-3p in the BL cells due to the large variability in 
replicates (beyond the scope of this study) but were able to show that miR-575 was 
significantly upregulated in the normal B-cell line L1439A. Whilst many studies have 
validated their array results one could question what result can be constituted as validated 
since the criteria for validation are unclear (Chuaqui et al., 2002; Allison et al., 2006). 
Correlations of qPCR and microarray data are rarely presented in the literature and non-
agreeing data is also rarely explained (Morey et al., 2006). 
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In the last part of our study we selected miR-575 to characterise in the context of HIV-
associated lymphomas. We first used bioinformatic online tools to identify predicted mRNA 
gene targets for miR-575. Although we followed what literature recommended with regards 
to prediction target softwares, we chose an experimentally validated target, BLID, that was 
validated as a target for miR-575 in NSCLC. At the mRNA level, BLID was downregulated 
in normal B-cells. This inverse relationship pointed to a potentially physiologically relevant 
role of miR-575 in HIV-associated NHLs. However, we could not detect the BLID protein 
expression in our cells. 
 
BLID has already been identified as a novel tumour suppressor gene in breast cancer and is a 
promising therapeutic agent for diagnosis in this cancer. However, its role in other cancers 
such as HIV-associated lymphomas remains unclear. We have attempted for the first time a 
study identifying miRNAs that are differentially expressed upon HIV-1 exposure. Few 
miRNA have known biological functions and validated experimental targets which is one of 
the reasons that miRNA studies remain complex (Chugh & Dittmer, 2012). In addition, the 
complex nature of miRNAs, its complexity of many levels of gene regulation and structure 
can create intricate patterns of miRNA expression (Palanichamy & Rao, 2014). Differential 
gene expression may also represent phenotypic variants within the same population 
(Mukherji et al., 2011) which may also depend on the number of miRNA binding sites in the 
3’ UTR of the mRNA and miRNA in the cell. An interesting question prompted by 
Palanichamy & Rao (2014) is whether we should be interpreting the roles of miRNAs in 
disease states the way in which we evaluate the role of proteins in oncogenesis; and what are 
the mechanisms that distinguish miRNAs as novel factors in disease causation and 
progression. Unfortunately, consensus and guidelines for studying miRNA by qPCR (Bustin, 
2000) is yet to be determined including what fold change can be considered biologically 
plausible and relevant but an attempt has been made by Chuquai et al., (2002). 
 
6.2 LIMITATIONS 
There were several limitations in this study ranging from the selection of miRNAs for 
profiling to the design of the array. Firstly, not all miRNAs which we identified in the 
literature to be relevant for our research could be included in the array as we were limited to 
the ones available for selection by the manufacturer which could have introduced a study 
bias. This led us to choose different miRNAs and could not investigate the expression of those 
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such as miR-93, miR-92, miR-801 (Robertus et al., 2010; Bueno et al., 2011). In addition, 
studies that were consulted for selecting mature miRNAs did not specify which pre-miRNA 
(3p or 5p arm) they had included in their study which made choosing specific miRNAs 
challenging since they differ in sequence from the different arms (Pritchard et al., 2012).  
 
A third limitation is that there was a serious time limiting constraint of the manufacturing of 
the array plate. As mentioned in the previous chapter, the array has a unique design (Section 
3.3; Figure 3.4) but another challenge arose when the microfluidic array cards did not disperse 
evenly after centrifugation as per the manufacturer’s protocol (Figure 6.1) (Wong et al., 
2015). According to the manufacturer’s protocol the results from those arrays should be 
omitted but fortunately we managed to resolve the distribution through additional 
centrifugation which redistributed the samples evenly within the reservoirs. Lastly, we could 
not quantify the amount of miRNA in our RNA samples for microarray analysis due to the 
expensive cost factor involved in using specific analysers such as the Agilent Bioanalyser 













Figure 6.1: Schematics of TaqMan® Array Cards when loading the sample. Samples are added through eight ports 
which are then evenly distributed by centrifugation. Instances can arise whereby samples are not distributed 
evenly and the sample or control is still present in the fill reservoir or the fill reservoir is completed drained. 
(Reproduced from https://www.thermofisher.com) 
 
 
The limitations in the second part of our study focused mainly on technical errors which can 
occur when pipetting small amounts for sensitive qPCR experiments. The inconsistency 
amongst replicates may have also occurred due to improper pipetting as well as evaporation 
of samples prior to sealing tubes. Lastly, in the final part of our study, we had two limitations. 
Firstly, we had challenges in culturing the slow growing L1439A normal B-cell line as it is a 
fragile cell line which limited the speed at which experiments were conducted. Although we 
could not use this cell line for the miRNA microarray analysis, by the time validation of 
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miRNAs were conducted we had reached a confluency of the cells that were adequate for 
downstream treatment and experimentation. Secondly, we were unable to detect the BLID 
protein despite several attempts. 
 
6.3 CONCLUSION & FUTURE DIRECTIONS 
 
Our profiling analysis has provided for the first time a starting point for HIV-associated NHLs 
but detailed studies are required to fully determine and validate the role of the miRNAs that 
were found as differentially expressed. In line with our aims we have provided evidence for 
miRNAs that are differentially expressed upon HIV exposure. miR-575 was found to be 
upregulated whilst BLID was found to be downregulated in normal B-cells. Further 
characterisation is required to understand its mechanism of action in HIV associated NHLs 
by investigating other mRNA targets of miR-575 and by functional analyses, such as measure 
of apoptosis, expression of key regulators of the cell cycle, and other cellular events 
characteristic of cancer. Future studies should also focus on validation and characterisation 
of the remaining differentially expressed miRNAs upon HIV exposure to fully elucidate and 
contribute to the emerging role of cellular miRNAs contributing towards HIV-associated 
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APPENDIX A: RECIPES AND REAGENTS  
 
Tissue Culture 
Complete growth media for Ramos cell line 
Add 5 mL (10%) of FBS and 0.5 mL of P/S to a 50 mL Falcon tube 
Fill up to 50 mL with RPMI media and mix 
Store at 4°C until needed 
 
Complete growth media for L1439A cell line 
Add 10 mL (20%) of FBS and 0.5 mL of P/S to a 50 mL Falcon tube 
Fill up to 50 mL with DMEM media and mix 
Store at 4°C until needed 
 
Low serum media for pre-treatment 
Add 0.25 mL of FBS and 0.5 mL of P/S to a 50 mL Falcon tube 
Fill up to 50 mL with RPMI media and mix before plating 
 
70% Ethanol 
Add 700 mL of 100% ethanol to a bottle and fill up to 1 L with autoclaved H2O 
 
0.1% diethyl pyrocarbonate- (DEPC) treated water 
Fill a 5 L beaker with autoclaved water and add 1 mL of DEPC per 500 mL of H2O 
Add a magnetic stirrer bar and place on the stirrer for a few hours (3-5 hrs) 
Place the beaker in the fume hood overnight, remove the stirrer bar and autoclave to inactivate 
the remaining DEPC 
Store the H2O at room temperature until needed 
 
0.1% diethyl pyrocarbonate- (DEPC) to treat plasticware 
Fill 5 L beaker with H2O and add 1 mL of DEPC per 1 L of H2O  
Add stirrer bar and plasticware (pipette tips, centrifuge tubes) 
Place in the stirrer for a few hours (3-5 hrs) 
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Place beaker in fume hood overnight 
Remove the pipette tips from the H2O and allow to air dry before autoclaving 
 
Trypsin-EDTA  
Dissolve 8 g NaCl; 1,26 g Na2HPO4; 0,2 g KCl;  0.2 g KH2PO4; 0.5 g Trypsin and 0.5 g EDTA 
in 800 mL deionized H2O 
Adjust to pH 7.4 
Filter using a 0.2 µM membrane 
Aliquot into 250 mL bottles and autoclave 




A ratio of 1:3 glacial acetic acid: Methanol 
Store at 4°C 
 
Mounting Fluid 
Mix 22.2 mL 0.1 M citric acid; 27.8 mL 0.2 M Na2HPO4.2H2O and 50 mL glycerol 
Adjust to pH 5.5 
 
RNA Extraction 
10X Tris/Borate/EDTA (TBE) buffer 
108 g Tris  
55 g Boric acid 
Dissolve in 900 mL H2O 
Add 40 mL (0.5M pH 8)  
Adjust to 1 L  
Store at room temperature 
 
1X TBE 
Measure 100 mL of 10X TBE stock 
Fill up to 1 L using autoclaved H2O 
 
2X RNA loading buffer (1 mL) 
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Add 900 µL formamide; 99 µL sucrose; 0.5 µL  Bromophenol Blue and 0.5 µL Xylene Cyanol  
Store at room temperature 
 
10X DNA loading dye 
Mix 0.025 g of Xylene cyanol; 0.025 g of Bromophenol Blue; 1.25 mL of 10% SDS; 12.5 mL 
of glycerol 
Dissolve in 6.25 mL of H2O 
Store at room temperature 
 
1%/1.5% agarose gel 
Weigh 1 g/1.5 g agarose in 100 mL 1X TBE 
Dissolve all the agarose by heating using a microwave 
Allow to cool and then add 6 µL Ethidium Bromide (EtBr, 0.5mg/mL) 
Pour gel on tray and allow to set 
 
Protein Extraction 
RIPA Buffer (50 mL) 
Mix 1.5 mL 150 nM NaCl; 0.5 mL 1% Triton X100; 0.5 mL 0.1% SDS; 0.5 mL 10 mM Tris 
pH 7.5; 0.5 g 1% deoxycholate powder 
Make up volume to 50 mL with deionized H2O  
 
7X protease inhibitor  
Add 1 protease inhibitor tablet with 2.5 mL 1X PBS 
 
RIPA solution 
Combine 858 µL RIPA buffer with 142 µL 7X protease inhibitor 
 
SDS-PAGE Reagents 
1.5M Tris pH 6.8 
Dissolve 60.5 g Tris base in 300 mL deionized H2O 
Adjust pH to 6.8 with concentrated HCl and volume to 500 mL with deionized H2O 
Store at 4°C 
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1.5M Tris pH 8.8 
Dissolve 60.5 g Tris base in 300 mL deionized H2O 
Adjust pH to 8.8 with concentrated HCl and volume to 500 mL with deionized H2O 
Store at 4°C 
 
10% Sodium dodecyl sulphate (SDS) 
Dissolve 10 g sodium dodecyl sulphate crystals in 90 mL H2O 
Adjust volume to 100 mL with H2O 
Store at room temperature 
 
10% Ammonium persulfate (APS) 
Dissolve 0.1 g ammonium persulfate in H2O 
Adjust volume to 1 mL with deionized H2O 
Store at 4°C 
 
30% acryl-bisacrylamide mix (100 mL) 
Dissolve 29 g acrylamide and 1 g N.N’-methylenebisacrylamde in 60 mL H2O 
Heat the solution to 37°C to dissolve the chemicals 
Adjust volume to 100 mL with H2O 
Filter through 0.45 µM membrane 
Store at 4°C protected from light 
 
10X SDS-PAGE running buffer (1 L) 
Dissolve 10 g SDS; 30.3 g Tris and 144.1 g glycin in 800 mL H2O 
Adjust volume to 1 L with H2O 
Store at room temperature 
 
1X SDS-PAGE running buffer (1 L) 
Add 100 mL 10X SDS-PAGE running buffer to 900 mL deionized H2O 
Store at room temperature 
 
10X SDS-PAGE transfer buffer (1 L) 
Mix 144 g glycine and 38 g Tris and make up to 1 L with deionized H2O 
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1X SDS-PAGE transfer buffer (1 L) 
Mix 100 mL 10X transfer buffer; 700 mL deionized H2O and 200 mL isopropanol 
Make fresh on day of running gel and store at 4°C 
1X Ponceau S staining solution (0.1% (w/v) Ponceau S in 5% acetic acid) (50 mL) 
Dissolve 0.1g Ponceau S in 5 mL acetic acid 
Adjust volume to 50 mL with deionized H2O and protect from light 
 
15% resolving gel for SDS-PAGE (7,5 mL) 
Mix 1.65 mL H2O; 3.75 mL 30% acryl-bisacrylamide mix; 1.95 mL 1.5M Tris (pH 8.8); 0.075 
mL 10% SDS; 0.075 mL APS and 0.003 mL tetramethylethylenediamine (TEMED) (under 
hood) 
Pour into 1 mm glass plate, minimise exposure to air 
Add 1% SDS to set the top of the gel 
 
5% stacking gel for denaturing SDS-PAGE 
Mix 2.1 mL H2O; 0.5 mL 30% acryl-bisacrylamide mix; 0.38 mL 1.5M Tris (pH 6.8); 0.03 mL 
10% SDS; 0.03 mL APS and 0.003 mL tetramethylethylenediamine (TEMED) (under hood) 
Pour into 1 mm glass plate which has the set resolving gel, add comb and leave to set  
 
5X SDS  loading dye 
Mix 12.5 mL 2 M Tris HCl pH 6.8; 10 g 10% SDS; 30 mL 100% glycerol; 5 mL β-
mercaptoethanol and 52 mL 0.04% Bromophenol Blue 





80 g NaCl 
2 g KCl 
26.8 g Na2HPO4-7H2o KH2PO4 
Dissolve in 800 mL H2O. Adjust pH to 7.4 with HCl and fill up to 1 L with H2O. 
Aliquot the PBS, sterilize by autoclaving for 20 minutes at 15 psi (1.05 kg/cm2) on liquid cycle 





Measure 100 mL of 10X PBS and add to 1 L bottle. Fill up to 1 L with H2O 
Aliquot as needed and store at room temperature 
 
1X PBS/0.1% Tween (PBST) 
Add 1 mL Tween 20 to 1X PBS made up to 1 L 
Mix well with magnetic stirrer bar  
Store at 4°C 
 
Blocking Solution 
Add 2.5 g non-fat powder milk (5%) and dissolve in 50 mL in PBST 
Store at 4°C 
 
1M Tris-HCl (pH 6.7) 
Dissolve 24.22 g Tris base in 160 mL deionized H2O 
Adjust pH to 6.7 with concentrated HCl and adjust volume to 200 mL with deionized H2O 
Store at 4°C 
 
Stripping buffer (100 mL) 
Combine 0.69 mL 100 mM β-mercaptoethanol; 10 mL 2% SDS; 6,25 mL 62.5 mM Tris HCl 
(pH 6.7) adjusted with deionized H2O to 100 mL 
Store at room temperature 
 
Protocol for using miScript primer assays 
 
The two-step process begins with cDNA synthesis using the miScript SYBR Green Kit II 
(Qiagen, Hilden, Germany). Briefly two samples (RNA extracted from Ramos cells treated 
with HIV-1 AT-2 of 91.47 ng/µL; RNA extracted from K562 sample of 500 ng/µL) were set 
up as described in Table A1 below for reverse transcription. The reactions were then incubated 
for 60 minutes at 37°C and then incubated for 5minutes at 95°C to inactivate the miScript 
reverse transcriptase mix and placed on ice. Thereafter single PCR 0.5 mL tubes were set up 
(Table A2) for qPCR using miScript primer assays (Qiagen, Hilden, Germany) for RNU6B for 
the two samples in triplicate with a no template control and a water control. The reaction was 
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run on the MultiGeneTM Gradient PCR Thermal Cycling System (Labnet International, 
California, USA) as per cycling conditions (Table A3). 
 
Table A1: Components of the reverse transcription using miScript SYBR Green Kit II 
Reagent Volume (µL) 
miScript HiSpec Buffer (5X) 4.00 
miScript Nucleics Mix (10X) 2.00 
Template RNA 2.00 
miScript Reverse Transcriptase Mix 2.00 
Nuclease-free water 10.00 
Total Volume 20.00 
 
Table A2: Components of the qPCR miScript primer assay 
Reagent Volume (µL) 
QuantiTect SYBR Green PCR Master Mix (2X) 5.00 
miScript universal primer (10X) 1.00 
miScript primer assay (10X) 1.00 
cDNA 1.00 
Nuclease-free water 2.00 
Total Volume 10.00 
 
 
Table A3: Cycling conditions for miScript qPCR primer assays 
Stage Temp Time Cycle 
Initial activation step 95.0°C 15 min Hold 
Denaturation 94.0°C 15 sec 
40 Cycles 
 Annealing 
55.0°C 30 sec 
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let-7a-2-3p DOWN Bueno et al., (2011); Jima et al., (2010) 
let-7a-1-3p DOWN Chang et al., (2008) 
let-7a-5p DOWN Jima et al., (2010); Bueno et al., (2011); Robertus et al., (2010) 
let-7b-5p UP Jima et al., (2010) 
let-7b-3p DOWN Chang et al., (2008) 
let-7c-5p DOWN Chang et al., (2008) 
let-7d-5p DOWN Bueno et al., (2011); Robertus et al., (2010); Chang et al., (2008)  
let-7e-5p DOWN Bueno et al., (2011) 
let-7e-3p DOWN Bueno et al., (2011) 
let-7f-5p DOWN Bueno et al., (2011); Jima et al., (2010) 
let-7f-1-3p DOWN Chang et al., (2008) 
let-7g-5p DOWN Bueno et al., (2011); Robertus et al., (2010); Chang et al., (2008); Jima et 
al., (2010) 
let-7i-5p - Cancer array (Lung, ovarian) 
miR-100-5p UP Robertus et al., (2010) 
miR-100-3p DOWN Cancer array (Brain, pancreatic, ovarian); Bueno et al., (2011) 
miR-101-3p UP Jima et al., (2010) 
miR-103a-3p DOWN Leucci et al., (2008); Jima et al., (2010) 
miR-105-5p DOWN Leucci et al., (2008) 
miR-105-3p DOWN Leucci et al., (2008) 
miR-106a-5p UP Bueno et al., (2011) 
miR-106a-3p UP Robertus et al., (2010) 
miR-106b-5p UP Robertus et al., (2010) 
miR-106b-3p UP Jima et al., (2010) 
miR-107 DOWN Leucci et al., (2008) 
miR-124-5p UP/DOWN Robertus et al., (2010); Chang et al., (2008) (DOWN) 
miR-125b-5p UP Robertus et al., (2010) 
miR-126-3p UP Leucci et al., (2010) 
miR-126-5p UP Leucci et al., (2010) 
miR-127-3p UP Bueno et al., (2011); Jima et al., (2010) 
miR-130b-3p UP Cancer array (skin, brain); Robertus et al., (2010) 
miR-132-3p UP Chiang et al., (2013) 
miR-133a-3p DOWN Bueno et al., (2011); Robertus et al., (2010) 
miR-138-5p DOWN Robertus et al., (2010) 
miR-140-3p UP Jima et al., (2010) 
miR-141-3p DOWN Bueno et al., (2011); Jima et al., (2010) 
miR-142-3p DOWN Leucci et al., (2008); Jima et al., (2010) 
miR-142-5p UP Robertus et al., (2010); Jima et al., (2010) 
miR-143-3p UP Robertus et al., (2010) 
miR-143-5p - - 
miR-145-3p DOWN Bueno et al., (2011) 
miR-145-5p DOWN Bueno et al., (2011); Robertus et al., (2010); Chang et al., (2008); Leucci 
et al., (2008); Jima et al., (2010) 
miR-146a-3p UP Jima et al., (2010) 
miR-146b-3p DOWN Leucci et al., (2008) 
miR-146b-5p DOWN Bueno et al., (2011); Jima et al., (2010) 
miR-148a-3p UP Cancer array (brain, prostate, skin); Robertus et al., (2010) 
miR-148a-5p UP Cancer array (brain, prostate, skin); Robertus et al., (2010) 
miR-149-5p DOWN Robertus et al., (2013); Chang et al., (2008) 
miR-150-5p DOWN Robertus et al., (2010) 
miR-150-3p DOWN Chang et al., (2010) 
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miR-151a-3p DOWN Bueno et al., (2011); Robertus et al., (2010); Leucci et al., (2008); Jima et 
al., (2010) 
miR-155-5p DOWN  Bueno et al., (2011); Robertus et al., (2010); Chang et al., (2008); Jima et 
al., (2010) 
miR-155-3p DOWN Jima et al., (2010) 
miR-15a-3p DOWN Bueno et al., (2011); Robertus et al., (2010); Jima et al., (2010) 
miR-15b-5p UP Cancer array (Brain, head, neck, prostate, skin); Robertus et al., (2010) 
miR-16-5p DOWN Robertus et al., (2010) 
miR-17-5p UP/DOWN Bueno et al., (2011); Jima et al., (2010); Sampson et al., (2007) (DOWN) 
miR-17-3p DOWN Jima et al., (2010) 
miR-18a-5p DOWN Bueno et al., (2011); Jima et al., (2010) 
miR-18b-5p - - 
miR-185-5p UP Bueno et al., (2011) 
miR-188-5p UP Bueno et al., (2011) 
miR-191-5p DOWN Robertus et al., (2010) 
miR-192-5p DOWN Leucci et al., (2008) 
miR-193a-5p DOWN Leucci et al., (2008) 
miR-194-3p UP Jima et al., (2010) 
miR-194-5p UP Jima et al., (2010) 
miR-195-5p DOWN Chang et al., (2008) 
miR-195-3p DOWN Chang et al., (2008) 
miR-196a-5p DOWN Robertus et al., (2010) 
miR-196a-3p DOWN Robertus et al., (2010)  
miR-196b-5p DOWN Robertus et al., (2010) 
miR-197 UP Bueno et al., (2011); Jima et al., (2010) 
miR-199a-3p UP Robertus et al., (2010) 
miR-19a-3p UP Bueno et al., (2011); Jima et al., (2010) 
miR-19b-3p UP Bueno et al., (2011); Jima et al., (2010) 
miR-20a-5p DOWN Robertus et al., (2010); Jima et al., (2010) 
miR-20b-5p UP/DOWN Bueno et al., (2011); Leucci et al., (2008) (DOWN) 
miR-200c-3p DOWN Cancer array (prostate, pancreatic); Robertus et al., (2010) 
miR-202-5p UP Bueno et al., (2011); Jima et al., (2010) 
miR-205-5p UP Bueno et al., (2011); Jima et al., (2010) 
miR-21-5p UP Bueno et al., (2011); Jima et al., (2010) 
miR-210-3p DOWN Robertus et al., (2010); Jima et al., (2010) 
miR-214-3p UP Robertus et al., (2010) 
miR-215-5p DOWN Cancer array (liver); Robertus et al., (2010) 
miR-218-5p - Cancer array (brain, head, neck) 
miR-22-3p UP/DOWN Bueno et al., (2011); Chang et al., (2008) (DOWN) 
miR-221-3p DOWN Leucci et al., (2008) 
miR-222-3p DOWN Robertus et al., (2010); Leucci et al., (2008); Jima et al., (2010); Imig et 
al., (2010) (UP) 
miR-223-5p UP Jima et al., (2010) 
miR-224-5p DOWN Robertus et al., (2010) 
miR-23a-3p DOWN Leucci et al., (2008) 
miR-23b-3p DOWN Bueno et al., (2011); Leucci et al., (2008) 
miR-24-3p UP Jima et al., (2010) 
miR-25-3p DOWN Jima et al., (2010) 
miR-26a-5p DOWN Chang et al., (2008); Jima et al., (2010) 
miR-26a-1-3p DOWN Leucci et al., (2008) 
miR-26b-5p DOWN Bueno et al., (2011); Robertus et al., (2010); Chang et al., (2008); Leucci 
et al., (2008); Jima et al., (2010) 
miR-26b-3p DOWN Leucci et al., 2008 
miR-27a-3p UP Di Lisio et al., 2012 
miR-27b-3p DOWN Bueno et al., 2011 
miR-28-3p DOWN Bueno et al., 2011; Robertus et al., 2010; Jima et al., 2010 
miR-29a-3p DOWN Bueno et al., 2011; Robertus et al., 2010; Chang et al., 2008; Jima et al., 
2010 
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miR-29b-3p DOWN Bueno et al., 2011; Leucci et al., 2008 
miR-29c-3p DOWN Chang et al., 2008; Jima et al., 2010 
miR-296-3p UP Bueno et al., 2011; Jima et al., 2010 
miR-30a-3p DOWN/UP Robertus et al., 2010; Jima et al., 2010 (UP); Leucci et al., 2008 
miR-30a-5p UP Jima et al., 2010 
miR-30b-3p DOWN Jima et al., 2010 
miR-30c-5p DOWN Jima et al., 2010; Chang et al., 2008 
miR-30d-5p DOWN Robertus et al., 2010; Jima et al., 2010; Leucci et al., 2008 
miR-30e-3p DOWN Robertus et al., 2010; Jima et al., 2010 
miR-30e-5p DOWN Chang et al., 2008 
miR-301a-3p DOWN Bueno et al., 2011 
miR-31-5p DOWN Robertus et al., 2010 
miR-32-5p DOWN Robertus et al., 2010; Jima et al., 2010 
miR-320a UP Bueno et al., 2011; Jima et al., 2010 
miR-324-3p DOWN Leucci et al., 2008 
miR-324-5p DOWN Leucci et al., 2008 
miR-326 DOWN Robertus et al., 2010; Leucci et al., 2008 
miR-328-3p DOWN Leucci et al., 2008; Jima et al., 2010 
miR-331-3p DOWN Bueno et al., 2011; Robertus et al., 2010; Jima et al., 2010 
miR-339-3p DOWN Robertus et al., 2010 
miR-339-5p DOWN Leucci et al., 2008 
miR-340-5p DOWN Leucci et al., 2008 
miR-342-5p DOWN Robertus et al., 2010; Jima et al., 2010 
miR-342-3p DOWN Leucci et al., 2008 
miR-345-5p UP Jima et al., 2010 
miR-34a-5p DOWN Chang et al., 2008 
miR-34b-5p DOWN Leucci et al., 2008 
miR-361-5p UP Jima et al., 2010 
miR-363-3p DOWN Bueno et al., 2011 
miR-365a-3p UP Di Lisio et al., 2012 
miR-370-3p UP Bueno et al., 2011 
miR-374a-5p UP Robertus et al., 2010  
miR-422a UP Bueno et al., 2011 
miR-423-5p UP Jima et al., 2010 
miR-425-5p UP Jima et al., 2010 
miR-429 DOWN Leucci et al., 2008 
miR-448 DOWN Leucci et al., 2008 
miR-454-3p DOWN Bueno et al., 2011 
miR-455-3p DOWN Robertus et al., 2010 
miR-483-3p DOWN Leucci et al., 2008 
miR-484-3p UP Bueno et al., 2011 
miR-485-3p DOWN Leucci et al., 2008 
miR-486-5p UP Jima et al., 2010 
miR-494-3p UP Bueno et al., 2011 
miR-497-5p DOWN Leucci et al., 2008 
miR-513a-3p DOWN Bueno et al., 2011 
miR-516b-3p UP Di Lisio et al., 2012 
miR-520d-3p UP Di Lisio et al., 2012 
miR-520d-5p UP Di Lisio et al., 2012 
miR-520f-5p - - 
miR-520f-3p - - 
miR-532-5p UP Jima et al., 2010 
miR-563 DOWN Robertus et al., 2010 
miR-573 UP Di Lisio et al., 2012 
miR-574-3p UP Bueno et al., 2011 
miR-575 UP Bueno et al., 2011 
miR-582-3p DOWN Bueno et al., 2011; Robertus et al., 2010 
miR-582-5p DOWN Bueno et al., 2011; Robertus et al., 2010 
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miR-590-3p UP Di Lisio et al., 2012 
miR-595 DOWN Robertus et al., 2010 
miR-624-5p DOWN Robertus et al., 2010 
miR-624-3p DOWN Robertus et al., 2010 
miR-627-3p DOWN Robertus et al., 2010 
miR-627-5p DOWN Robertus et al., 2010 
miR-628-5p UP Robertus et al., 2010; Di Lisio et al., 2012; Jima et al., 2010 
miR-629-5p DOWN Robertus et al., 2010 
miR-634 - - 
miR-650 - - 
miR-660-5p UP Bueno et al., 2011; Robertus et al., 2010; Di Lisio et al., 2012; Jima et al., 
2010 
miR-7-2-3p DOWN Robertus et al., 2010 
miR-765 DOWN Robertus et al., 2010 
miR-766-3p DOWN Robertus et al., 2010 
miR-769-5p UP Bueno et al., 2011 
miR-9-3p UP Leucci et al., 2008; Jima et al., 2010 
miR-9-5p UP Bueno et al., 2011; Di Lisio et al., 2012; Jima et al., 2010 
miR-92a-3p UP Jima et al., 2010 
miR-92a-1-5p DOWN Jima et al., 2010 
miR-92a-2-5p DOWN Jima et al., 2010 
miR-93-3p UP Bueno et al., 2011; Jima et al., 2010 
miR-95-3p DOWN Robertus et al., 2010 
miR-96-3p DOWN/UP Bueno et al., 2011; Sampson et al., 2007 (UP); Jima et al., 2010 
miR-98-5p DOWN Chang et al., 2008 
miR-99a-5p DOWN Malumbres et al., 2009; Chang et al., 2008 
RNU6B CONTROL Malumbres et al., 2009 
RNU48 CONTROL Forte et al., 2012 
RNU44 CONTROL Linda et al., 2010 
miR – microRNA; RNU – small nucleolar RNA; - Added onto array based on availability of the assay 
 
 
Table B2: Stem loop primers for miRNA PCR Array 





































































































































































































































































Table B3: Raw data – expression of miR-575 in fold change, in the Ramos cell line normalised to the endogenous controls 
 
Rep – replicate 
* p<0,05 when compared with microvesicle treated control cells 
 
Table B4: Raw data - Cut-off values for validation of miR-363-3p and miR-222-3p and miR-200c-3p in the Ramos cell line   
Sample miR-363-3p miR-200c-3p miR-222-3p miR-575 Rep. 1 Rep.2 Rep. 1 Rep. 2 Rep. 1 Rep. 2 Rep. 1 Rep. 2 
MV1 40 31.380 35.534 34.121 36.623 33.509 34.166 38.289 
MV2 40 32.426 38.255 36.846 34.420 35.221 35.352 34.767 
HIV1 40 31.748 35.688 33.809 40 39.105 34.841 33.411 
HIV2 40 31.479 34.368 33.702 34.995 40 33.839 34.718 
Rep – replicate  
 







                                               
 













Figure B3: Ponceau S stained membrane representing successful protein transfer for western blotting 
HIV – HIV-1 treated cells, MV – microvesicle treated cells; +MD-MBA231 – positive control cells 
 














Sample RNU6B RNU48 
Rep. 1.1 1.049* 0.654* 
Rep. 1.2 0.609* 0.765* 
Rep. 2.1 0.993* 0.804* 
Rep. 2.2 0.644* 0.623* 
Sample miR-363-3p miR-200c-3p miR-222-3p miR-575 RNU6B RNU48 RNU6B RNU48 RNU6B RNU48 RNU6B RNU48 
Rep. 1.1 0.900 0.834 0.925 0.864 0.645 0.602 0.563 0.526 
Rep. 1.2 1.337 0.878 0.810 0.806 1.045 1.041 0.967 0.963 
Rep. 2.1 1.395 0.848 0.669 0.701 0.947 0.993 0.423 0.443 




                                                                   *       * 
 
















Figure B4: BLID mRNA is upregulated after HIV-1 AT-2 treatment in Ramos cells relative to microvesicle treated control 
cells. Upregulation of BLID mRNA expressed as fold changes in HIV-treated cells relative to microvesicle-treated 
control cells, which has been normalised to one. The housekeeping gene, GAPDH was used as the endogenous control. 
Two independent experiments with each sample performed in duplicate. Error bars represent the standard deviation. 
An upregulated fold change was observed ranging from 4,857-5,578 (p<0,05)* when compared to microvesicle treated 
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Figure B5: BLID expression in L1439A cells relative to microvesicle treated control cells. Western blot analysis displaying BLID 
expression (~11.8 kDa) in the normal B-cell line which could not be detected. 5 µL of 5X SDS loading dye and 1 µL of 
DTT was added to 20 µg of protein (varying volumes) in RIPA buffer and boiled at 95 °C for five minutes before being 
loaded and separated on a 15 % SDS-PAGE gel at 100 V for 2 hours in 1X running buffer. The protein was then 
transferred onto a nitrocellulose membrane (Bio-Rad, California, USA) for 1 hour at 100 V in 1X transfer buffer. This 
was then detected using the Clarity™ Western ECL Blotting Substrate (Bio-Rad, USA). To detect BLID, mouse anti-
BLID antibody (Novus Biologicals, Singapore, Malaysia) was used, with a HRP bound goat anti-mouse secondary 
antibody (Bio-Rad, California, USA). BLID – BH3-like motif containing inducer of cell death; HIV – HIV-AT2 treated 













Figure B6: BLID expression in Ramos cells relative to microvesicle treated control cells. Western blot analysis displaying BLID 
expression (~11.8 kDa) in the Ramos cell line which could not be detected. 5 µL of 5X SDS loading dye and 1 µL of 
DTT was added to 25 µg of protein (varying volumes) in RIPA buffer and boiled at 95 °C for five minutes before being 
loaded and separated on a 15 % SDS-PAGE gel at 100 V for 2 hours in 1X running buffer. The protein was then 
transferred onto a nitrocellulose membrane (Bio- Rad, California, USA) for one hour at 100 V in 1X transfer buffer. This 
was then detected using the Clarity™ Western ECL Blotting Substrate (Bio-Rad, California, USA). To detect BLID, 
mouse anti-BLID antibody (Novus Biologicals, Singapore, Malaysia) was used, with a HRP bound goat anti-mouse 
secondary antibody (Bio-Rad, California, USA). The p38 protein was used as a loading control and detected using rabbit 
anti-p38 antibody (Sigma-Aldrich, Mossouri, USA) and the HRP bound goat anti-rabbit secondary antibody (Bio-Rad, 
California, USA). BLID – BH3-like motif containing inducer of cell death; HIV – HIV-AT2 treated cells; MV – 






















Figure B7: BLID expression in normal B-cells relative to microvesicle treated control cells. Western blot analysis displaying 
BLID expression in the L1439A cell line which could not be detected. 5 µL of 5X SDS loading dye and 1 µL of DTT 
was added to 25 µg of protein (varying volumes) in RIPA buffer and boiled at 95 °C for five minutes before being loaded 
and separated on a 15 % SDS-PAGE gel at 100 V for two hours in 1X running buffer. The protein was then transferred 
onto a nitrocellulose membrane (Bio-Rad, California, USA) for 1 hour at 100 V in 1X transfer buffer. This was then 
detected using the Clarity™ Western ECL Blotting Substrate (Bio-Rad, California, USA). To detect BLID, mouse anti-
BLID antibody (Novus Biologicals, Singapore, Malaysia) was used, with a HRP bound goat anti-mouse secondary 
antibody (Bio-Rad, California, USA). The p38 protein was used as a loading control and detected using the rabbit anti-
p38 antibody (Sigma-Aldrich, Missouri, USA) and the HRP bound goat anti-rabbit secondary antibody (Bio-Rad, 
California, USA). BLID – BH3-like motif containing inducer of cell death; HIV – HIV-AT2 treated cells; MV – 






































Figure B5:  Output from TargetScan for the mRNA:miRNA possible interaction between miR-575 and BLID
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1. Background and Samples Submitted 
The aim of this study is to investigate the differential expression of miRNA in a B cell lymphoma cell 
line treated with attenuated HIV, compared to microvesicle treated and untreated negative controls, 
as measured by an Applied Biosystems Custom TaqMan® MicroRNA qRT-PCR Assay by the CPGR 
(project ID 0530ABI_MOWLA_RT_PCR). The sample preparation and assay QC were reported in 
document 13012015_001. 
A brief summary of the experiment reported herein is as follows: Nine B cell cancer cell line samples 
(Table 1) were submitted by the client to the CPGR for RNA extraction and gene expression analysis 
via qRT-PCR array. The client provided all materials and reagents and CPGR provided assistance with 
experimental analysis.   
Table 1. B cell cancer cell line RNA samples and details submitted by the client. 
Sample ID Details Categorical  comparison group 
HIV1 HIV treated HIV 
HIV2 HIV treated HIV 
HIV3 HIV treated HIV 
MV1 Microvesicle treated control MV 
MV2 Microvesicle treated control MV 
MV3 Microvesicle treated control MV 
UT1 Untreated control (1) - 
UT2 Untreated control (2.3) - 
No-RT No-RT control - 
The SDS output files were converted to plain text using Applied Biosystem’s RQ Manager (version 
1.2), which served as input for the remainder of the differential expression experiment. 
Bioconductor’s HTqPCR package (Dvinge & Bertone, 2009) was used in R (R Development Core 
Team, 2013) to analyse the qRT-PCR data. It is expected that the samples treated with HIV will 
exhibit a different expression profile to the microvesicle treated controls. 
2. Abbreviations 
Ct Cycle threshold 
ddCt method to analyse relative changes in qRT-PCR data, if target and calibrator gene 
amplification efficiencies are approximately equal (Pfaffl, 2001) 
FDR false discovery rate (Benjamini-Hochberg/false discovery rate (0.06) multiple testing 
correction for p-value) (Benjamini & Hochberg, 1995) 
miRNA   microRNA 
PCA   Principal Component Analysis  
qRT-PCR  quantitative real-time PCR 
adjusted p-value  FDR  adjusted (0.1) p-value 
SDS file output format from the Applied Biosystem’s qRT-PCR instrument ABI7900HT 
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3. Analysis Synopsis 
Applied Biosystems qRT-PCR Ct values generated from 384 well plates (1 plate per sample) were 
analysed with Bioconductor’s HTqPCR package (Dvinge & Bertone, 2009) in R (R Development Core 
Team, 2013) to determine differentially expressed miRNA’s in B cell cancer cell lines treated with HIV 
compared to controls. Raw data quality was assessed and normalised. Differential expression of 
miRNA’s in the HIV-treated cells was compared to that in the MV controls. Untreated samples were 
not included in the differential expression analysis as there were not enough replicates to calculate 
significance. Significance was determined by an FDR adjusted p-value < 0.06, corrected for multiple 
testing. 
4. Detailed Analysis 
qRT-PCR allows the simultaneous detection and relative quantitation of a target through 
measurement of the amplification of this sequence. Sufficient presence of the target DNA molecule 
in a given sample results in an increase in fluorescent signal over a set number of PCR cycles (usually 
40). Ct values are measured as the cycle number at which point the curve intersects a fluorescence 
threshold (set to exceed baseline noise). The amount of target template contained within a sample is 
therefore inversely proportional to the Ct value, i.e. lower Ct values are indicative of a large amount 
of target present and vice versa. In general, Ct values of below 29 are characteristic of strong 
positive amplifications suggesting abundant target molecule present in the sample. Those Ct values 
of between 30 and 37 are indicative of positive reactions characterising moderate levels of target 
molecule present in the sample. Ct values of above 38 are characteristic of weak amplification 
suggesting minimal amounts or lack of target molecule present within the respective sample. 
Raw data visualisation 
HIV1_21102014, HIV2_21102014, HIV3_21102014, MV1_22102014, MV2_22102014, 
MV3_22102014, Untreated1_21102014, Untreated2.3_22102014 and Test2_noRT 02102014.txt files 
were loaded into R using the HTqPCR package. Overall the raw Ct values were quite high or 
“Undetermined” indicating a low level of target present. This was probably due to the low amount of 
RNA template that was used in the experiment (see document number 13012015_001).  
The average Ct values for all features across all samples revealed an overall similar pattern as 
expected (see Appendix). Spatial visualisation of the raw Ct values (see Appendix) indicated there 
were a large number of “Undetermined” Ct values (grey circles) on each plate, suggesting minimal or 
no target present in the samples. Measured Ct values ranged mostly from 20 – 40; however it should 
be highlighted that lower Ct values may in fact be a result of peak noise from the baseline and raw 
data should be consulted before drawing any conclusions from these findings. The no-RT control 
indicated generally very high Ct values for all wells as expected, however it is important to note that 
there were 35 features that displayed Ct values of < 40 (see Appendix). These features also need to 
be considered when interpreting any findings from this study. 
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Concordance between feature replicates within samples was not good, with a number of feature 
replicates indicating large variation between replicates (more than 20% difference from their means) 
(Table 2 and see Appendix). Boxplot comparisons of standard deviations of the raw data revealed a 
similar pattern between sample groups (excluding the no-RT control; Figure 1) and variation versus 
mean plots for each sample revealed a few outlying features within each sample (see Appendix).  
Table 2. Number of features with large variation between replicates  
(more than 20% difference from their means) 











Figure 1. Summary of standard deviation between raw replicated features within samples. 
The HTqPCR package allows us to assign a reliability category of “OK”, “Undetermined” or 
“Unreliable” to each Ct value. All features are still tested for differential expression; however each 
feature result is flagged accordingly (see below). The “Undetermined” flag is automatically assigned 
to any features with Ct values undetermined by the qRT-PCR instrument. An “Unreliable” category is 
assigned to feature replicates displaying large variation or extremely low values that may be 
problematic (set in this case for a Ct of below 3). Based on the amplification curves we observed in 
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RQ Manager, we filtered these data using minimum and maximum Ct thresholds of 3 and 40 
respectively with a 90% confidence interval. Figure 2A demonstrates the breakdown of features into 
their “OK”, “Undetermined” and “Unreliable” categories after this filtering, demonstrating that more 
than half of the features within each sample retained an “OK” flag. Figure 2B stratifies this 
information per feature set. We have also included these figures containing only HIV and MV sample 
comparisons in the Appendix. 
A 
 
B       
 
Figure 2. Summary of the categories after filtering either for (A) each sample individually or (B) each sample 
stratified by feature class.  
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Normalisation and quality assessment 
Because the Student’s t-test requires at least three replicates for significance testing, and the 
triplicate MV controls better represent a true control for the triplicate HIV treated samples 
compared to the UT controls (only 2 samples), we continued our differential expression analysis with 
only the HIV and MV control samples. HIV1-3 and MV1-3 sample data were reloaded alone into 
HTqPCR and normalised using the geometric mean (Mestdagh et al., 2009), delta Ct, quantile and 
rank invariant methods. As each method has its own advantages and disadvantages, it can be useful 
to use more than one method of normalisation to see how the data best fits a normalisation 
algorithm. Quality assessment of raw and normalised Ct values for each method (Figure 3) suggest 
that all methods work well for larger Ct values, with the Geometric mean and Delta Ct methods 
displaying the most similar patterns to the raw data for all Ct values. Quantile and Rank invariant 
methods showed some large deviations from the raw data for Ct values below 25, which suggests a 
possibility of over-normalisation using these methods. Boxplot summaries of normalised results are 
available in Figure 4.  
 
Figure 3. Normalised versus raw Ct data for each normalisation method performed.  
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Correlation between samples for raw and normalised data sets (Figure 5) indicated some correlation 
within sample groups (please note that 1 minus the correlation is plotted). Quantile normalisation 
resulted in the highest correlation between samples with a dendrogram structure most fitting of the 
sample groups. Rank invariant normalisation resulted in the lowest correlation between samples 
compared to the other normalisation methods and raw data. 
 
 
      Raw data 
 
       Geometric Mean             Delta Ct 
 
                    Quantile            Rank invariant 
 
Figure 5. Correlation between samples for the raw data and each normalisation method between Ct values 
(1 minus the correlation is plotted). 
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Initial analysis of normalised qRT-PCR data 
The distributions of Ct values are similar for all datasets (raw and normalised) and are plotted in 
Figure 6. Please note that the peak at Ct = 40 for all of the plots is due to the large number of 
“Undetermined” Ct values which are automatically assigned a value of 40 for the generation of this 
plot. These plots therefore suggest a normal-like distribution of the data, albeit with a possible right 





Figure 6. Distribution of Ct values for the individual samples before and after each normalisation method. 
The large number of “Undetermined” features are automatically assigned a Ct of 40  in this function, 
resulting in the large peak at the high end of the x-axis scale. 
Analytical Report 0679BIX_SMOWLA_EXHIV 
Confidential 
5 February 2015 
Document number BIX03022015-001 Version 1.0 
 
Centre for Proteomic and Genomic Research  Page 11 of 17 
Institute of infectious Diseases and Molecular Medicine, Faculty of Health Sciences, UCT 
Wernher and Beit Building South, Lab S2.09, Anzio Road, Observatory. Laboratory Report Ver. 2.0 
Heatmaps generated to visualise the Euclidean distance clustering of features and samples (Figure 7; 
please see Appendix for Pearson correlation clustering), as well as PCA plots (Figure 8), revealed that 






Geometric mean             Delta Ct 
 
 Quantile      Rank invariant 
 
Figure 7. Heatmaps for raw and normalised data sets based on Euclidean distance clustering between Ct 
values revealing no clustering of sample groups. 
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         Raw data 
 
     Geometric mean      Delta Ct 
 
               Quantile                Rank invariant 
 
Figure 8. PCA plots of raw and normalised samples revealing no clustering of sample groups. 
Overall, the quality assessment of each of the normalisation methods suggests that Quantile 
normalisation will be the most reliable method due to the concordance between samples and the 
clustering of the data. It should be noted that there is some indication that for low Ct values the data 
may be slightly over-normalised with Quantile normalisation (Figure 3), and the raw data should be 
consulted before drawing any conclusions from these findings. We should also point out that the 
HTqPCR documentation mentions that there is some suggestion that Geometric mean normalisation 
has some advantages over others particularly for miRNA studies (Dvinge & Bertone, 2009; Mestdagh 
et al., 2009). Based on these quality assessments, we feel that Rank invariant normalisation seems to 
be the least reliable method, and this normalised data set was therefore omitted from subsequent 
differential expression analyses. 
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Determining differentially expressed genes 
The samples loaded into the HTqPCR for normalisation (above; HIV1-3 and MV1-3) were assigned 
into the categorical comparison groups “HIV” (target) and “MV” (calibrator). Comparison groups 
were designated by biological replication, and replicates were assigned to their respective groups 
(see Table 1). As the data displayed a normal-like distribution (Figure 6), the Student’s t-test was 
used to test for significance of differences in Ct values between the microvesicle treated controls 
and the HIV treated cells. All features are included in the t-test calculation regardless of reliability 
flag, however each feature result indicates its reliability with an “OK” or “Undetermined” category 
flag for each sample group (categoryHIV and categoryMV); the latter indicating that at least a single 
feature within at least a single sample contained an “Undetermined” or “Unreliable” flag for that 
sample group. 
The results are provided in spreadsheet format, with each normalisation method analysed on an 
individual sheet within the spreadsheet (see Appendix). Each sheet is provided in order of increasing 
adjusted p-value (adj.p.value in the spreadsheet), and can be manipulated by sorting according to a 
field of interest by clicking on the down arrow in the header of that field. Other fields include the t 
statistic (t.test), the raw p-value not adjusted for multiple testing (p.value), delta delta Ct (ddCt; 
(Pfaffl, 2001)), the fold change (FC) calculated from ddCt using the Pfaffl method (Pfaffl, 2001), and 
the log of this fold change (log(FC)). It is important to note that while the Pfaffl method is extremely 
convenient to calculate fold change from Ct values, it is only completely accurate when the 
amplification efficiency of both the target and the calibrator sequences are approximately equal. 
Therefore all conclusions made from these findings (and confirmed with the raw data) need to be 
experimentally validated. Log(FC) values are coloured by scale (blue and red for respective decreases 
and increases in fold change), and features with “Undetermined” or “OK” Ct value flags are indicated 
in red and green respectively for HIV (categoryHIV) and MV (categoryMV) samples.  
The t-test revealed significant (FDR adjusted p-value < 0.06), albeit modest, differential expression 
for hsa-miR-532-001518 and hsa-miR-342-3p-002260 from the quantile normalised data set (Table 3 
and see Appendix for full t-test results table; FDR adjusted p-values < 0.06 are indicated in yellow). 
There was no significant differential expression observed from the t-tests of the geometric mean and 
delta Ct normalised data sets, both of which displayed more similar distributions to the raw data 
compared to Quantile normalisation. It is important to remember that the lower Ct values may have 
been over-normalised using certain normalisation algorithms, and that the raw data and category 
flags should be consulted before drawing any conclusions from these results.  
Table 3. Significantly differentially expressed miRNA’s as determined by Quantile normalised  
qRT-PCR array data (adjusted p-value < 0.1) (An “Undetermined” flag indicates undetermined or  











hsa-miR-532-001518 0.0584 0.432 OK Undetermined 
hsa-miR-342-3p-002260 0.0584 1.630 OK OK 
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Minimal differential expressed gene list mitigation 
We would also like to highlight that there were a number of genes that, while not significantly 
differentially regulated, demonstrated fold changes which may be of interest (please see the full t-
test results table which is currently ordered from smallest to largest adjusted p-value, but can easily 
be ordered by largest increase to largest decrease in FC by clicking the small down arrow in the FC or 
log(FC) header). For example, in the t-test results for all three normalised data sets, hsa-miR-92a-2#-
002138 demonstrated the highest increase of between 1.955 and 2.21 fold, while hsa-miR-627-
001560 and hsa-miR-9-000583 displayed the largest decreases of between of more than 1.45 fold 
(see Appendix). These large fold changes do warrant further investigation as their non-significant 
adjusted p-values may be due to a single outlying sample contributing large variation to the sample 
group. As mentioned above however, it is also very important to note that the raw data and 
category flags for each feature should be consulted before drawing any conclusions from these 
results.  
5. Deviations 
Because the Student’s t-test requires at least three replicates for significance testing and the UT 
controls only contained two biological replicates, differential expression was only analysed in HIV 
treated samples compared to MV controls and not HIV treated compared to untreated controls.  
 
As not much significant differential expression was identified from these analyses, a secondary 
approach was suggested whereby fold change is assessed without consideration for adjusted p-
value, or significance. This was in order to extract as much biological information from the study as 
possible, despite the above being an invalid methodology which is not publishable. It is important to 
highlight that one needs to consult the individual feature Ct flags and the raw data before drawing 
any conclusions from these results, whether significant or not. 
6. Enquiries 
Your application specialist on this project is Wendy Kröger; do not hesitate to contact her on 021 447 
5669 or wendy.kroger@cpgr.org.za, for additional discussion or information on this report.  Please 
feel free to contact us to organise a meeting to come and have a look at your raw data on our RQ 
Manager software once you have had a chance to analyse our findings. 
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The files detailed below are provided in the data_visualisation/ folder: 
spatial_layout Spatial visualisation of each array in PDF format (grey = Undetermined Ct). 
noRT_features_over40 Features found on the no-RT control array with Ct values below 40. 
average_Ct/ See below 
concordance/ See below 
variation/ See below 
feature_categories/ See below 
The files detailed below are provided in the data_visualisation/average_Ct folder: 
ave_Ct Plot of average Ct values for each feature and all samples (provided in PDF and PNG formats). 
The files detailed below are provided in the data_visualisation/concordance folder: 
replicate_ 
concordance 
Concordance between duplicated Ct values in all samples, marking features 
differing > 20% from their mean in PDF format. 
reps_diff_more_than_20/ Text files containing feature names for all feature replicates differing > 20% 
from their mean. 
The files detailed below are provided in the data_visualisation/variation folder: 
SD_of_reps Summary of standard deviation between raw replicated features within samples (in PDF and 
PNG formats). 
var_vs_mean Variation versus mean plots for each sample (in PDF and PNG formats; Figure 1). 
The files detailed below are provided in the data_visualisation/feature_categories folder: 
feature_categories Summary of the categories after filtering either for each sample individually (in PDF 
and PNG formats; Figure 2A). 
feature_categories
_by_feature 
Summary of the categories after filtering either for each sample stratified by feature 
class individually (in PDF and PNG formats; Figure 2B). 
Normalisation and quality assessment 
The files detailed below are provided in the QC_normalised/ folder: 
raw_vs_norm Normalised versus raw Ct data for each normalisation method (in PDF and PNG 
formats; Figure 3). 
SD_of_reps Summary of standard deviation between each normalised set of replicated 
features within samples (in PDF and PNG formats; Figure 4). 
correlation/ Correlation between samples for the raw data and each normalisation method 
between Ct values. 1 minus the correlation is plotted in PNG format (Figure 5). 
Ct_distributions/ Distribution of Ct values for the individual samples before and after each 
normalisation method in PNG format (Figure 6). 
heatmaps/ Heatmaps based on Euclidean distance (Figure 7) and Pearson correlation 
clustering. 
PCA/ PCA plots raw and normalised data in PNG format (Figure 8). 
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Differentially expressed genes 
The files detailed below are provided in the differential_expression/ folder: 
t_test/ 
Directory containing tab separated plain text files for t-test results on 
data sets from each normalisation method. Please see section entitled 
“Determining differentially expressed genes” for explanation of field 
headers. 
t_test_results.xlsx 
Spreadsheet with all t-test results with each normalisation method on 
an individual sheet. Please see section entitled “Determining 
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